

390
(000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

Mo-6305/HR-199

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

09/830514

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/EP99/07952

October 20, 1999

October 31, 1998

TITLE OF INVENTION Construction of Production Strains for Producing Substituted Phenols By Specifically
Inactivating Genes of the Eugenol and Ferulic Acid Catabolism

APPLICANT(S) FOR DO/EO/US RABENHORST, Jurgén; STEINBUCHER, Alexander; PRIEFERT, Horst and
OVERHAGE, Jorg

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Preliminary Amendment w/Abstract, Sequence Listing (Paper Copy and Disk Copy)
Form PTO 1449 w/references

U.S. APPLICATION NO. (known as 37 CFR 1.53) To Be Assigned 09/830514		INTERNATIONAL APPLICATION NO. PCT/EP99/07952		ATTORNEY'S DOCKET NUMBER Mo-6305/HR-199	
--	--	---	--	--	--

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1000.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	15 -20 =	0	x \$18.00
Independent claims	5 -3 =	2	x \$80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+
SUBTOTAL =			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			
TOTAL NATIONAL FEE =			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			
TOTAL FEES ENCLOSED =			

CALCULATIONS PTO USE ONLY	
\$	860.00
\$	0.00
\$	0.00
\$	160.00
\$	0.00
\$	1,020.00
\$	0.00
\$	1,020.00
\$	0.00
\$	40.00
\$	1,060.00
Amount to be refunded:	\$
charged:	\$

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.


b. ☒ Please charge my Deposit Account No. 13-3848 in the amount of \$ 1,060.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3848. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO



00157

PATENT TRADEMARK OFFICE

SIGNATURE

Noland J. Cheung
NAME

39,138
REGISTRATION NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES RECEIVING OFFICE

JC18 Rec'd PCT/PTO 27 APR 2001

Date	April 27, 2001
International Application No.	PCT/EP99/07952
Attorney Docket No.	Mo-6305/HR-199

I. Certification under 37 CFR 1.10 (if applicable)

ET146893673US
Express Mail mailing number

April 27, 2001
Date of Deposit

I hereby certify that the application/correspondence attached hereto is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of person mailing correspondence

Donna J. Veatch
Typed or printed name of person mailing correspondence

II. ☒ New International Application

TITLE	CONSTRUCTION OF PRODUCTION STRAINS FOR PRODUCING SUBSTITUTED PHENOLS BY SPECIFICALLY INACTIVATING GENES OF THE EUGENOL AND FERULIC ACID CATABOLISM
-------	--

Earliest priority date (Day/Mon/Year)
(31/10/98)

SCREENING DISCLOSURE INFORMATION: In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

- A. ☒ The invention disclosed was not made in the United States.
- B. ☒ There is no prior U.S. application relating to this invention.
- C. ☐ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claim for priority.)

application no.		filed on	
application no.		filed on	

- D. ☐ The present international application ☐ contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C. above. The additional subject matter is found on pages
- and ☐ DOES NOT ALTER ☐ MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 CFR 5.1. See 37 CFR 5.15

III. ☐ A Response to an Invitation from the RO/US. The following document(s) is(are) enclosed:

- A. ☐ A Request for An Extension of Time to File a Response
- B. ☐ A Power of Attorney (General or Regular)
- C. ☐ Replacement pages:

pages		of the request (PCT/RO/101)	pages		of the figures
pages		of the description	pages		of the abstract
pages		of the claims			

- D. ☐ Submission of Priority Documents

Priority document		Priority document	
-------------------	--	-------------------	--

- E. ☐ Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

IV. ☐ A Request for Rectification under PCT 91 ☐ A Petition ☐ A Sequence Listing Diskette

- V. ☒ Other (please specify): Preliminary Amendment w/Abstract, Sequence Listing (Paper and Disk Copy)
Form PTO 1449 w/references
Drawings (3 sheets)

The person
signing this
form is the:

<input type="checkbox"/> Applicant	Notand J. Cheung
<input checked="" type="checkbox"/> Attorney/Agent (Reg. No.) 39,138	Typed name of signer
<input type="checkbox"/> Common Representative	Signature

09/830514

JC18 Rec'd PCT/PTO 27 APR 2001

PATENT APPLICATION

Mo-6305

HR-199

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF)
JÜRGEN RABENHORST, ET AL.) PCT/EP99/07952
SERIAL NUMBER: TO BE ASSIGNED)
FILED: HERewith)
TITLE: CONSTRUCTION OF)
PRODUCTION STRAINS FOR)
PRODUCING SUBSTITUTED)
PHENOLS BY SPECIFICALLY)
INACTIVATING GENES OF THE)
EUGENOL AND FERULIC ACID)
CATABOLISM)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Upon the granting of a Serial Number and Filing Date and prior to the examination of the subject application, kindly amend the Specification and Claims as follows:

"Express Mail" mailing label number ET146893673US

Date of Deposit April 27, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231

Donna J. Veatch

(Name of person mailing paper or fee)


Signature of person mailing paper or fee)

IN THE SPECIFICATION:

Kindly replace the Title of the Invention with the following:

-- CONSTRUCTION OF PRODUCTION STRAINS FOR PRODUCING
SUBSTITUTED PHENOLS BY SPECIFICALLY INACTIVATING GENES OF THE
EUGENOL AND FERULIC ACID CATABOLISM --.

Kindly insert the following "ABSTRACT" page

-- The present invention relates to a transformed and/or mutagenated
unicellular or multicellular organism which is characterized in that enzymes
of the eugenol and/or ferulic acid catabolism are deactivated in such a
manner that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic
acid, vanillin and/or vanillic acid are accumulated. --

On page 1, line 4, kindly insert the following:

-- FIELD OF THE INVENTION --.

On page 1, line 7, kindly insert the following:

--BACKGROUND OF THE INVENTION--.

On page 2, after line 9, kindly insert the following:

-- BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1a to 1r show gene structures for isolating organisms and
mutants.

FIG. 2a: shows a nucleotide sequence of the *ca/A Ω Km* gene structure
(SEQ ID NO: 1).

FIG. 2b: shows a nucleotide sequence of the *ca/A Ω Gm* gene structure
(SEQ ID NO: 2).

FIG. 2c: shows a nucleotide sequence of the *ca/A Δ* gene structure
(SEQ ID NO: 3).

FIG. 2d: shows a nucleotide sequence of the *ca/B Ω Km* gene structure
(SEQ ID NO: 4).

FIG. 2e: shows a nucleotide sequence of the *calB* Ω Gm gene structure (SEQ ID NO: 5).

FIG. 2f: shows a nucleotide sequence of the *calB* Δ gene structure (SEQ ID NO: 6).

FIG. 2g: shows a nucleotide sequence of the *fcs* Ω Km gene structure (SEQ ID NO: 7).

FIG. 2h: shows a nucleotide sequence of the *fcs* Ω Gm gene structure (SEQ ID NO: 8).

FIG. 2i: shows a nucleotide sequence of the *fcs* Δ gene structure (SEQ ID NO: 9).

FIG. 2j: shows a nucleotide sequence of the *ech* Ω Km gene structure (SEQ ID NO: 10).

FIG. 2k: shows a nucleotide sequence of the *ech* Ω Gm gene structure (SEQ ID NO: 11).

FIG. 2l: shows a nucleotide sequence of the *ech* Δ gene structure (SEQ ID NO: 12).

FIG. 2m: shows a nucleotide sequence of the *vdh* Ω Km gene structure (SEQ ID NO: 13).

FIG. 2n: shows a nucleotide sequence of the *vdh* Ω Gm gene structure (SEQ ID NO: 14).

FIG. 2o: shows a nucleotide sequence of the *vdh* Δ gene structure (SEQ ID NO: 15).

FIG. 2p: shows a nucleotide sequence of the *aat* Ω Km gene structure (SEQ ID NO: 16).

FIG. 2q: shows a nucleotide sequence of the *aat* Ω Gm gene structure (SEQ ID NO: 17).

FIG. 2r: shows a nucleotide sequence of the *aat* Δ gene structure (SEQ ID NO: 18). --.

On page 2, line 10, kindly insert the following:

--SUMMARY OF THE INVENTION--.

On page 2, line 19, kindly insert the following:

--DETAILED DESCRIPTION OF THE INVENTION--.

IN THE CLAIMS:

Kindly cancel Claims 1 - 16.

Kindly add the following new claims:

-- 17. Transformed and/or mutagenized unicellular or multicellular organism comprising enzymes of eugenol and/or ferulic acid catabolism which are inactivated such that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.

18. An organism according to Claim 17, wherein eugenol and/or ferulic acid catabolism is altered by inserting Ω elements, or introducing deletions, into corresponding genes.

19. Organism according to Claim 17, wherein one or more genes encoding the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin dehydrogenases or vanillic acid demethylases is/are altered and/or inactivated.

20. An organism according to Claim 17, wherein said organism is unicellular.

21. An organism according to Claim 20, wherein said organism is selected from a group consisting of a microorganism, a plant or animal cell.

22. An organism according to Claim 17, wherein said organism is a bacterium.

23. An organism according to Claim 22, wherein said organism is of the *Pseudomonas* species.

24. Gene structures comprising nucleotide sequences which encode the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin-dehydrogenases or vanillic acid demethylases, or two or more of these enzymes, and are altered and/or inactivated.

25. Gene structures having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

26. Vectors comprising at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

27. A transformed organism according to Claim 17, wherein said organism comprises at least one vector comprising at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

28. Organism according to Claim 17, wherein said organism comprises at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18 which is integrated into the genome instead of the respective intact gene.

29. Process for the biotechnological preparation of alcohols, aldehydes and organic acids, comprising the step of adding an organism comprising enzymes of eugenol and/or ferulic acid catabolism which are inactivated such that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.

30. Process for preparing an organism according to Claim 17, wherein the alteration eugenol and/or ferulic acid catabolism is achieved by microbiological culturing methods.

31. Process for preparing an organism according to Claim 29, wherein the alteration in eugenol and/or ferulic acid catabolism, and/or the inactivation of the corresponding genes, is achieved by means of recombinant DNA methods. --.

093054 042704
T02704 450250

REMARKS


The Applicants respectfully request the Preliminary Amendment be entered as the amendment places the claims as well as the Specification in proper form.

New Claims 17 - 31 replace now cancelled Claims 1 - 16. Support for the new claims are found in the respective original cancelled claims. The Applicants respectfully submit that no new matter is added.

Additionally, the Applicants hereby submit a paper copy of the "Sequence Listing" as well as a copy of the "Sequence Listing" in computer readable form. The "Sequence Listing" has been amended to place it in proper form for U.S. filing. The Applicants also state that the information recorded in computer readable form is identical to the written sequence listing.

The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

By 
Noland J. Cheung
Attorney for Applicants
Reg. No. 39,138

Bayer Corporation
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
(412) 777-8338
FACSIMILE PHONE NUMBER:
(412) 777-8363
s:\ks\NJC1008

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Kindly replace the Title of the Invention with the following:

-- CONSTRUCTION OF PRODUCTION STRAINS FOR PRODUCING
SUBSTITUTED PHENOLS BY SPECIFICALLY INACTIVATING GENES OF THE
EUGENOL AND FERULIC ACID CATABOLISM --.

Kindly insert the following "ABSTRACT" page

-- The present invention relates to a transformed and/or mutagenated
unicellular or multicellular organism which is characterized in that enzymes
of the eugenol and/or ferulic acid catabolism are deactivated in such a
manner that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic
acid, vanillin and/or vanillic acid are accumulated. --

On page 1, line 4, kindly insert the following:

-- FIELD OF THE INVENTION --.

On page 1, line 7, kindly insert the following:

--BACKGROUND OF THE INVENTION--.

On page 2, after line 9, kindly insert the following:

-- BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1a to 1r show gene structures for isolating organisms and
mutants.

FIG. 2a: shows a nucleotide sequence of the *calA* Δ Km gene structure
(SEQ ID NO: 1).

FIG. 2b: shows a nucleotide sequence of the *calA* Δ Gm gene structure
(SEQ ID NO: 2).

FIG. 2c: shows a nucleotide sequence of the *calA* Δ gene structure
(SEQ ID NO: 3).

FIG. 2d: shows a nucleotide sequence of the *ca/B Ω Km* gene structure (SEQ ID NO: 4).

FIG. 2e: shows a nucleotide sequence of the *ca/B Ω Gm* gene structure (SEQ ID NO: 5).

FIG. 2f: shows a nucleotide sequence of the *calB*_Δ gene structure (SEQ ID NO: 6).

FIG. 2g: shows a nucleotide sequence of the *fcs*_ΩKm gene structure (SEQ ID NO: 7).

FIG. 2h: shows a nucleotide sequence of the *fcs* Ω Gm gene structure (SEQ ID NO: 8).

FIG. 2i: shows a nucleotide sequence of the *fcs* Δ gene structure (SEQ ID NO: 9).

FIG. 2j: shows a nucleotide sequence of the *echΩKm* gene structure (SEQ ID NO: 10).

FIG. 2k: shows a nucleotide sequence of the *ech* Ω Gm gene structure (SEQ ID NO: 11).

FIG. 2I: shows a nucleotide sequence of the *ech*_Δ gene structure (SEQ ID NO: 12).

FIG. 2m: shows a nucleotide sequence of the *vdh* Ω Km gene structure (SEQ ID NO: 13).

FIG. 2n: shows a nucleotide sequence of the *vdh*_ΩGm gene structure (SEQ ID NO: 14).

FIG. 2o: shows a nucleotide sequence of the *vdh*_Δ gene structure (SEQ ID NO: 15).

FIG. 2p: shows a nucleotide sequence of the *aat* Ω Km gene structure (SEQ ID NO: 16).

FIG. 2q: shows a nucleotide sequence of the *aat* Ω Gm gene structure (SEQ ID NO: 17).

FIG. 2r: shows a nucleotide sequence of the *aat* Δ gene structure (SEQ ID NO: 18). --.

On page 2, line 10, kindly insert the following:

--SUMMARY OF THE INVENTION--.

On page 2, line 19, kindly insert the following:

--DETAILED DESCRIPTION OF THE INVENTION--.

IN THE CLAIMS:

Kindly cancel Claims 1 - 16.

Kindly add the following new claims:

-- 17. Transformed and/or mutagenized unicellular or multicellular organism comprising enzymes of eugenol and/or ferulic acid catabolism which are inactivated such that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.

18. An organism according to Claim 17, wherein eugenol and/or ferulic acid catabolism is altered by inserting Ω elements, or introducing deletions, into corresponding genes.

19. Organism according to Claim 17, wherein one or more genes encoding the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin dehydrogenases or vanillic acid demethylases is/are altered and/or inactivated.

20. An organism according to Claim 17, wherein said organism is unicellular.

21. An organism according to Claim 20, wherein said organism is selected from a group consisting of a microorganism, a plant or animal cell.

22. An organism according to Claim 17, wherein said organism is a bacterium.

23. An organism according to Claim 22, wherein said organism is of the *Pseudomonas* species.

24. Gene structures comprising nucleotide sequences which encode the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin-dehydrogenases or vanillic acid demethylases, or two or more of these enzymes, and are altered and/or inactivated.

25. Gene structures having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

26. Vectors comprising at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

27. A transformed organism according to Claim 17, wherein said organism comprises at least one vector comprising at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18.

28. Organism according to Claim 17, wherein said organism comprises at least one gene structure having the sequences corresponding to SEQ ID NO:1 to SEQ ID NO: 18 which is integrated into the genome instead of the respective intact gene.

29. Process for the biotechnological preparation of alcohols, aldehydes and organic acids, comprising the step of adding an organism comprising enzymes of eugenol and/or ferulic acid catabolism which are inactivated such that the

intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.

30. Process for preparing an organism according to Claim 17, wherein the alteration eugenol and/or ferulic acid catabolism is achieved by microbiological culturing methods.

31. Process for preparing an organism according to Claim 29, wherein the alteration in eugenol and/or ferulic acid catabolism, and/or the inactivation of the corresponding genes, is achieved by means of recombinant DNA methods. --.

10240452360

- 37 -

CONSTRUCTION OF PRODUCTION STRAINS
FOR PRODUCING SUBSTITUTED PHENOLS
BY SPECIFICALLY INACTIVATING GENES OF
THE EUGENOL AND FERULIC ACID CATABOLISM

ABSTRACT OF THE DISCLOSURE

The present invention relates to a transformed and/or mutagenated unicellular or multicellular organism which is characterized in that enzymes of the eugenol and/or ferulic acid catabolism are deactivated in such a manner that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid are accumulated.

T 0 2 3 4 0 " 4 4 0 0 0 0 0

Constructing production strains for the preparation of substituted phenols by specifically inactivating genes of eugenol and ferulic acid catabolism

5 The present invention relates to the construction of production strains and to a process for preparing substituted methoxyphenols, in particular vanillin.

DE-A 4 227 076 (process for preparing substituted methoxyphenols, and microorganism which is suitable for this purpose) describes the preparation of substituted methoxyphenols using a novel *Pseudomonas* sp.. The starting material in this context is eugenol and the products are ferulic acid, vanillic acid, coniferyl alcohol and coniferyl aldehyde.

15 An extensive review of the biotransformations which were possible using ferulic acid, which was written by Rosazza et al. (Biocatalytic transformation of ferulic acid: an abundant aromatic natural product; J. Ind. Microbiol. 15:457-471), also appeared in 1995.

20 The genes and enzymes for synthesizing coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillic and vanillin acid from *Pseudomonas* sp. were described in EP-A 0 845 532.

25 The enzymes for converting *trans*-ferulic acid into *trans*-feruloyl-SCoA ester and subsequently into vanillin, and also the gene for cleaving the ester, were described by the Institute of Food Research, Norwich, GB, in WO 97/35999. In 1998, the content of the patent also appeared in the form of scientific publications (Gasson et al. 1998. Metabolism of ferulic acid to vanillin. J. Biol. Chem. 273:4163-4170; Narbad and Gasson 1998. Metabolism of ferulic acid via vanillin using a novel CoA-dependent pathway in a newly isolated strain of *Pseudomonas fluorescens*. Microbiology 30 144:1397 - 1405).

"Express Mail" mailing label number ET146093673US

Date of Deposit April 27, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231

Donna J. Veatch

(Name of person mailing paper or fee)

Donna J. Veatch
Signature of person mailing paper or fee

HR 199

DE-A 195 32 317 describes the use of *Amycolatopsis* sp. for obtaining vanillin from ferulic acid fermentatively in high yields.

5 The known processes suffer from the disadvantage that they either achieve only very low yields of vanillin or make use of relatively expensive starting compounds. While the last-mentioned process (DE-A 195 32 317) does achieve high yields, the use of *Pseudomonas* sp. HR199 and *Amycolatopsis* sp. HR167 for biotransforming eugenol into vanillin requires a fermentation which is carried out in two steps, consequently leading to substantial expense and consumption of time.

10 The object of the present invention is therefore to construct organisms which are able to convert the relatively inexpensive raw material eugenol into vanillin in a one-step process.

15 This object is achieved by means of constructing production strains of unicellular or multicellular organisms, which strains are characterized in that enzymes of eugenol and/or ferulic acid catabolism are inactivated such that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.

20 The production strain may be unicellular or multicellular. Accordingly, the invention can relate to microorganisms, plants or animals. Furthermore, use can also be made of extracts which are obtained from the production strain. According to the invention, preference is given to using unicellular organisms. These latter organisms can be microorganisms or animal or plant cells. According to the invention, particular
25 preference is given to using fungi and bacteria. The highest preference is given to bacterial species. Those bacteria which may in particular be used, after their eugenol and/or ferulic acid catabolism has/have been altered, are species of *Rhodococcus*, *Pseudomonas* und *Escherichia*.

30 In the simplest case, known, conventional microbiological methods can be used for isolating the organisms which may be employed in accordance with the invention.

Thus, the enzymic activity of the proteins involved in eugenol and/or ferulic acid catabolism can be altered by using enzyme inhibitors. Furthermore, the enzymic activity of the proteins involved in eugenol and/or ferulic acid catabolism can be altered by mutating the genes which encode these proteins. Such mutations can be generated in a random manner by means of classical methods, for example by using UV irradiation or mutation-inducing chemicals.

Recombinant DNA methods, such as deletions, insertions and/or nucleotide exchanges, are likewise suitable for isolating the novel organisms. Thus, the genes of the organisms can, for example, be inactivated using other DNA elements (Ω elements). Suitable vectors can likewise be used for replacing the intact genes with gene structures which are altered and/or inactivated. In this context, the genes which are to be inactivated, and the DNA elements which are employed for the inactivation, can be obtained by means of classical cloning techniques or by means of polymerase chain reactions (PCR).

For example, in one possible embodiment of the invention, eugenol catabolism and ferulic acid catabolism can be altered by inserting Ω elements, or introducing deletions, into appropriate genes. In this context, the abovementioned recombinant DNA methods can be used to inactivate the functions of the genes, which encode dehydrogenases, synthetases, hydratase-adolases, thiolases or demethylases, such that production of the relevant enzymes is blocked. Preferably, the genes are those which encode coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin dehydrogenases or vanillic acid demethylases. Very particular preference is given to genes which encode the amino acid sequences specified in EP-A 0845532 and/or nucleotide sequences which encode their allelic variations.

The invention accordingly also relates to gene structures for preparing transformed organisms and mutants.

Preference is given to employing gene structures in which the nucleotide sequences encoding dehydrogenases, synthetases, hydratase-aldolases, thiolases or demethylases are inactivated for isolating the organisms and mutants. Particular preference is given to gene structures in which the nucleotide sequences encoding coniferyl alcohol
5 dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin dehydrogenases or vanillic acid demethylases are inactivated. Very particular preference is given to gene structures which exhibit the structures given in Figures 1a to 1r having the nucleotide sequences which are depicted in Figures 2a to 2r and/or nucleotide sequences
10 encoding their allelic variations. In this context, particular preference is given to nucleotide sequences 1 to 18.

The invention also encompasses the part sequences of these gene structures as well as functional equivalents. Functional equivalents are to be understood as meaning those
15 derivatives of the DNA in which individual nucleobases have been exchanged (wobble exchanges) without the function being altered. Amino acids may also be exchanged at the protein level without this resulting in an alteration in function.

One or more DNA sequences can be inserted upstream and/or downstream of the
20 gene structures. By cloning the gene structures, it is possible to obtain plasmids or vectors which are suitable for the transformation and/or transfection of an organism and/or for conjugative transfer into an organism.

The invention furthermore relates to plasmids and/or vectors for preparing the
25 organisms and mutants which are transformed in accordance with the invention. These organisms and mutants consequently harbour the gene structures which have been described. The present invention accordingly also relates to organisms which harbour the said plasmids and/or vectors.

30 The nature of the plasmids and/or vectors depends on what they are being used for. In order, for example, to be able to replace the intact genes of eugenol and/or ferulic

acid catabolism in pseudomonads with the genes which have been inactivated with omega elements, there is a need for vectors which, on the one hand, can be transferred into pseudomonads (conjugatively transferable plasmids) but which, on the other hand, cannot be replicated in these organisms and are consequently unstable in pseudomonads (so-called suicide plasmids). DNA segments which are transferred into pseudomonads with the aid of such a plasmid system can only be retained if they become integrated by homologous recombination into the genome of the bacterial cell.

The described gene structures, vectors and plasmids may be used for preparing different transformed organisms or mutants. The said gene structures can be used for replacing intact nucleic acid sequences with altered and/or inactivated gene structures. In the cells, which can be obtained by transformation or transfection or conjugation, the intact gene is replaced, by homologous recombination, with the altered and/or inactivated gene structure, as a consequence of which the resulting cells now only possess the altered and/or inactivated gene structure in their genome. In this way, preferably genes can be altered and/or inactivated, in accordance with the invention, such that the relevant organisms are able to produce coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid.

Mutants of the strain *Pseudomonas* sp. HR199 (DSM 7063), which was described in detail in DE-A 4 227 076 and EP-A 0845532, are examples of production strains which have been constructed in this way in accordance with the invention, with the corresponding gene structures ensuing, inter alia, from Figures 1a to 1r, in combination with Figures 2a to 2r:

1. *Pseudomonas* sp. HR199 Δ calA Ω Km, which contains the Ω Km-inactivated *calA* gene in place of the intact *calA* gene encoding coniferyl alcohol dehydrogenase (Fig. 1a; Fig. 2a).

2. *Pseudomonas* sp. HR199 $\text{calA}\Omega\text{Gm}$, which contains the ΩGm -inactivated *calA* gene in place of the intact *calA* gene encoding coniferyl alcohol dehydrogenase (Fig. 1b; Fig. 2b).
3. *Pseudomonas* sp. HR199 $\text{calA}\Delta$, which contains the deletion-inactivated *calA* gene in place of the intact *calA* gene encoding coniferyl alcohol dehydrogenase (Fig. 1c; Fig. 2c).
4. *Pseudomonas* sp. HR199 $\text{calB}\Omega\text{Km}$, which contains the ΩKm -inactivated *calB* gene in place of the intact *calB* gene encoding coniferyl aldehyde dehydrogenase (Fig. 1d; Fig. 2d)
5. *Pseudomonas* sp. HR199 $\text{calB}\Omega\text{Gm}$, which contains the ΩGm -inactivated *calB* gene in place of the intact *calB* gene encoding coniferyl aldehyde dehydrogenase (Fig. 1e; Fig. 2e).
6. *Pseudomonas* sp. HR199 $\text{calB}\Delta$, which contains the deletion-inactivated *calB* gene in place of the intact *calB* gene encoding coniferyl aldehyde dehydrogenase (Fig.1f; Fig. 2f).
7. *Pseudomonas* sp. HR199 $\text{fcs}\Omega\text{Km}$, which contains the ΩKm -inactivated *fcs* gene in place of the intact *fcs* gene encoding feruloyl-CoA synthetase (Fig.1g; Fig. 2g).
8. *Pseudomonas* sp. HR199 $\text{fcs}\Omega\text{Gm}$, which contains the ΩGm -inactivated *fcs* gene in place of the intact *fcs* gene encoding feruloyl-CoA synthetase (Fig.1h; Fig. 2h).
9. *Pseudomonas* sp. HR199 $\text{fcs}\Delta$, which contains the deletion-inactivated *fcs* gene in place of the intact *fcs* gene encoding feruloyl-CoA synthetase (Fig.1i; Fig. 2i).
10. *Pseudomonas* sp. HR199 $\text{ech}\Omega\text{Km}$, which contains the ΩKm -inactivated *ech* gene in place of the intact *ech* gene encoding enoyl-CoA hydratase-aldolase (Fig.1j; Fig. 2j).
11. *Pseudomonas* sp. HR199 $\text{ech}\Omega\text{Gm}$, which contains the ΩGm -inactivated *ech* gene in place of the intact *ech* gene encoding enoyl-CoA hydratase-aldolase (Fig.1k; Fig. 2k).

12. *Pseudomonas* sp. HR199 $\text{ech}\Delta$, which contains the deletion-inactivated *ech* gene in place of the intact *ech* gene encoding enoyl-CoA hydratase-aldolase (Fig.1l; Fig. 2l).
13. *Pseudomonas* sp. HR199 $\text{aat}\Omega\text{Km}$, which contains the ΩKm -inactivated *aat* gene in place of the intact *aat* gene encoding beta-ketothiolase (Fig. 1m; Fig. 2m).
14. *Pseudomonas* sp. HR199 $\text{aat}\Omega\text{Gm}$, which contains the ΩGm -inactivated *aat* gene in place of the intact *aat* gene encoding beta-ketothiolase (Fig. 1n; Fig. 2n).
15. *Pseudomonas* sp. HR199 $\text{aat}\Delta$, which contains the deletion-inactivated *aat* gene in place of the intact *aat* gene encoding beta-ketothiolase (Fig. 1o; 2o).
16. *Pseudomonas* sp. HR199 $\text{vdh}\Omega\text{Km}$, which contains the ΩKm -inactivated *vdh* gene in place of the intact *vdh* gene encoding vanillin dehydrogenase (Fig. 1p; Fig. 2p).
17. *Pseudomonas* sp. HR199 $\text{vdh}\Omega\text{Gm}$, which contains the ΩGm -inactivated *vdh* gene in place of the intact *vdh* gene encoding vanillin dehydrogenase (Fig. 1q; Fig. 2q).
18. *Pseudomonas* sp. HR199 $\text{vdh}\Delta$, which contains the deletion-inactivated *vdh* gene in place of the intact *vdh* gene encoding vanillin dehydrogenase (Fig. 1r; Fig. 2r).
19. *Pseudomonas* sp. HR199 $\text{vdhB}\Omega\text{Km}$, which contains the ΩKm -inactivated *vdhB* gene in place of the intact *vdhB* gene encoding vanillin dehydrogenase II.
20. *Pseudomonas* sp. HR199 $\text{vdhB}\Omega\text{Gm}$, which contains the ΩGm -inactivated *vdhB* gene in place of the intact *vdhB* gene encoding vanillin dehydrogenase II.
21. *Pseudomonas* sp. HR199 $\text{vdhB}\Delta$, which contains the deletion-inactivated *vdhB* gene in place of the intact *vdhB* gene encoding vanillin dehydrogenase II.
22. *Pseudomonas* sp. HR199 $\text{adh}\Omega\text{Km}$, which contains the ΩKm -inactivated *adh* gene in place of the intact *adh* gene encoding alcohol dehydrogenase.

23. *Pseudomonas* sp. HR199 $\Delta adh\Omega Gm$, which contains the ΩGm -inactivated *adh* gene in place of the intact *adh* gene encoding alcohol dehydrogenase.
24. *Pseudomonas* sp. HR199 Δadh which contains the deletion-inactivated *adh* gene in place of the intact *adh* gene encoding alcohol dehydrogenase.
- 5 25. *Pseudomonas* sp. HR199 $\Delta vanA\Omega Km$, which contains the ΩKm -inactivated *vanA* gene in place of the intact *vanA* gene encoding the α -subunit of vanillic acid demethylase.
26. *Pseudomonas* sp. HR199 $\Delta vanA\Omega Gm$, which contains the ΩGm -inactivated *vanA* gene in place of the intact *vanA* gene encoding the α -subunit of vanillic acid demethylase.
- 10 27. *Pseudomonas* sp. HR199 $\Delta vanA$, which contains the deletion-inactivated *vanA* gene in place of the intact *vanA* gene encoding the α -subunit of vanillic acid demethylase.
28. *Pseudomonas* sp. HR199 $\Delta vanB\Omega Km$, which contains the ΩKm -inactivated *vanB* gene in place of the intact *vanB* gene encoding the β -subunit of vanillic acid demethylase.
- 15 29. *Pseudomonas* sp. HR199 $\Delta vanB\Omega Gm$, which contains the ΩGm -inactivated *vanB* gene in place of the intact *vanB* gene encoding the β -subunit of vanillic acid demethylase.
- 20 30. *Pseudomonas* sp. HR199 $\Delta vanB$, which contains the deletion-inactivated *vanB* gene in place of the intact *vanB* gene encoding the β -subunit of vanillic acid demethylase.

25 The invention additionally relates to a process for the biotechnological preparation of organic compounds. In particular, this process can be used to prepare alcohols, aldehydes and organic acids. The latter are preferably coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and vanillic acid.

30 The above-described organisms are employed in the novel process. The organisms which are very particularly preferred include bacteria, in particular the *Pseudomonas*

species. Specifically, the abovementioned *Pseudomonas* species can preferably be employed for the following processes:

1. *Pseudomonas* sp. HR199calA Ω Km, *Pseudomonas* sp. HR199calA Ω Gm and
5 *Pseudomonas* sp. HR199calA Δ for preparing coniferyl alcohol from eugenol.
2. *Pseudomonas* sp. HR199calB Ω Km, *Pseudomonas* sp. HR199calB Ω Gm and
10 *Pseudomonas* sp. HR199calB Δ for preparing coniferyl aldehyde from eugenol
or coniferyl alcohol.
3. *Pseudomonas* sp. HR199fcs Ω Km, *Pseudomonas* sp. HR199fcs Ω Gm, *Pseu-*
15 *domonas* sp. HR199fcs Δ , *Pseudomonas* sp. HR199ech Ω Km, *Pseudomonas*
sp. HR199ech Ω Gm and *Pseudomonas* sp. HR199ech Δ for preparing ferulic
acid from eugenol or coniferyl alcohol or coniferyl aldehyde.
4. *Pseudomonas* sp. HR199vdh Ω Km, *Pseudomonas* sp. HR199vdh Ω Gm, *Pseu-*
20 *domonas* sp. HR199vdh Δ , *Pseudomonas* sp. HR199vdh Ω GmvdhB Ω Km,
Pseudomonas sp. HR199vdh Ω KmvdhB Ω Gm, *Pseudomonas* sp. HR199vdh Δ
vdhB Ω Gm and *Pseudomonas* sp. HR199vdh Δ vdhB Ω Km for preparing
vanillin from eugenol or coniferyl alcohol or coniferyl aldehyde or ferulic
acid.
5. *Pseudomonas* sp. HR199vanA Ω Km, *Pseudomonas* sp. HR199vanA Ω Gm,
25 *Pseudomonas* sp. HR199vanA Δ , *Pseudomonas* sp. HR199vanB Ω Km,
Pseudomonas sp. HR199vanB Ω Gm and *Pseudomonas* sp. HR199vanB Δ for
preparing vanillic acid from eugenol or coniferyl alcohol or coniferyl
aldehyde or ferulic acid or vanillin.

Eugenol is the preferred substrate. However, it is also possible to add further
30 substrates or even to replace the eugenol with another substrate.

Suitable nutrient media for the organisms which are employed in accordance with the invention are synthetic, semisynthetic or complex culture media. These media may comprise carbon-containing and nitrogen-containing compounds, inorganic salts, where appropriate trace elements, and vitamins.

5

Carbon-containing compounds which may be suitable are carbohydrates, hydrocarbons or organic standard chemicals. Examples of compounds which may preferably be used are sugars, alcohols or sugar alcohols, organic acids or complex mixtures.

10

The sugar is preferably glucose. The organic acids which may preferably be employed are citric or acetic acid. Examples of the complex mixtures are malt extract, yeast extract, casein or casein hydrolysate.

15

Inorganic compounds are suitable nitrogen-containing substrates. Examples of these are nitrates and ammonium salts. Organic nitrogen sources can also be used. These sources include yeast extract, soya bean meal, casein, casein hydrolysate and corn steep liquor.

20

Examples of the inorganic salts which may be employed are sulphates, nitrates, chlorides, carbonates and phosphates. The metals which the said salts contain are preferably sodium, potassium, magnesium, manganese, calcium, zinc and iron.

25

The temperature for the culture is preferably in the range from 5 to 100°C. The range from 15 to 60°C is particularly preferred, with 22 to 37°C being most preferred.

The pH of the medium is preferably 2 to 12. The range from 4 to 8 is particularly preferred.

30

In principle, any bioreactor known to the skilled person can be employed for carrying out the novel process. Preferential consideration is given to any appliance which is

suitable for submerged processes. This means that vessels which do or do not possess a mechanical mixing device may be employed in accordance with the invention. Examples of the latter are shaking apparatuses, and bubble column reactors or loop reactors. The former preferably include all the known appliances which are fitted with stirrers of any design.

The novel process can be carried out continuously or batchwise. The fermentation time required for achieving a maximum quantity of product depends on the specific nature of the organism employed. However, in principle, the fermentation times are between 2 and 200 hours.

The invention is explained in more detail below while referring to examples:

Mutants of the eugenol-utilizing strain *Pseudomonas* sp. HR199 (DSM 7063) were generated in a targeted manner by specifically inactivating genes of eugenol catabolism by means of inserting omega elements or introducing deletions. The omega elements employed were DNA segments which encoded resistances to the antibiotics kanamycin (Ω Km) and gentamycin (Ω Gm). These resistance genes were isolated from Tn5 and the plasmid pBBR1MCS-5 using standard methods. The genes *calA*, *calB*, *fcs*, *ech*, *aat*, *vdh*, *adh*, *vdhB*, *vanA* and *vanB*, which encode coniferyl alcohol dehydrogenase, coniferyl aldehyde dehydrogenase, feruloyl-CoA synthetase, enoyl-CoA hydratase-aldolase, beta-ketothiolase, vanillin dehydrogenase, alcohol dehydrogenase, vanillin dehydrogenase II and vanillic acid demethylase, were isolated from genomic DNA of the strain *Pseudomonas* sp. HR199 using standard methods and cloned into pBluescript SK⁻. By means of digesting with suitable restriction endonucleases, DNA segments were removed from these genes (deletion) or substituted with Ω elements (insertion), resulting in the respective gene being inactivated. The genes which had been mutated in this manner were recloned into conjugatively transferable vectors and subsequently introduced into the strain *Pseudomonas* sp. HR199. Suitable selection was used to obtain transconjugants which had replaced the respective functional wild-type gene with the newly

introduced inactivated gene. The insertion and deletion mutants which were obtained in this way now only possessed the respective inactivated gene. This procedure was used to obtain both mutants possessing only one defective gene and multiple mutants, in which several genes had been inactivated in this manner. These mutants were employed for biotransforming

a) eugenol into coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid;

b) coniferyl alcohol into coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid;

c) coniferyl aldehyde into ferulic acid, vanillin and/or vanillic acid;

d) ferulic acid into vanillin and/or vanillic acid, and

e) vanillin into vanillic acid.

Materials and Methods

Conditions for growing the bacteria.

5 Strains of *Escherichia coli* were propagated at 37°C in Luria-Bertani (LB) or M9 mineral medium (J. Sambrook, E. F. Fritsch and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd Edition., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). Strains of *Pseudomonas* sp. were propagated at 30°C in Nutrient Broth (NB, 0.8%, wt/vol) or in mineral medium (MM) (H. G. Schlegel, et al. 1961. Arch. Mikrobiol. **38**:209-222) or HR mineral medium (HR-MM) (J. Rabenhorst, 1996. Appl. Microbiol. Biotechnol. **46**:470-474.). Ferulic acid, 10 vanillin, vanillic acid and protocatechuic acid were dissolved in dimethyl sulphoxide and added to the respective medium to give a final concentration of 0.1% (wt/vol). Eugenol was either added directly to the medium to give a final concentration of 0.1% (vol/vol) or applied to filter paper (circular filter 595, Schleicher & Schuell, 15 Dassel, Germany) in the lids of MM agar plates. When transconjugants and mutants of *Pseudomonas* sp. were being propagated, tetracycline, kanamycin and gentamycin were employed in final concentrations of 25 µg/ml, 100 µg/ml and 7.5 µg/ml, respectively.

20 Qualitative and quantitative detection of metabolic intermediates in culture supernatants.

Culture supernatants were analysed by high pressure liquid chromatography (Knauer HPLC) either directly or after dilution with doubly distilled H₂O. The chromatography was carried out on Nucleosil 100 C18 (7 µm, 250 x 4 mm). 0.1% 25 (vol/vol) formic acid and acetonitrile was used as the solvent. The course of the gradient employed for eluting the substances was as follows:

00:00 - 06:30 → 26% acetonitrile
06:30 - 08:00 → 100% acetonitrile
30 08:00 - 12:00 → 100% acetonitrile
12:00 - 13:00 → 26% acetonitrile
13:00 - 18:00 → 26% acetonitrile

Purification of vanillin dehydrogenase II.

The purification was carried out at 4°C.

5 Crude extract.

Pseudomonas sp. HR199 cells which had been propagated on eugenol were washed in 10 mM sodium phosphate buffer, pH 6.0, then resuspended in the same buffer and disrupted by being passed twice through a French press (Amicon, Silver Spring, Maryland, USA) at a pressure of 1000 psi. The cell homogenate was subjected to an
10 ultracentrifugation (1 h, 100,000 x g, 4°C), resulting in the soluble fraction of crude extract being obtained as the supernatant.

Anion exchange chromatography on DEAE Sephacel.

The soluble fraction of the crude extract was dialysed overnight against 10 mM
15 sodium phosphate buffer, pH 6.0. The dialysate was loaded onto a DEAE-Sephacel column (2.6 cm x 35 cm, bed volume[BV]: 186 ml) which had been equilibrated with 10 mM sodium phosphate buffer, pH 6.0, and which had a flow rate of 0.8 ml/min. The column was rinsed with two BV of 10 mM sodium phosphate buffer, pH 6.0. The vanillin dehydrogenase II (VDH II) was eluted with a linear salt
20 gradient of from 0 to 400 mM NaCl in 10 mM sodium phosphate buffer, pH 6.0 (750 ml). 10 ml fractions were collected. Fractions having a high VDH II activity were combined to form the DEAE pool.

Determining the vanillin dehydrogenase activity.

25 The VDH activity was determined at 30°C using an optical enzymic test. The reaction mixture, whose volume was 1 ml, contained 0.1 mmol of potassium phosphate (pH 7.1), 0.125 µmol of vanillin, 0.5 µmol of NAD, 1.2 µmol of pyruvate (Na salt), lactate dehydrogenase (1 U; from pig heart) and enzyme solution. The oxidation of vanillin was monitored at $\lambda = 340$ nm ($\epsilon_{\text{vanillin}} = 11.6 \text{ cm}^2/\mu\text{mol}$). The
30 enzyme activity was given in units (U), with 1 U corresponding to the quantity of enzyme which converts 1 µmol of vanillin per minute. The protein concentrations in

the samples were determined using the method of Lowry et al. (O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall. 1951. J. Biol. Chem. **193**:265-275).

Determining the coniferyl alcohol dehydrogenase activity.

5 The CADH activity was determined at 30°C using an optical enzymic test in accordance with Jaeger et al. (E. L. Jaeger, Eggeling and H. Sahm. 1981. Current Microbiology. **6**:333-336). The reaction mixture, whose volume was 1 ml, contained 0.2 mmol of tris/HCl (pH 9.0), 0.4 μ mol of coniferyl alcohol, 2 μ mol of NAD, 0.1 mmol of semicarbazide and enzyme solution. The reduction of NAD was
10 monitored at $\lambda = 340$ nm ($\epsilon = 6.3$ cm²/ μ mol). The enzyme activity was given units (U), with 1 U corresponding to the quantity of enzyme which converts 1 μ mol of substrate per minute. The protein concentrations in the samples were determined by the method of Lowry et al. (O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall. 1951. J. Biol. Chem. **193**:265-275).

15

Determining the coniferyl aldehyde dehydrogenase activity.

The CALDH activity was determined at 30°C using an optical enzymic test. The reaction mixture, whose volume was 1 ml, contained 0.1 mmol of tris/HCl (pH 8.8), 0.08 μ mol of coniferyl aldehyde, 2.7 μ mol of NAD and enzyme solution. The
20 oxidation of coniferyl aldehyde to ferulic acid was monitored at $\lambda = 400$ nm ($\epsilon = 34$ cm²/ μ mol). The enzymic activity was given in units (U) with 1 U corresponding to the quantity of enzyme which converts 1 μ mol of substrate per minute. The protein concentrations in the samples were determined by the method of Lowry et al. (O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall. 1951. J. Biol. Chem.
25 **193**:265-275).

Determining the feruloyl-CoA synthetase (ferulic acid thiokinase) activity.

The FCS activity was determined at 30°C using an optical enzymic test which was a modification of that of Zenk et al. (Zenk et al. 1980. Anal. Biochem. **101**:182-187).
30 The reaction mixture, whose volume was 1 ml, contained 0.09 mmol of potassium phosphate (pH 7.0), 2.1 μ mol of MgCl₂, 0.7 μ mol of ferulic acid, 2 μ mol of ATP,

0.4 μmol of coenzyme A and enzyme solution. The formation of the CoA ester from ferulic acid was monitored at $\lambda = 345 \text{ nm}$ ($\epsilon = 10 \text{ cm}^2/\mu\text{mol}$). The enzymic activity was given in units (U), with 1 U corresponding to the quantity of enzyme which converts 1 μmol of substrate per minute. The protein concentrations in the samples were determined using the method of Lowry et al. (O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall. 1951. J. Biol. Chem. **193**:265-275).

Electrophoretic methods.

Protein-containing extracts were fractionated under native conditions in 7.4% (wt/vol) polyacrylamide gels using the method of Stegmann et al. (Stegmann et al. 1973. Z. Naturforsch. **28c**:722-732) and under denaturing conditions in 11.5% (wt/vol) polyacrylamide gels using the method of Laemmli (Laemmli, U. K. 1970. Nature (London) **227**:680-685). Serva Blue R was used for non-specific protein staining. For specifically staining the coniferyl alcohol dehydrogenase, coniferyl aldehyde dehydrogenase and vanillin dehydrogenase, the gels were rebuffed for 20 min in 100 mM KP buffer (pH 7.0) and subsequently incubated at 30°C in the same buffer to which 0.08% (wt/vol) NAD, 0.04% (wt/vol) p-nitro blue tetrazolium chloride, 0.003% (wt/vol) phenazine methosulphate and 1 mM of the respective substrate had been added until corresponding colour bands became visible.

Transfer of proteins from polyacrylamide gels to PVDF membranes.

Proteins were transferred from SDS-polyacrylamide gels to PVDF membranes (Waters-Millipore, Bedford, Mass., USA) using a Semidry Fastblot appliance (B32/33, Biometra, Göttingen, Germany) in accordance with the manufacturer's instructions.

Determining N-terminal amino acid sequences.

N-terminal amino acid sequences were determined using a Protein Peptide Sequencer (Type 477 A, Applied Biosystems, Foster City, USA) and a PTH analyser in accordance with the manufacturer's instructions.

Isolating and manipulating DNA

Genomic DNA was isolated using the method of Marmur (J. Marmur, 1961. J. Mol. Biol. 3:208-218). Other plasmid DNA and/or DNA restriction fragments was/were isolated and analysed using standard methods (J. E. Sambrook, F. Fritsch and
5 T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd Edition., Cold Spring Harbor Laboratory Press, Cold Spring Habor, New York).

Transferring DNA.

Competent *Escherichia coli* cells were prepared and transformed using the method of
10 Hanahan (D. Hanahan, 1983. J. Mol. Biol. 166:557-580). Conjugative plasmid transfer between plasmid-harboursing *Escherichia coli* S17-1 strains (donor) and *Pseudomonas* sp.strains (recipient) was performed on NB agar plates in accordance with the method of Friedrich et al. (B. Friedrich et al. 1981. J. Bacteriol. 147:198-205), or by means of a "minicomplementation method" on MM agar plates
15 containing 0.5% (wt/vol) gluconate as the C source and 25 µg of tetracycline/ml or 100 µg of kanamycin/ml. In this case, cells of the recipient were applied in one direction as an inoculation streak. After 5 min, cells of the donor strains were then applied as inoculation streaks, with these streaks crossing the recipient inoculation streak. After incubating at 30°C for 48 h, the transconjugants grew directly
20 downstream of the crossing site whereas neither the donor strain nor the recipient strain was able to grow.

Hybridization experiments.

DNA restriction fragments were fractionated electrophoretically in a 0.8% (wt/vol)
25 agarose gel in 50 mM tris- 50 mM boric acid- 1.25 mM EDTA buffer (pH 8.5) (J. E. Sambrook, F. Fritsch and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.). The transfer of the denatured DNA out of the gel onto a positively charged nylon membrane (pore size: 0.45 µm, Pall Filtrationstechnik, Dreieich, Germany), the
30 subsequent hybridization with biotinylated or digoxigenin-labelled DNA probes, and the preparation of these DNA probes, were all performed using standard methods

(J. E. Sambrook, F. Fritsch and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

5 **DNA sequencing.**

Nucleotide sequences were determined "non-radioactively" in accordance with the Sanger et al. (Sanger et al. 1977. Proc. Natl. Acad. Sci. USA 74:5463-5467) dideoxy chain termination method using a "LI-COR" DNA Sequencer Model 4000L" (LI-COR Inc., Biotechnology Division, Lincoln, NE, USA) and using a "thermo
10 sequenase fluorescent labelled primer cycle sequencing kit with 7-deaza-dGTP" (Amersham Life Science, Amersham International plc., Little Chalfont, Buckinghamshire, England), in each case in accordance with the manufacturer's instructions.

15 Synthetic oligonucleotides were used to carry out sequencing in accordance with the "primer-hopping strategy" of Strauss et al. (E. C. Strauss et al. 1986. Anal. Biochem. 154:353-360).

Chemicals, biochemicals and enzymes.

20 Restriction enzymes, T4 DNA ligase, lambda DNA and enzymes and substrates for the optical enzymic tests were obtained from C.F. Boehringer & Söhne (Mannheim, Germany) or from GIBCO/BRL (Eggenstein, Germany). [γ -³²P]ATP was from Amersham/Buchler (Braunschweig, Germany). Oligonucleotides were obtained from MWG-Biotech GmbH (Ebersberg, Germany). Type NA agarose was obtained from
25 Pharmacia-LKB (Uppsala, Sweden). All other chemicals were from Haarmann & Reimer (Holzminden, Germany), E. Merck AG (Darmstadt, Germany), Fluka Chemie (Buchs, Switzerland), Serva Feinbiochemica (Heidelberg, Germany) or Sigma Chemie (Deisenhofen, Germany).

Examples

Example 1

Constructing omega elements which mediate resistances to kanamycin (Ω Km) or gentamycin (Ω Gm).

For constructing the Ω Km element, the 2099 bp *Bgl*II fragment of Transposons Tn5 (E. A. Auerswald, G. Ludwig and H. Schaller. 1981. Cold Spring Harb. Symp. Quant. Biol. **45**:107-113; E. Beck, G. Ludwig, E. A. Auerswald, B. Reiss and H. Schaller. 1982. Genes **19**:327-336; P. Mazodier, P. Cossart, E. Giraud and F. Gasser. 1985. Nucleic Acids Res. **13**:195-205) was isolated on a preparative scale. The fragment was shortened down to approx. 990 bp by treating it with Bal 31 nuclease. This fragment, which now only comprised the kanamycin resistance gene (encoding an aminoglycoside-3'-O-phosphotransferase), was then ligated to *Sma*I-cut pSKsym DNA (pBluescript SK⁻ derivative which contains a symmetrically constructed multiple cloning site [*Sal*I, *Hind*III, *Eco*RI, *Sma*I, *Eco*RI, *Hind*III, *Sal*I]). It was possible to reisolate the Ω Km element from the resulting plasmid as a *Sma*I fragment, an *Eco*RI fragment, a *Hind*III fragment or a *Sal*I fragment.

For constructing the Ω Gm element, the 983 bp *Eae*I fragment of the plasmid pBR1MCS-5 (M. E. Kovach, P. H. Elzer, D. S. Hill, G. T. Robertson, M. A. Farris, R. M. Roop and K. M. Peterson. 1995. Genes **166**:175-176) was isolated on a preparative scale and then treated with mung bean nuclease (progressive digestion of single-stranded DNA molecule ends). This fragment, which now only comprised the gentamycin resistance gene (encoding a gentamycin-3-acetyltransferase), was then ligated to *Sma*I-cleaved pSKsym DNA (see above). It was possible to reisolate the Ω Gm element from the resulting plasmid as a *Sma*I fragment, an *Eco*RI fragment, a *Hind*III fragment or a *Sal*I fragment.

Example 2

Cloning the genes from *Pseudomonas* sp. HR199 (DSM7063) which were to be inactivated by inserting Ω elements or by means of deletions.

5 The *fcs*, *ech*, *vdh* and *aat* genes were cloned separately proceeding from the *E. coli* S17-1 strains DSM 10439 and DSM 10440 and using the plasmids pE207 and pE5-1 (see EP-A 0845532). The given fragments were isolated on a preparative scale from these plasmids and treated as described below:

10 For cloning the *fcs* gene, the 2350 bp *SalI*/*EcoRI* fragment from plasmid pE207 and the 3700 bp *EcoRI*/*SalI* fragment from plasmid pE5-1 were cloned together in pBluescript SK⁻ such that the two fragments were joined together by way of the *EcoRI* ends. The 6050 bp *SalI* fragment was isolated on a preparative scale from the resulting hybrid plasmid and shortened down to approx. 2480 bp by being treated
15 with Bal 31 nuclease. *PstI* linkers were subsequently ligated to the ends of the fragment and, after digestion with *PstI*, the fragment was cloned into pBluescript SK⁻ (pSK*fcs*). After transformation of *E. coli* XL1 blue, clones were obtained which expressed the *fcs* gene and exhibited an FCS activity of 0.2 U/mg of protein.

20 For cloning the *ech* gene, the 3800 bp *HindIII*/*EcoRI* fragment from plasmid pE207 was isolated on a preparative scale and shortened down to approx. 1470 bp by treating it with Bal 31 nuclease. *EcoRI* linkers were then ligated to the ends of the fragment and, after digestion with *EcoRI*, the fragment was cloned into pBluescript SK⁻ (pSK*ech*).

25 For cloning the *vdh* gene, the 2350 bp *SalI*/*EcoRI* fragment from plasmid pE207 was isolated on a preparative scale. After cloning into pBluescript SK⁻, the fragment was truncated at one end by approx. 1530 bp using an exonuclease III/mung bean nuclease system. An *EcoRI* linker was then ligated to the end of the fragment and,
30 after digestion with *EcoRI*, the fragment was cloned into pBluescript SK⁻ (pSK*vdh*).

Following transformation of *E. coli* XL1 blue, clones were obtained which expressed the VDH gene and exhibited a VDH activity of 0.01 U/mg of protein.

For cloning the *aat* gene, the 3700 bp *EcoRI/SalI* fragment from plasmid pE5-1 was isolated on a preparative scale and shortened down to approx. 1590 bp by treating it with Bal 31 nuclease. *EcoRI* linkers were then ligated to the ends of the fragment and, after digestion with *EcoRI*, the fragment was cloned into pBluescript SK⁻ (pSK_{*aat*}).

Example 3

Inactivating the above-described genes by inserting Ω elements or by deleting constituent regions of these genes.

Plasmid pSK_{*fcs*}, which contained the *fcs* gene, was digested with *Bss*HII, resulting in a 1290 bp fragment being excised from the *fcs* gene. Following religation, the deletion derivative of the *fcs* gene (*fcs* Δ) (see Figs. 1i and 2i) was obtained in cloned form in pBluescript SK⁻ (pSK_{*fcs*} Δ). In addition, after the fragment had been excised, the omega elements Ω Km and Ω Gm were ligated in its stead. This resulted in the Ω -inactivated derivatives of the *fcs* gene (*fcs* Ω Km, see Figs. 1g and 2g) and (*fcs* Ω Gm, see Fig. 1h and 2h) being obtained in cloned form in pBluescript SK⁻ (pSK_{*fcs*} Ω Km and pSK_{*fcs*} Ω Gm). It was not possible to detect any FCS activity in crude extracts of the resulting *E. coli* clones, whose hybrid plasmids possessed an *fcs* gene which was inactivated by deletion or by Ω element insertion.

Plasmid pSK_{*ech*}, which contained the *ech* gene, was digested with *Nru*I, resulting in a 53 bp fragment and a 430 bp fragment being excised from the *ech* gene. After religation, the deletion derivative of the *ech* gene (*ech* Δ , see Fig. 1l and 2l) was obtained in cloned form in pBluescript SK⁻ (pSK_{*ech*} Δ). In addition, after the fragments had been excised, the omega elements Ω Km and Ω Gm were ligated in their stead. This resulted in the Ω -inactivated derivatives of the *ech* gene (*ech* Ω Km

and *ech*ΩGm) being obtained in cloned form in pBluescript SK⁻ (pSK*ech*ΩKm and pSK*ech*ΩGm).

5 Plasmid pSK*vdh*, which contained the *vdh* gene, was digested with BssHII, resulting in a 210 bp fragment being excised from the *vdh* gene. After religation, the deletion derivative of the *vdh* gene (*vdh*Δ, see Figs. 1o and 2o) was obtained in cloned form in pBluescript SK⁻ (pSK*vdh*Δ). In addition, after the fragment had been excised, the omega elements ΩKm and ΩGm were ligated in its stead. This resulted in the Ω-inactivated derivatives of the *vdh* gene (*vdh*ΩKm and *vdh*ΩGm) being obtained in
10 cloned form in pBluescript SK⁻ (pSK*vdh*ΩKm, see Figs. 1m and 2m) and (pSK*vdh*ΩGm, see Figs. 1n and 2n). It was not possible to detect any VDH activity in crude extracts of the resulting *E. coli* clones, whose hybrid plasmids possessed a *vdh* gene which was inactivated by deletion or by Ω element insertion.

15 Plasmid pSK*aat*, which contained the *aat* gene, was digested with BssHII, resulting in a 59 bp fragment being excised from the *aat* gene. After religation, the deletion derivative of the *aat* gene (*aat*Δ, see Figs. 1r and 2r) was obtained in cloned form in pBluescript SK⁻ (pSK*aat*Δ). In addition, after the fragment had been excised, the omega elements ΩKm and ΩGm were ligated in its stead. This resulted in the Ω-inactivated derivatives of the *aat* gene (*aat*ΩKm, see Figs. 1p and 2p) and (*aat*ΩGm, see Figs. 1q and 2q) being obtained in cloned form in pBluescript SK⁻ (pSK*aat*ΩKm and pSK*aat*ΩGm).
20

Example 4

Subcloning the Ω element-inactivated genes into the conjugatively transferable "suicide plasmid" pSUP202.

5 In order to be able to replace the intact genes in *Pseudomonas* sp. HR199 with the Ω -element inactivated genes, there is a need for a vector which can, on the one hand, be transferred into pseudomonads (conjugatively transferable plasmids) but which, on the other hand, cannot replicate in these bacteria and is consequently unstable in pseudomonads ("suicide plasmid"). DNA segments which are transferred into
10 pseudomonads using such a plasmid system can only be retained if they are integrated by means of homologous recombination (RecA-dependent recombination) into the genome of the bacterial cell. In the present case, the "suicide plasmid" pSUP202 (Simon et al. 1983. In: A. Pühler. Molecular genetics of the bacteria-plant interaction. Springer Verlag, Berlin, Heidelberg, New York, pp. 98-106) was used.

15 Following digestion with *Pst*I, the inactivated genes *fcs* Ω Km and *fcs* Ω Gm were isolated from plasmids pSK*fcs* Ω Km and pSK*fcs* Ω Gm and ligated to *Pst*I-cleaved pSUP202 DNA. The ligation mixtures were transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium which also contained kanamycin or
20 gentamycin, respectively. Kanamycin-resistant transformants whose hybrid plasmid (pSUP*fcs* Ω Km) contained the inactivated gene *fcs* Ω Km were obtained. The corresponding hybrid plasmid (pSUP*fcs* Ω Gm) of the gentamycin-resistant transformants contained the inactivated gene *fcs* Ω Gm.

25 Following *Eco*RI digestion, the inactivated genes *ech* Ω Km and *ech* Ω Gm were isolated from plasmids pSKE*ech* Ω Km and pSKE*ech* Ω Gm and ligated to *Eco*RI-cleaved pSUP202 DNA. The ligation mixtures were transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium which also contained kanamycin or gentamycin, respectively. Kanamycin-resistant transformants whose hybrid plasmid
30 (pSUP*ech* Ω Km) contained the inactivated gene *ech* Ω Km were obtained. The

corresponding hybrid plasmid (pSUP ϵ ch Ω Gm) of the gentamycin-resistant transformants contained the inactivated gene *ech* Ω Gm.

Following *Eco*RI digestion, the inactivated genes *vdh* Ω Km and *vdh* Ω Gm were isolated from plasmids pSK*vdh* Ω Km and pSK*vdh* Ω Gm and ligated to *Eco*RI-cleaved pSUP202 DNA. The ligation mixtures were transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium which also contained kanamycin or gentamycin, respectively. Kanamycin-resistant transformants whose hybrid plasmid (pSUP*vdh* Ω Km) contained the inactivated gene *vdh* Ω Km were obtained. The corresponding hybrid plasmid (pSUP*vdh* Ω Gm) of the gentamycin-resistant transformants contained the inactivated gene *vdh* Ω Gm.

Following *Eco*RI digestion, the inactivated genes *aat* Ω Km and *aat* Ω Gm were isolated from plasmids pSK*aat* Ω Km and pSK*aat* Ω Gm and ligated to *Eco*RI-cleaved pSUP202 DNA. The ligation mixtures were transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium which also contained kanamycin or gentamycin, respectively. Kanamycin-resistant transformants whose hybrid plasmid (pSUP*aat* Ω Km) contained the inactivated gene *aat* Ω Km were obtained. The corresponding hybrid plasmid (pSUP*aat* Ω Gm) of the gentamycin-resistant transformants contained the inactivated gene *aat* Ω Gm.

Example 5

Subcloning the deletion-inactivated genes into the conjugatively transferable “suicide plasmid” PHE55, which possesses the “*sacB* selection system”.

In order to be able to replace the intact genes in *Pseudomonas* sp. HR199 with the deletion-inactivated genes, there is a need for a vector which possesses the properties which have already been described in the case of pSUP202. Since no possibility (no antibiotic resistance) exists of selecting for successful replacement of the genes in *Pseudomonas* sp. HR199 in the case of deletion-inactivated genes, in contrast to the Ω element-inactivated genes, another selection system had to be used. In the “*sacB*

selection system", the replacing, deletion-inactivated gene is cloned in a plasmid which possesses the *sacB* gene in addition to an antibiotic resistance gene. Following the conjugative transfer of this hybrid plasmid into a pseudomonad, the plasmid is integrated by means of homologous recombination at the site in the genome at which the intact gene is located (first crossover). This results in a "heterogenetic" strain which possesses both an intact gene and a deletion-inactivated gene, with these genes being separated from each other by the pHE55 DNA. These strains exhibit the resistance which is encoded by the vector and also possess an active *sacB* gene. The intention then is that the pHE55 DNA, together with the intact gene, should then be separated out of the genomic DNA by means of a second homologous recombination event (second crossover). This recombination event results in a strain which now only possesses the inactivated gene. In addition, the pHE55-coded antibiotic resistance and the *sacB* gene are both lost. If strains are streaked on sucrose-containing media, the growth of strains which express the *sacB* gene is inhibited since the gene product converts sucrose into a polymer which is accumulated in the periplasm of the cells. The growth of cells which no longer carry the *sacB* gene as a result of the second recombination event having taken place is consequently not inhibited. In order to have a possibility of selecting phenotypically for the integration of the deletion-inactivated gene, this gene is not exchanged for an intact gene; instead, use is made of a strain in which the gene to be replaced is already "labelled" by the insertion of an Ω element. When successful replacement takes place, the resulting strain loses the antibiotic resistance which is encoded by the Ω element.

Following digestion with *Pst*I, the inactivated gene *fcs* Δ was isolated from plasmid pSK*fcs* Δ and ligated to *Pst*I-cleaved pHE55 DNA. The ligation mixture was transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium. Tetracycline-resistant transformants, whose hybrid plasmid (pHE*fcs* Δ) contained the inactivated gene *fcs* Δ , were obtained.

Following digestion with *Eco*RI, the inactivated gene *ech* Δ was isolated from plasmid pSK*ech* Δ and treated with mung bean nuclease (generation of blunt ends).

The fragment was ligated to *Bam*HI-cleaved and mung bean nuclease-treated pHE55 DNA. The ligation mixture was transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium. Tetracycline-resistant transformants, whose hybrid plasmid (pHE*ech*Δ) contained the inactivated gene *ech*Δ, were obtained

5

Following digestion with *Eco*RI, the inactivated gene *vdh*Δ was isolated from plasmid pSK*vdh*Δ and treated with mung bean nuclease. The fragment was ligated to *Bam*HI-cleaved and mung bean nuclease-treated pHE55 DNA. The ligation mixture was transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium. Tetracycline-resistant transformants, whose hybrid plasmid (pHE*vdh*Δ) contained the inactivated gene *vdh*Δ, were obtained.

10

Following digestion with *Eco*RI, the inactivated gene *aat*Δ was isolated from plasmid pSK*aat*Δ and treated with mung bean nuclease. The fragment was ligated to *Bam*HI-cleaved and mung bean nuclease-treated pHE55 DNA. The ligation mixture was transformed into *E. coli* S17-1. Selection took place on tetracycline-containing LB medium. Tetracycline-resistant transformants, whose hybrid plasmid (pHE*aat*Δ) contained the inactivated gene *aat*Δ, were obtained.

15

20

Example 6

Generating mutants of the strain *Pseudomonas* sp. HR199 in which genes of eugenol catabolism have been specifically inactivated by inserting an Ω -element.

5 The strain *Pseudomonas* sp. HR199 was employed as the recipient in conjugation experiments in which strains of *E. coli* S17-1 harbouring the hybrid plasmids of pSUP202 which are listed below were used as donors. The transconjugants were selected on gluconate-containing mineral medium which contained the antibiotic corresponding to the Ω element. It was possible to distinguish between
10 “homogenotic” (replacement of the intact gene with the Ω element insertion-inactivated gene by means of a double crossover) and “heterogenotic” (integration of the hybrid plasmid into the genome by means of a single crossover) transconjugants on the basis of the pSUP202-encoded tetracycline resistance.

15 The mutants *Pseudomonas* sp. HR199 *fcs* Ω Km and *Pseudomonas* sp. HR199 *fcs* Ω Gm were obtained after conjugating *Pseudomonas* sp. HR199 with *E. coli* S17-1 (pSUP*fcs* Ω Km) and *E. coli* S17-1 (pSUP*fcs* Ω Gm), respectively. The replacement of the intact *fcs* gene with the Ω Km-inactivated or Ω Gm-inactivated gene (*fcs* Ω Km and *fcs* Ω Gm, respectively) was verified by means of DNA sequencing.

20 The mutants *Pseudomonas* sp. HR199 *ech* Ω Km and *Pseudomonas* sp. HR199 *ech* Ω Gm were obtained after conjugating *Pseudomonas* sp. HR199 with *E. coli* S17-1 (pSUP*ech* Ω Km) and *E. coli* S17-1 (pSUP*ech* Ω Gm), respectively. The replacement of the intact *ech* gene with the Ω Km-inactivated or Ω Gm-inactivated
25 gene (*ech* Ω Km and *ech* Ω Gm, respectively) was verified by means of DNA sequencing.

The mutants *Pseudomonas* sp. HR199 *vdh* Ω Km and *Pseudomonas* sp. HR199 *vdh* Ω Gm were obtained after conjugating *Pseudomonas* sp. HR199 with *E. coli*
30 S17-1 (pSUP*vdh* Ω Km) and *E. coli* S17-1 (pSUP*vdh* Ω Gm), respectively. The

replacement of the intact *vdh* gene with the Ω Km-inactivated or Ω Gm-inactivated gene (*vdh* Ω Km and *vdh* Ω Gm, respectively) was verified by means of DNA sequencing.

5 The mutants *Pseudomonas* sp. HR199 *aat* Ω Km and *Pseudomonas* sp. HR199 *aat* Ω Gm were obtained after conjugating *Pseudomonas* sp. HR199 with *E. coli* S17-1 (pSUP*aat* Ω Km) and *E. coli* S17-1 (pSUP*aat* Ω Gm), respectively. The replacement of the intact *aat* gene with the Ω Km-inactivated or Ω Gm-inactivated gene (*aat* Ω Km and *aat* Ω Gm, respectively) was verified by means of DNA sequencing.

10 The mutant *Pseudomonas* sp. HR199 *fcs* Ω Km*vdh* Ω Gm was obtained after conjugating *Pseudomonas* sp. HR199 *fcs* Ω Km with *E. coli* S17-1 (pSUP*vdh* Ω Gm). The replacement of the intact *vdh* gene with the Ω Gm-inactivated gene (*vdh* Ω Gm) was verified by means of DNA sequencing.

15 The mutant *Pseudomonas* sp. HR199 *vdh* Ω Km*aat* Ω Gm was obtained after conjugating *Pseudomonas* sp. HR199 *vdh* Ω Km with *E. coli* S17-1 (pSUP*aat* Ω Gm). The replacement of the intact *aat* gene with the Ω Gm-inactivated gene (*aat* Ω Gm) was verified by means of DNA sequencing.

20 The mutant *Pseudomonas* sp. HR199 *vdh* Ω Km*ech* Ω Gm was obtained after conjugating *Pseudomonas* sp. HR199 *vdh* Ω Km with *E. coli* S17-1 (pSUP*ech* Ω Gm). The replacement of the intact *ech* gene with the Ω Gm-inactivated gene (*ech* Ω Gm) was verified by means of DNA sequencing.

25

Example 7

Generating of mutants of the strain *Pseudomonas* sp. HR199 in which genes of eugenol catabolism have been specifically inactivated by deleting a constituent region.

The strains *Pseudomonas* sp. HR199 *fcs*ΩKm, *Pseudomonas* sp. HR199 *ech*ΩKm, *Pseudomonas* sp. HR199 *vdh*ΩKm and *Pseudomonas* sp. HR199 *aat*ΩKm were employed as recipients in conjugation experiments in which strains of *E. coli* S17-1 harbouring the hybrid plasmids of pHE55 which are listed below were used as donors. The “heterogenotic” transconjugants were selected on gluconate-containing mineral medium which also contained the antibiotic corresponding to the Ω element in addition to tetracycline (pHE55-encoded resistance). After streaking out on sucrose-containing mineral medium, transconjugants were obtained which had eliminated the vector DNA by means of a second recombination event (second crossover). By streaking out on mineral medium which was without antibiotic or which contained the antibiotic corresponding to the Ω element, it was possible to identify the mutants in which the Ω element-inactivated gene had been replaced with the deletion-inactivated gene (no antibiotic resistance).

The mutant *Pseudomonas* sp. HR199 *fcs*Δ was obtained after conjugating *Pseudomonas* sp. HR199 *fcs*ΩKm with *E. coli* S17-1 (pHE*fcs*Δ). The replacement of the ΩKm inactivated gene (*fcs*ΩKm) with the deletion-inactivated gene (*fcs*Δ) was verified by means of DNA sequencing.

The mutant *Pseudomonas* sp. HR199 *ech*Δ was obtained after conjugating *Pseudomonas* sp. HR199 *ech*ΩKm with *E. coli* S17-1 (pHE*ech*Δ). The replacement of the ΩKm-inactivated gene (*ech*ΩKm) with the deletion-inactivated gene (*ech*Δ) was verified by means of DNA sequencing.

The mutant *Pseudomonas* sp. HR199 *vdh*Δ was obtained after conjugating *Pseudomonas* sp. HR199 *vdh*ΩKm with *E. coli* S17-1 (pHE*vdh*Δ). The replacement

of the Ω Km-inactivated gene (*vdh* Ω Km) with the deletion-inactivated gene (*vdh* Δ) was verified by means of DNA sequencing.

5 The mutant *Pseudomonas* sp. HR199 *aat* Δ was obtained after conjugating *Pseudomonas* sp. HR199 *aat* Ω Km with *E. coli* S17-1 (pHE*aat* Δ). The replacement of the Ω Km-inactivated gene (*aat* Ω Km) with the deletion-inactivated gene (*aat* Δ) was verified by means of DNA sequencing.

Example 8

10

Biotransforming eugenol into vanillin using the mutant *Pseudomonas* sp. HR199 *vdh* Ω Km.

15 The strain *Pseudomonas* sp. HR199 *vdh* Ω Km was propagated in 50 ml of HR-MM containing 6 mM eugenol up to an optical density of approx. OD_{600nm} = 0.6. After 17 h, it was possible to detect 2.9 mM vanillin, 1.4 mM ferulic acid and 0.4 mM vanillic acid in the culture supernatant.

Example 9

20 **Biotransforming eugenol into ferulic acid using the mutant *Pseudomonas* sp. HR199 *vdh* Ω G*maat* Ω Km.**

25 The strain *Pseudomonas* sp. HR199 *vdh* Ω G*maat* Ω Km was propagated in 50 ml of HR-MM containing 6 mM eugenol up to an optical density of approx. OD_{600nm} = 0.6. After 18 h, it was possible to detect 1.9 mM vanillin, 2.4 mM ferulic acid and 0.6 mM vanillic acid in the culture supernatant.

Example 10

Biotransforming eugenol into coniferyl alcohol using the mutant *Pseudomonas* sp. HR199 *vdh* Ω Gmaat Ω Km.

5 The strain *Pseudomonas* sp. HR199 *vdh* Ω Gmaat Ω Km was propagated in 50 ml of HR-MM containing 6 mM eugenol up to an optical density of approx. OD_{600nm} = 0.4. After 15 h, it was possible to detect 1.7 mM coniferyl alcohol, 1.4 mM vanillin, 1.4 mM ferulic acid and 0.2 mM vanillic acid in the culture supernatant.

Example 11

Fermentatively producing natural vanillin from eugenol in a 10 l fermenter using mutant *Pseudomonas* sp. HR 199 *vdh* Ω Km.

15 The production fermenter was inoculated with 100 ml of a 24-hour-old preliminary culture which had been propagated at 32°C on a shaking incubator (120 rpm) in a medium which was adjusted to pH 7.0 and which consisted of 12.5 g of glycerol/l, 10 g of yeast extract/l and 0.37 g of acetic acid/l. The fermenter contained 9.9 l of medium of the following composition: 1.5 g of yeast extract/l, 1.6 g of KH₂PO₄/l, 0.2 g of NaCl/l, 0.2 g of MgSO₄/l. The pH was adjusted to pH 7.0 with sodium hydroxide solution. After sterilization, 4 g of eugenol were added to the medium. The
20 temperature was 32°C, the aeration was 3 NI/min and the stirrer speed was 600 rpm. The pH was maintained at pH 6.5 with sodium hydroxide solution.

At 4 hours after the inoculation, continuous addition of eugenol was begun such that
25 255 g of eugenol had been added to the culture when fermentation ended after 65 hours. 40 g of yeast extract were also fed in during the fermentation. At the end of the fermentation, the concentration of eugenol was 0.2 g/l. The content of vanillin was 2.6 g/l. 3.4 g of ferulic acid/l were also present.

The vanillin which is obtained in this way can be isolated by known physical methods such as chromatography, distillation and/or extraction and used for preparing natural flavourings.

5 Explanatory notes regarding the figures:

FIG. 1a to 1r:

Gene structures for isolating organisms and mutants

10

*calA**: Part of the inactivated gene for coniferyl alcohol dehydrogenase

*calB**: Part of the inactivated gene for coniferyl aldehyde dehydrogenase

*fcs**: Part of the inactivated gene for feruloyl-CoA synthetase

*ech**: Part of the inactivated gene for enoyl-CoA hydratase-aldolase

15

*vdh**: Part of the inactivated gene for vanillin dehydrogenase

*aat**: Part of the inactivated gene for beta-ketothiolase

While the restriction enzyme cleavage sites labelled "*" were used for the construction, they are no longer functional in the resulting construct.

20

FIG. 2a: Nucleotide sequence of the *calA*ΩKm gene structure

FIG. 2b: Nucleotide sequence of the *calA*ΩGm gene structure:

FIG. 2c: Nucleotide sequence of the *calA*Δ gene structure

FIG. 2d: Nucleotide sequence of the *calB*ΩKm gene structure

5 FIG. 2e: Nucleotide sequence of the *calB*ΩGm gene structure

FIG. 2f: Nucleotide sequence of the *calB*Δ gene structure

FIG. 2g: Nucleotide sequence of the *fcs*ΩKm gene structure

FIG. 2h: Nucleotide sequence of the *fcs*ΩGm gene structure

FIG. 2i: Nucleotide sequence of the *fcs*Δ gene structure

10 FIG. 2j: Nucleotide sequence of the *ech*ΩKm gene structure

FIG. 2k: Nucleotide sequence of the *ech*ΩGm gene structure

FIG. 2l: Nucleotide sequence of the *ech*Δ gene structure

FIG. 2m: Nucleotide sequence of the *vdh*ΩKm gene structure

FIG. 2n: Nucleotide sequence of the *vdh*ΩGm gene structure

15 FIG. 2o: Nucleotide sequence of the *vdh*Δ gene structure

FIG. 2p: Nucleotide sequence of the *aat*ΩKm gene structure

FIG. 2q: Nucleotide sequence of the *aat*ΩGm gene structure

FIG. 2r: Nucleotide sequence of the *aat*Δ gene structure

Patent claims

1. Transformed and/or mutagenized unicellular or multicellular organism which is characterized in that enzymes of eugenol and/or ferulic acid catabolism are inactivated such that the intermediates coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid accumulate.
2. Organism according to Claim 1, characterized in that eugenol and/or ferulic acid catabolism is altered by inserting Ω elements, or introducing deletions, into corresponding genes.
3. Organism according to either Claim 1 or 2, characterized in that one or more genes encoding the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin dehydrogenases or vanillic acid demethylases is/are altered and/or inactivated.
4. Organism according to one of Claims 1 to 3, characterized in that it is unicellular, preferably a microorganism or a plant or animal cell.
5. Organism according to one of Claims 1 to 4, characterized in that it is a bacterium, preferably a *Pseudomonas* species.
6. Gene structures in which the nucleotide sequences encoding the enzymes coniferyl alcohol dehydrogenases, coniferyl aldehyde dehydrogenases, feruloyl-CoA synthetases, enoyl-CoA hydratase-aldolases, beta-ketothiolases, vanillin-dehydrogenases or vanillic acid demethylases, or two or more of these enzymes, are altered and/or inactivated.
7. Gene structures having the sequences given in Figures 1a to 1r.

8. Gene structures having the sequences given in Figures 2a to 2r.
9. Vectors which contain at least one gene structure according to one of Claims 6 to 8.
- 5 10. Transformed organism according to one of Claims 1 to 5, characterized in that it harbours at least one vector according to Claim 9.
- 10 11. Organism according to one of Claims 1 to 5, characterized in that it contains at least one gene structure according to one of Claims 6 to 8 which is integrated into the genome instead of the respective intact gene.
- 15 12. Process for the biotechnological preparation of organic compounds, in particular alcohols, aldehydes and organic acids, characterized in that an organism according to one of Claims 1 to 5 or 10 to 11 is employed.
- 20 13. Process for preparing the organisms according to one of Claims 1 to 5, characterized in that the alteration eugenol and/or ferulic acid catabolism is achieved by means of microbiological culturing methods which are known per se.
- 25 14. Process for preparing an organism according to one of Claims 1 to 5 or 10 to 11, characterized in that the alteration in eugenol and/or ferulic acid catabolism, and/or the inactivation of the corresponding genes, is achieved by means of recombinant DNA methods.
15. Use of the organisms according to one of Claims 1 to 5 or 10 to 11 for preparing coniferyl alcohol, coniferyl aldehyde, ferulic acid, vanillin and/or vanillic acid.

16. Use of gene structures according to one of Claims 6 to 8 or of a vector according to Claim 9 for preparing transformed and/or mutagenized organisms.

093054.0470
T02404505660

Sequences

CTGCAGCCAG	GGCTGAAAAAG	GAGGGATTCA	GTGAGGTCAT	GAAGGGAGGG	GACGGCGCCT		60
GGCTCCAATT	GCTCGATGGC	GCCGCGATTG	AGTGTCTTGG	GCGCGGTC TT	GGAGAGTT CG		120
GCTAGGGAGA	TAAATTTGCT	GGCCATGGTG	GCGGCCCTTG	ATGGGT T GGA	TGATTTTCTG		180
CATTCTGCAT	CATGAAATTC	ATGAAATCAT	CAC'TTTTTCGG	GGGGTGGGTG	CACGGGATTG		240
AAGGTTGCTA	GGAGAGTGCA	TTGCTCGTAA	GCCCAGGAAG	CACGCGGGTT	TCAGGATGGT		300
GCATGGAAAT	GGCATGAGCT	TTGCTGGATA	TGATTAGAGA	CATTA ACTAT	TTTGGCGGAA		360
TGGAAGCACG	ATT CCTCGCC	CGGTAGAGCG	GTAACCGCGA	CATT CAGGAC	CGTAAA AAGG		420
AAAGAGCATG	CAA CTG ACC AAC AAG AAA ATC GTC GTC ACC GGA GTG TCC TCC						472
	Met Gln Leu Thr Asn Lys Lys Ile Val Val Thr Gly Val Ser Ser						
	1 5 10 15						
GGT ATC GGT GCC GAA ACT GCC CGC GTT CTG CGC TCT CAC GGC GCC ACA							520
Gly Ile Gly Ala Glu Thr Ala Arg Val Leu Arg Ser His Gly Ala Thr							
	20 25 30						
GTG ATT GGC GTA GAT CGC AAC ATG CCG AGC CTG ACT CTG GAT GCT TTC							568
Val Ile Gly Val Asp Arg Asn Met Pro Ser Leu Thr Leu Asp Ala Phe							
	35 40 45						
GTT CAG GCT GAC CTG AGC CAT CCT GAA GGC ATC GAT AAG GCC ATC GGG							616
Val Gln Ala Asp Leu Ser His Pro Glu Gly Ile Asp Lys Ala Ile							
	50 55 60 62						
ACAGCAAGCG	AACCGGAATT	GCCAGCTGGG	GCGCCCTCTG	GTAAGGTTGG	GAAGCCCTGC		676
AAAGTAAACT	GGATGGCTTT	CTTGCCGCCA	AGGATCTGAT	GGCGCAGGGG	ATCAAGATCT		736
GATCAAGAGA	CAGGATGAGG	ATCGTTTTGC	ATG ATT GAA CAA GAT GGA TTG CAC				790
			Met Ile Glu Gln Asp Gly Leu His				
			1 5				
GCA GGT TCT CCG GCC GCT TGG GTG GAG AGG CTA TTC GGC TAT GAC TGG							838
Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp							
	10 15 20						
GCA CAA CAG ACA ATC GGC TGC TCT GAT GCC GCC GTG TTC CGG CTG TCA							886
Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser							
	25 30 35 40						
GCG CAG GGG CGC CCG GTT CTT TTT GTC AAG ACC GAC CTG TCC GGT GCC							934
Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala							
	45 50 55						
CTG AAT GAA CTG CAG GAC GAG GCA GCG CGG CTA TCG TGG CTG GCC ACG							982
Leu Asn Glu Leu Gln Asp Glu Ala Arg Leu Ser Trp Leu Ala Thr							
	60 65 70						

ACG GGC GTT CCT TGC GCA GCT GTG CTC GAC GTT GTC ACT GAA GCG GGA	1030
Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly	
75 80 85	
AGG GAC TGG CTG CTA TTG GGC GAA GTG CCG GGG CAG GAT CTC CTG TCA	1078
Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser	
90 95 100	
TCT CAC CTT GCT CCT GCC GAG AAA GTA TCC ATC ATG GCT GAT GCA ATG	1126
Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met	
105 110 115 120	
CGG CGG CTG CAT ACG CTT GAT CCG GCT ACC TGC CCA TTC GAC CAC CAA	1174
Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln	
125 130 135	
GCG AAA CAT CGC ATC GAG CGA GCA CGT ACT CGG ATG GAA GCC GGT CTT	1222
Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu	
140 145 150	
GTC GAT CAG GAT GAT CTG GAC GAA GAG CAT CAG GGG CTC GCG CCA GCC	1270
Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala	
155 160 165	
GAA CTG TTC GCC AGG CTC AAG GCG CGC ATG CCC GAC GGC GAG GAT CTC	1318
Glu Leu Phe Ala Arg Leu Lys Ala Arg Met Pro Asp Gly Glu Asp Leu	
170 175 180	
GTC GTG ACC CAT GGC GAT GCC TGC TTG CCG AAT ATC ATG GTG GAA AAT	1366
Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn	
185 190 195 200	
GGC CGC TTT TCT GGA TTC ATC GAC TGT GGC CGG CTG GGT GTG GCG GAC	1414
Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp	
205 210 215	
CGC TAT CAG GAC ATA GCG TTG GCT ACC CGT GAT ATT GCT GAA GAG CTT	1462
Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu	
220 225 230	
GGC GGC GAA TGG GCT GAC CGC TTC CTC GTG CTT TAC GGT ATC GCC GCT	1510
Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala	
235 240 245	
CCC GAT TCG CAG CGC ATC GCC TTC TAT CGC CTT CTT GAC GAG TTC TTC	1558
Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe	
250 255 260 264	
TGAGCGGGAC TCTGGGGTTC GAAATGACCG ACCAAGCGAC GCCCTG GCC GCG GTG	1613
Ala Ala Val	
225	
ATT GCA TTC ATG TGT GCT GAG GAG TCA CGT TGG ATC AAC GGC ATA AAT	1661
Ile Ala Phe Met Cys Ala Glu Glu Ser Arg Trp Ile Asn Gly Ile Asn	
230 235 240	

FIG. 2a:

FIG. 2a:

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

CAA CAT CAG CCG GAC TCC GAT TAC CTC GGG AAC TTG CTC CGT AGT AAG	1225
Gln His Gln Pro Asp Ser Asp Tyr Leu Gly Asn Leu Leu Arg Ser Lys	
60 65 70	
ACA TTC ATC GCG CTT GCT GCC TTC GAC CAA GAA GCG GTT GTT GGC GCT	1273
Thr Phe Ile Ala Leu Ala Ala Phe Asp Gln Glu Ala Val Val Gly Ala	
75 80 85 90	
CTC GCG GCT TAC GTT CTG CCC AGG TTT GAG CAG CCG CGT AGT GAG ATC	1321
Leu Ala Ala Tyr Val Leu Pro Arg Phe Glu Gln Pro Arg Ser Glu Ile	
95 100 105	
TAT ATC TAT GAT CTC GCA GTC TCC GGC GAG CAC CGG AGG CAG GGC ATT	1369
Tyr Ile Tyr Asp Leu Ala Val Ser Gly Glu His Arg Arg Gln Gly Ile	
110 115 120	
GCC ACC GCG CTC ATC AAT CTC CTC AAG CAT GAG GCC AAC GCG CTT GGT	1417
Ala Thr Ala Leu Ile Asn Leu Leu Lys His Glu Ala Asn Ala Leu Gly	
125 130 135	
GCT TAT GTG ATC TAC GTG CAA GCA GAT TAC GGT GAC GAT CCC GCA GTG	1465
Ala Tyr Val Ile Tyr Val Gln Ala Asp Tyr Gly Asp Asp Pro Ala Val	
140 145 150	
GCT CTC TAT ACA AAG TTG GGC ATA CGG GAA GAA GTG ATG CAC TTT GAT	1513
Ala Leu Tyr Thr Lys Leu Gly Ile Arg Glu Glu Val Met His Phe Asp	
155 160 165 170	
ATC GAC CCA AGT ACC GCC ACC TAA CAATTCGTTT AAGCCGAGAT CGGCTTCCCT	1567
Ile Asp Pro Ser Thr Ala Thr	
175 177	
G ATT GCA TTC ATG TGT GCT GAG GAG TCA CGT TGG ATC AAC GGC ATA AAT	1616
Ile Ala Phe Met Cys Ala Glu Glu Ser Arg Trp Ile Asn Gly Ile Asn	
228 230 235 240	
ATT CCA GTG GAC GGA GGT TTG GCA TCG ACC TAC GTG TAA GTTCGTGGAC	1665
Ile Pro Val Asp Gly Gly Leu Ala Ser Thr Tyr Val	
245 250 255	
GCCCTTTGCA CGCGCACTAT ATCTCTATGC AGCAGCTGAA AGCAGCTTTG GTTTTGATCG	1725
GAGGTAGCGG GCGGAAAGGT GCAGAATGTC TAAATAATAA AGGATTCTTG TGAAGCTTTA	1785
GTTGTCCGTA AACGAAAATA AAAATAAAGA GGAATGATAT GAAAGCAAGT AGATCAGTCT	1845
GCACTTTCAA AATAGCTACC CTGGCAGGCG CCATTTATGC AGCGCTGCCA ATGTCAGCTG	1905
CAAACCTCGAT GCAGCTGGAT GTAGGTAGCT CGGATTGGAC GGTGCGTTGG GGACAACACC	1965
CTCAAGTATA GCCTTGCCTC TCGCCTGAAT GAGCAAGACT CAAGTCTGAC AAATGCGCCG	2025
ACTGTCAATG GTTATATCCG GATATTCAAA GTCAGGGTGA TCGTAACTTT GACCGGGGGC	2085
TTGGTATCCA ATCGTCTCGA TATTCTGGCT GCAG	2119

FIG. 2b:

CTGCAGCCAG GGCTGAAAAG GAGGGATTCA GTGAGGTCAT GAAGGGAGGG GACGGCGCCT 60

GGCTCCAATT GCTCGATGGC GCCGCGATTG AGTGTCTTGG GCGCGGTCTT GGAGAGTTTCG 120

GCTAGGGAGA TAAATTTGCT GGCCATGGTG GCGGCCCCCTG ATGGGTTGGA TGATTTTCTG 180

CATTCTGCAT CATGAAATTC ATGAAATCAT CACTTTTTCGG GGGGTGGGTG CACGGGATTG 240

AAGGTTGCTA GGAGAGTGCA TTGCTCGTAA GCCCAGGAAG CACGCGGGTT TCAGGATGGT 300

GCATGGAAAT GGCATGAGCT TTGCTGGATA TGATTAGAGA CATTAACAT TTTGGCGGAA 360

TGGAAGCACG ATTCCTCGCC CGGTAGAGCG GTAACCGCGA CATTACAGGAC CGTAAAAAGG 420

AAAGAGCATG CAA CTG ACC AAC AAG AAA ATC GTC GTC ACC GGA GTG TCC TCC 472
Met Gln Leu Thr Asn Lys Lys Ile Val Val Thr Gly Val Ser Ser
1 5 10 15

GGT ATC GGT GCC GAA ACT GCC CGC GTT CTG CGC TCT CAC GGC GCC ACA 520
Gly Ile Gly Ala Glu Thr Ala Arg Val Leu Arg Ser His Gly Ala Thr
20 25 30

GTG ATT GGC GTA GAT CGC AAC ATG CCG AGC CTG ACT CTG GAT GCT TTC 568
Val Ile Gly Val Asp Arg Asn Met Pro Ser Leu Thr Leu Asp Ala Phe
35 40 45

GTT CAG GCT GAC CTG AGC CAT CCT GAA GGC ATC GATC AAC GGC ATA AAT 617
Val Gln Ala Asp Leu Ser His Pro Glu Gly Ile Asn Gly Ile Asn
50 55 58 240

ATT CCA GTG GAC GGA GGT TTG GCA TCG ACC TAC GTG TAA GTTCGTGGAC 666
Ile Pro Val Asp Gly Gly Leu Ala Ser Thr Tyr Val
245 250 255

GCCCTTTGCA CGCGCACTAT ATCTCTATGC AGCAGCTGAA AGCAGCTTTG GTTTTGATCG 726

GAGGTAGCGG GCGGAAAGGT GCAGAATGTC TAAATAATAA AGGATTCTTG TGAAGCTTTA 786

GTTGTCCGTA AACGAAAATA AAAATAAAGA GGAATGATAT GAAAGCAAGT AGATCAGTCT 846

GCACTTTCAA AATAGCTACC CTGGCAGGCG CCATTTATGC AGCGCTGCCA ATGTCAGCTG 906

CAAACCTCGAT GCAGCTGGAT GTAGGTAGCT CGGATTGGAC GGTGCGTTGG GGACAACACC 966

CTCAAGTATA GCCTTGCCCTC TCGCCTGAAT GAGCAAGACT CAAGTCTGAC AAATGCGCCG 1026

ACTGTCAATG GTTATATCCG GATATTCAAA GTCAGGGTGA TCGTAACTTT GACCGGGGGC 1086

TTGGTATCCA ATCGTCTCGA TATTCTGGCT GCAG 1120

FIG. 2c:

090314 0420

GAATTCGCG TATCGCCCGG TTCTATCAGC GGGCCGCTTT CGAAAGTCAT GGTGTTAGCC	60
GGTAGGGTCT TTTTCTTGGC CATGCTTGTT GCCTGAACCT TCGTTGACAT AGGGCAGAGG	120
TGCGTTTGCC GCTTCGCTTC GCGATGAACC GCATCGAGAT GCTGAGGTCA GGATTTTTC	180
TTAACTCGCG TAAGCATTCT GTCATTTTTT TGGTGGCTTT GAACAGCCTG ATGAAAGGTG	240
GTCTCGCCCT TTGAGGCCGA TTCTTGGGCG CTTGGCGGCG TCGAAGCGAT GCTCCACTAC	300
CGATTAAGAT AATTAAAATA AGGAAACCGC ATGGTTTCTT ATGTGAATTT GTCTGGCATA	360
CTCCAGCTCA AGGGCAATTT TTGGGCTATT GGCTGAGCAG TTGCCTCTAT ATGGTTATTC	420
AGAATAACAA TTGACTCCTC AGGAGGTCAG CG ATG AGC ATT CTT GGT TTG AAT	473
Met Ser Ile Leu Gly Leu Asn	
1 5	
GGT GCC CCG GTC GGA GCT GAG CAG CTG GGC TCG GCT CTT GAT CGC ATG	521
Gly Ala Pro Val Gly Ala Glu Gln Leu Gly Ser Ala Leu Asp Arg Met	
10 15 20	
AAG AAG GCG CAC CTG GAG CAG GGG CCT GCA AAC TTG GAG CTG CGT CTG	569
Lys Lys Ala His Leu Glu Gln Gly Pro Ala Asn Leu Glu Leu Arg Leu	
25 30 35	
AGT AGG CTG GAT CGT GCG ATT GCA ATG CTT CTG GAA AAT CGT GAA GCA	617
Ser Arg Leu Asp Arg Ala Ile Ala Met Leu Leu Glu Asn Arg Glu Ala	
40 45 50 55	
ATT GCC GAC GCG GTT TCT GCT GAC TTT GGC AAT CGC AGC CGT GAG CAA	665
Ile Ala Asp Ala Val Ser Ala Asp Phe Gly Asn Arg Ser Arg Glu Gln	
60 65 70	
ACA CTG CTT TGC GAC ATT GCT GGC TCG GTG GCA AGC CTG AAG GAT AGC	713
Thr Leu Leu Cys Asp Ile Ala Gly Ser Val Ala Ser Leu Lys Asp Ser	
75 80 85	
CGC GAG CAC GTG GCC AAA TGG ATG GAG CCC GAA CAT CAC AAG GCG ATG	761
Arg Glu His Val Ala Lys Trp Met Glu Pro Glu His His Lys Ala Met	
90 95 100	
TTT CCA GGG GCG GAG GCA CGC GTT GAG TTT CAG CCG CTG GGT GTC GTT	809
Phe Pro Gly Ala Glu Ala Arg Val Glu Phe Gln Pro Leu Gly Val Val	
105 110 115	
GGG GTC ATT AGT CCC TGG AAC TTC CCT ATC GTA CTG GCC TTT GGG CCG	857
Gly Val Ile Ser Pro Trp Asn Phe Pro Ile Val Leu Ala Phe Gly Pro	
120 125 130 135	
CTG GCC GGC ATA TTC GCA GCA GGT AAT CGC GCC ATG CTC AAG CCG TCC	905
Leu Ala Gly Ile Phe Ala Ala Gly Asn Arg Ala Met Leu Lys Pro Ser	
140 145 150	
GAG CTT ACC CCG CGG ACT TCT GCC CTG CTT GCG GAG CTA ATT GCT CGT	953
Glu Leu Thr Pro Arg Thr Ser Ala Leu Leu Ala Glu Leu Ile Ala Arg	
155 160 165	

00980544-042704

TAC Tyr	TTC Phe	GAT Asp	GAA Glu	ACT Thr	GAG Glu	CTG Leu	ACT Thr	ACA Thr	GTG Val	CTG Leu	GGC Gly	GAC Asp	GCT Ala	GAA Glu	GTC Val	1001			
170																175	180		
GGT Gly	GCG Ala	CTG Leu	TTC Phe	AGT Ser	GCT Ala	CAG Gln	CCT Pro	TTC Phe	GAT Asp	CAT His	CTG Leu	ATC Ile	TTC Phe	ACC Thr	GGC Gly	1049			
185																190	195		
GGC Gly	ACT Thr	GCC Ala	GTG Val	GCC Ala	AAG Lys	CAC His	ATC Ile	ATG Met	CGT Arg	GCC Ala	GCG Ala	GCG Ala	GAT Asp	AAC Asn	CTA Leu	1097			
200																205	210		215
GTG Val	CCC Pro	GTT Val	ACC Thr	CTG Leu	GAA Glu	TTG Leu	GGT Gly	GGC Gly	AAA Lys	TCG Ser	CCG Pro	GTG Val	ATC Ile	GTT Val	TCC Ser	1145			
220																225	230		
CGC Arg	AGT Ser	GCA Ala	GAT Asp	ATG Met	GCG Ala	GAC Asp	GTT Val	GCA Ala	CAA Gln	CGG Arg	GTG Val	TTG Leu	ACG Thr	GTG Val	AAA Lys	1193			
235																240	245		
ACC Thr	TTC Phe	AAT Asn	GCC Ala	GGG Gly	CAA Gln	ATC Ile	TGT Cys	CTG Leu	GCA Ala	CCG Pro	GAC Asp	TAT Tyr	GTG Val	CTG Leu	CTG Leu	1241			
250																255	260		
CCG Pro	GAA Glu	GGGACAGCAA			GCGAACCGGA			ATTGCCAGCT			GGGGCGCCCT			CTGGTAAGGT			1297		
265																			
TGCGAAGCCC			TGCAAAGTAA			ACTGGATGGC			TTTCTTGCCG			CCAAGGATCT			GATGGCGCAG			1357	
GGGATCAAGA			TCTGATCAAG			AGACAGGATG			AGGATCGTTT			CGC	ATG Met	ATT Ile	GAA Glu	CAA Gln	1412		
1																			
GAT Asp	GGA Gly	TTG Leu	CAC His	GCA Ala	GGT Gly	TCT Ser	CCG Pro	GCC Ala	GCT Ala	TGG Trp	GTG Val	GAG Glu	AGG Arg	CTA Leu	TTC Phe	1460			
5																10	15		20
GGC Gly	TAT Tyr	GAC Asp	TGG Trp	GCA Ala	CAA Gln	CAG Gln	ACA Thr	ATC Ile	GGC Gly	TGC Cys	TCT Ser	GAT Asp	GCC Ala	GCC Ala	GTG Val	1508			
25																30	35		
TTC Phe	CGG Arg	CTG Leu	TCA Ser	GCG Ala	CAG Gln	GGG Gly	CGC Arg	CCG Pro	GTT Val	CTT Leu	TTT Phe	GTC Val	AAG Lys	ACC Thr	GAC Asp	1556			
40																45	50		
CTG Leu	TCC Ser	GGT Gly	GCC Ala	CTG Leu	AAT Asn	GAA Glu	CTG Leu	CAG Gln	GAC Asp	GAG Glu	GCA Ala	GCG Ala	CGG Arg	CTA Leu	TCG Ser	1604			
55																60	65		
TGG Trp	CTG Leu	GCC Ala	ACG Thr	ACG Thr	GGC Gly	GTT Val	CCT Pro	TGC Cys	GCA Ala	GCT Ala	GTG Val	CTC Leu	GAC Asp	GTT Val	GTC Val	1652			
70																75	80		

ACT Thr 85	GAA Glu	GCG Ala	GGA Gly	AGG Arg	GAC Asp 90	TGG Trp	CTG Leu	CTA Leu	TTG Leu	GGC Gly 95	GAA Glu	GTG Val	CCG Pro	GGG Gly	CAG Gln 100	1700
GAT Asp	CTC Leu	CTG Leu	TCA Ser	TCT Ser 105	CAC His	CTT Leu	GCT Ala	CCT Pro	GCC Ala 110	GAG Glu	AAA Lys	GTA Val	TCC Ser	ATC Ile 115	ATG Met	1748
GCT Ala	GAT Asp	GCA Ala	ATG Met 120	CGG Arg	CGG Arg	CTG Leu	CAT His	ACG Thr 125	CTT Leu	GAT Asp	CCG Pro	GCT Ala	ACC Thr 130	TGC Cys	CCA Pro	1796
TTC Phe	GAC Asp	CAC His 135	CAA Gln	GCG Ala	AAA Lys	CAT His	CGC Arg 140	ATC Ile	GAG Glu	CGA Arg	GCA Ala	CGT Arg 145	ACT Thr	CGG Arg	ATG Met	1844
GAA Glu 150	GCC Ala	GGT Gly	CTT Leu	GTC Val	GAT Asp 155	CAG Gln	GAT Asp	GAT Asp	CTG Leu	GAC Asp 160	GAA Glu	GAG Glu	CAT His	CAG Gln	GGG Gly	1892
CTC Leu 165	GCG Ala	CCA Pro	GCC Ala	GAA Glu 170	CTG Leu 170	TTC Phe	GCC Ala	AGG Arg	CTC Leu	AAG Lys 175	GCG Ala	CGC Arg	ATG Met	CCC Pro	GAC Asp 180	1940
GGC Gly	GAG Glu	GAT Asp	CTC Leu 185	GTC Val 185	GTG Val	ACC Thr	CAT His	GGC Gly 190	GAT Asp 190	GCC Ala	TGC Cys	TTG Leu	CCG Pro	AAT Asn 195	ATC Ile	1988
ATG Met	GTG Val	GAA Glu 200	AAT Asn 200	GGC Gly	CGC Arg	TTT Phe	TCT Ser	GGA Gly 205	TTC Phe	ATC Ile	GAC Asp	TGT Cys 210	GGC Gly 210	CGG Arg	CTG Leu	2036
GGT Gly	GTG Val 215	GCG Ala	GAC Asp	CGC Arg	TAT Tyr	CAG Gln	GAC Asp 220	ATA Ile	GCG Ala	TTG Leu	GCT Ala	ACC Thr 225	CGT Arg	GAT Asp	ATT Ile	2084
GCT Ala 230	GAA Glu 230	GAG Glu	CTT Leu	GGC Gly	GGC Gly	GAA Glu 235	TGG Trp	GCT Ala	GAC Asp	CGC Arg	TTC Phe 240	CTC Leu	GTG Val	CTT Leu	TAC Tyr	2132
GGT Gly 245	ATC Ile	GCC Ala	GCT Ala	CCC Pro 250	GAT Asp 250	TCG Ser	CAG Gln	CGC Arg	ATC Ile 255	GCC Ala 255	TTC Phe	TAT Tyr	CGC Arg	CTT Leu 260	CTT Leu 260	2180
GAC Asp	GAG Glu	TTC Phe	TTC Phe 264	TGA	GCGGGACTCT	GCGGGACTCT	GGGGTTTCGAA	ATGACCGACC	AAGCGACGCC							2235
CGC	CAT His 444	GCC Ala 445	AAG Lys	CCT Pro	GTT Val	CTC Leu	GTG Val 450	CAA Gln	AGT Ser	CCT Pro	GTG Val 455	GGT Gly 455	GAG Glu	TCG Ser	AAC Asn	2283
TTG Leu	GCG Ala 460	ATG Met	CGC Arg	GCA Ala	CCC Pro 465	TAC Tyr 465	GGA Gly 465	GAA Glu	GCG Ala	ATC Ile 470	CAC His 470	GGA Gly	CTG Leu	CTC Leu	TCT Ser	2331

FIG. 2d:

GAG CTT ACC CCG CGG ACT TCT GCC CTG CTT GCG GAG CTA ATT GCT CGT
Glu Leu Thr Pro Arg Thr Ser Ala Leu Leu Ala Glu Leu Ile Ala Arg
155 160 165

TAC TTC GAT GAA ACT GAG CTG ACT ACA GTG CTG GGC GAC GCT GAA GTC	1001
Tyr Phe Asp Glu Thr Glu Leu Thr Thr Val Leu Gly Asp Ala Glu Val	
170 175 180	
GGT GCG CTG TTC AGT GCT CAG CCT TTC GAT CAT CTG ATC TTC ACC GGC	1049
Gly Ala Leu Phe Ser Ala Gln Pro Phe Asp His Leu Ile Phe Thr Gly	
185 190 195	
GGC ACT GCC GTG GCC AAG CAC ATC ATG CGT GCC GCG GCG GAT AAC CTA	1097
Gly Thr Ala Val Ala Lys His Ile Met Arg Ala Ala Ala Asp Asn Leu	
200 205 210 215	
GTG CCC GTT ACC CTG GAA TTG GGT GGC AAA TCG CCG GTG ATC GTT TCC	1145
Val Pro Val Thr Leu Glu Leu Gly Gly Lys Ser Pro Val Ile Val Ser	
220 225 230	
CGC AGT GCA GAT ATG GCG GAC GTT GCA CAA CGG GTG TTG ACG GTG AAA	1193
Arg Ser Ala Asp Met Ala Asp Val Ala Gln Arg Val Leu Thr Val Lys	
235 240 245	
ACC TTC AAT GCC GGG CAA ATC TGT CTG GCA CCG GAC TAT GTG CTG GGG	1241
Thr Phe Asn Ala Gly Gln Ile Cys Leu Ala Pro Asp Tyr Val Leu	
250 255 260 262	
GAGAGGCGGT TTGCGTATTG GGCGCATGCA TAAAACTGT TGTAATTCAT TAAGCATTCCT	1301
GCCGACATGG AAGCCATCAC AAACGGCATG ATGAACCTGA ATCGCCAGCG GCATCAGCAC	1361
CTTGTCGCCT TGCCTATAAT ATTTGCCCAT GGACGCACAC CGTGGAAACG GATGAAGGCA	1421
CGAACCCAGT TGACATAAGC CTGTTCCGGTT CGTAAACTGT AATGCAAGTA GCGTATGCGC	1481
TCACGCAACT GGTCCAGAAC CTTGACCGAA CGCAGCGGTG GTAACGGCGC AGTGCGGGTT	1541
TTCATGGCTT GTTATGACTG TTTTTTTTGTA CAGTCTATGC CTCGGGCATC CAAGCAGCAA	1601
GCGCGTTACG CCGTGGGTCG ATGTTTGATG TTATGGAGCA GCAACG ATG TTA CGC	1656
Met Leu Arg	
1	
AGC AGC AAC GAT GTT ACG CAG CAG GGC AGT CGC CCT AAA ACA AAG TTA	1704
Ser Ser Asn Asp Val Thr Gln Gln Gly Ser Arg Pro Lys Thr Lys Leu	
5 10 15	
GGT GGC TCA AGT ATG GGC ATC ATT CGC ACA TGT AGG CTC GGC CCT GAC	1752
Gly Gly Ser Ser Met Gly Ile Ile Arg Thr Cys Arg Leu Gly Pro Asp	
20 25 30 35	
CAA GTC AAA TCC ATG CGG GCT GCT CTT GAT CTT TTC GGT CGT GAG TTC	1800
Gln Val Lys Ser Met Arg Ala Ala Leu Asp Leu Phe Gly Arg Glu Phe	
40 45 50	
GGA GAC GTA GCC ACC TAC TCC CAA CAT CAG CCG GAC TCC GAT TAC CTC	1848
Gly Asp Val Ala Thr Tyr Ser Gln His Gln Pro Asp Ser Asp Tyr Leu	
55 60 65	
GGG AAC TTG CTC CGT AGT AAG ACA TTC ATC GCG CTT GCT GCC TTC GAC	1896
Gly Asn Leu Leu Arg Ser Lys Thr Phe Ile Ala Leu Ala Ala Phe Asp	
70 75 80	
CAA GAA GCG GTT GTT GGC GCT CTC GCG GCT TAC GTT CTG CCC AGG TTT	1944

Gln	Glu	Ala	Val	Val	Gly	Ala	Leu	Ala	Ala	Tyr	Val	Leu	Pro	Arg	Phe	
	85					90					95					
GAG	CAG	CCG	CGT	AGT	GAG	ATC	TAT	ATC	TAT	GAT	CTC	GCA	GTC	TCC	GGC	1992
Glu	Gln	Pro	Arg	Ser	Glu	Ile	Tyr	Ile	Tyr	Asp	Leu	Ala	Val	Ser	Gly	
100					105					110					115	
GAG	CAC	CGG	AGG	CAG	GGC	ATT	GCC	ACC	GCG	CTC	ATC	AAT	CTC	CTC	AAG	2040
Glu	His	Arg	Arg	Gln	Gly	Ile	Ala	Thr	Ala	Leu	Ile	Asn	Leu	Leu	Lys	
				120					125					130		
CAT	GAG	GCC	AAC	GCG	CTT	GGT	GCT	TAT	GTG	ATC	TAC	GTG	CAA	GCA	GAT	2088
His	Glu	Ala	Asn	Ala	Leu	Gly	Ala	Tyr	Val	Ile	Tyr	Val	Gln	Ala	Asp	
			135					140					145			
TAC	GGT	GAC	GAT	CCC	GCA	GTG	GCT	CTC	TAT	ACA	AAG	TTG	GGC	ATA	CGG	2136
Tyr	Gly	Asp	Asp	Pro	Ala	Val	Ala	Leu	Tyr	Thr	Lys	Leu	Gly	Ile	Arg	
		150					155					160				
GAA	GAA	GTG	ATG	CAC	TTT	GAT	ATC	GAC	CCA	AGT	ACC	GCC	ACC	TAA	CAA	2184
Glu	Glu	Val	Met	His	Phe	Asp	Ile	Asp	Pro	Ser	Thr	Ala	Thr			
	165					170					175		177			
TTCGTTCAAG	CCGAGATCGG	CTTCCCTG	CAA	AGT	CCT	GTG	GGT	GAG	TCG	AAC						2236
			Gln	Ser	Pro	Val	Gly	Glu	Ser	Asn						
			451				455									
TTG	GCG	ATG	CGC	GCA	CCC	TAC	GGA	GAA	GCG	ATC	CAC	GGA	CTG	CTC	TCT	2284
Leu	Ala	Met	Arg	Ala	Pro	Tyr	Gly	Glu	Ala	Ile	His	Gly	Leu	Leu	Ser	
	460					465					470					
GTC	CTC	CTT	TCA	ACG	GAG	TGT	TAG	AACCGTTGGT	AGTGGTTTTG	GACGGGCCCA						2338
Val	Leu	Leu	Ser	Thr	Glu	Cys										
475					480	481										
GGAGCATGCG	CTTCTGGGCC	CGTTTCTTGA	GTATTCATTG	GATAGTCACG	CGTGGTAGCT											2398
TCGAGCCTGC	ACAGCTGATG	AGCACCTGG	AAGGCGCGCT	GTACGCGGAC	GACTGGGTTC											2458
ATCTTCGCCA	TTCATGACGG	AACTCCGTTC	CCCAGTACCG	CGATGACTAT	TTTGCCTCTT											2518
CCGATGTCCG	ATTCCACGCC	GCCTGACGCT	AAGCGGGGGC	GGGGGCGCCC	GCATCCCAGC											2578
CCAGACAGCA	ACAAATGAGT	AGGCTCTTGG	ATGCCGCGGC	GGCTGAGATT	GGTAACGGCA											2638
ATTTCTGCAA	TGTGACGATG	GATTCGATTG	CCCGTGCTGC	CGGCGTCTCA	AAAAAACGC											2698
TGTACGTCTT	GGTGGCGAGC	AAGGAAGAAC	TCATTTCCCG	GTTAGTGGCT	CGAGACATGT											2758
CCAACCTTGA	GGAATTC															2775

FIG. 2e:

GAATTCCGCG TATCGCCCGG TTCTATCAGC GGGCCGCTTT CGAAAGTCAT GGTGTTAGCC	60
GGTAGGGTCT TTTTCTTGGC CATGCTTGTT GCCTGAACCT TCGTTGACAT AGGGCAGAGG	120
TGCGTTTGCC GCTTCGCTTC GCGATGAACC GCATCGAGAT GCTGAGGTCA GGATTTTTC	180
TTAACTCGCG TAAGCATTCT GTCATTTTTT TGGTGGCTTT GAACAGCCTG ATGAAAGGTG	240
GTCTCGCCCT TTGAGGCCGA TTCTTGCGCG CTTGGCGGCG TCGAAGCGAT GCTCCACTAC	300
CGATTAAGAT AATTAAAATA AGGAAACCGC ATGGTTTCTT ATGTGAATTT GTCTGGCATA	360
CTCCAGCTCA AGGGCAATTT TTGGGCTATT GGCTGAGCAG TTGCCTCTAT ATGGTTATTC	420
AGAATAACAA TTGACTCCTC AGGAGGTCAG CG ATG AGC ATT CTT GGT TTG AAT	473
Met Ser Ile Leu Gly Leu Asn	
1 5	
GGT GCC CCG GTC GGA GCT GAG CAG CTG GGC TCG GCT CTT GAT CGC ATG	521
Gly Ala Pro Val Gly Ala Glu Gln Leu Gly Ser Ala Leu Asp Arg Met	
10 15 20	
AAG AAG GCG CAC CTG GAG CAG GGG CCT GCA AAC TTG GAG CTG CGT CTG	569
Lys Lys Ala His Leu Glu Gln Gly Pro Ala Asn Leu Glu Leu Arg Leu	
25 30 35	
AGT AGG CTG GAT CGT GCG ATT GCA ATG CTT CTG GAA AAT CGT GAA GCA	617
Ser Arg Leu Asp Arg Ala Ile Ala Met Leu Leu Glu Asn Arg Glu Ala	
40 45 50 55	
ATT GCC GAC GCG GTT TCT GCT GAC TTT GGC AAT CGC AGC CGT GAG CAA	665
Ile Ala Asp Ala Val Ser Ala Asp Phe Gly Asn Arg Ser Arg Glu Gln	
60 65 70	
ACA CTG CTT TGC GAC ATT GCT GGC TCG GTG GCA AGC CTG AAG GAT AGC	713
Thr Leu Leu Cys Asp Ile Ala Gly Ser Val Ala Ser Leu Lys Asp Ser	
75 80 85	
CGC GAG CAC GTG GCC AAA TGG ATG GAG CCC GAA CAT CAC AAG GCG ATG	761
Arg Glu His Val Ala Lys Trp Met Glu Pro Glu His His Lys Ala Met	
90 95 100	
TTT CCA GGG GCG GAG GCA CGC GTT GAG TTT CAG CCG CTG GGT GTC GTT	809
Phe Pro Gly Ala Glu Ala Arg Val Glu Phe Gln Pro Leu Gly Val Val	
105 110 115	
GGG GTC ATT AGT CCC TGG AAC TTC CCT ATC GTA CTG GCC TTT GGG CCG	857
Gly Val Ile Ser Pro Trp Asn Phe Pro Ile Val Leu Ala Phe Gly Pro	
120 125 130 135	
CTG GCC GGC ATA TTC GCA GCA GGT AAT CGC GCC ATG CTC AAG CCG TCC	905
Leu Ala Gly Ile Phe Ala Ala Gly Asn Arg Ala Met Leu Lys Pro Ser	
140 145 150	
GAG CTT ACC CCG CGG ACT TCT GCC CTG CTT GCG GAG CTA ATT GCT CGT	953
Glu Leu Thr Pro Arg Thr Ser Ala Leu Leu Ala Glu Leu Ile Ala Arg	
155 160 165	

09030544 0420

FIG. 2f:

FIG. 2f:

CTGCAGCCGA GCATCGATTG AGCACTTTAC CCAGCTGCGC TGGCTGACCA TTCAGAATGG	60
CCCGCGGCAC TATCCAATCT AAATCGATCT TCGGGCGCCG CGGGCATCAT GCCC GCGGCG	120
CTCGCCTCAT TTCAATCTCT AACTTGATAA AACAGAGCT GTTCTCCGGT CTTGGTGGAT	180
CAAGGCCAGT CGCGGAGAGT CTCGAAGAGG AGAGTACAGT GAACGCCGAG TCCACATTGC	240
AACCGCAGGC ATCATCATGC TCTGCTCAGC CACGCTACCG CAGTGTGTCG ATTGGTCATC	300
CTCCGGTTGA GGTACGCAA GACGCTGGAG GTATTGTCCG G ATG CGT TCT CTC GAG	356
	Met Arg Ser Leu Glu
	1 5
GCG CTT CTT CCC TTC CCG GGT CGA ATT CTT GAG CGT CTC GAG CAT TGG	404
Ala Leu Leu Pro Phe Pro Gly Arg Ile Leu Glu Arg Leu Glu His Trp	
	10 15 20
GCT AAG ACC CGT CCA GAA CAA ACC TGC GTT GCT GCC AGG GCG GCA AAT	452
Ala Lys Thr Arg Pro Glu Gln Thr Cys Val Ala Ala Arg Ala Ala Asn	
	25 30 35
GGG GAA TGG CGT CGT ATC AGC TAC GCG GAA ATG TTC CAC AAC GTC CGC	500
Gly Glu Trp Arg Arg Ile Ser Tyr Ala Glu Met Phe His Asn Val Arg	
	40 45 50
GCC ATC GCA CAG AGC TTG CTT CCT TAC GGA CTA TCG GCA GAG CGT CCG	548
Ala Ile Ala Gln Ser Leu Leu Pro Tyr Gly Leu Ser Ala Glu Arg Pro	
	55 60 65
CTG CTT ATC GTC TCT GGA AAT GAC CTG GAA CAT CTT CAG CTG GCA TTT	596
Leu Leu Ile Val Ser Gly Asn Asp Leu Glu His Leu Gln Leu Ala Phe	
	70 75 80 85
GGG GCT ATG TAT GCG GGC ATT CCC TAT TGC CCG GTG TCT CCT GCT TAT	644
Gly Ala Met Tyr Ala Gly Ile Pro Tyr Cys Pro Val Ser Pro Ala Tyr	
	90 95 100
TCA CTG CTG TCG CAA GAT TTG GCG AAG CTG CGT CAC ATC GTA GGT CTT	692
Ser Leu Leu Ser Gln Asp Leu Ala Lys Leu Arg His Ile Val Gly Leu	
	105 110 115
CTG CAA CCG GGA CTG GTC TTT GCT GCC GAT GCA GCA CCT TTC CAG GGG	740
Leu Gln Pro Gly Leu Val Phe Ala Ala Asp Ala Ala Pro Phe Gln	
	120 125 130 132
ACAGCAAGCG AACCGGAATT GCCAGCTGGG GCGCCCTCTG GTAAGGTTGG GAAGCCCTGC	800
AAAGTAAACT GGATGGCTTT CTTGCCGCCA AGGATCTGAT GGCGCAGGGG ATCAAGATCT	860
GATCAAGAGA CAGGATGAGG ATCGTTTCGC ATG ATT GAA CAA GAT GGA TTG CAC	914
	Met Ile Glu Gln Asp Gly Leu His
	1 5
GCA GGT TCT CCG GCC GCT TGG GTG GAG AGG CTA TTC GGC TAT GAC TGG	962
Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp	
	10 15 20

CCC GAT TCG CAG CGC ATC GCC TTC TAT CGC CTT CTT GAC GAG TTC TTC	1682
Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe	
250 255 260 264	
TGAGCGGGAC TCTGGGGTTC GAAATGACCG ACCAAGCGAC GCCCCCT GTT TTG CAA	1737
Val Leu Gln	
563 565	
TGG CGG TCG GCG AAA GTT GAT GCG CTG TAT CGT GGT GAA GAT CAA TCC	1785
Trp Arg Ser Ala Lys Val Asp Ala Leu Tyr Arg Gly Glu Asp Gln Ser	
570 575 580	
ATG CTG CGT GAC GAG GCC ACA CTG TGA GTTGGTCAGG GGGGGCTTAC	1832
Met Leu Arg Asp Glu Ala Thr Leu	
585 589	
TCGGCGTTTT CCGACACTGC GTTGGTTGCG GCAGTGC GCA CCCCCTGGAT TGATTGCGGG	1892
GGTGCCCTGT CGCTGGTGTC GCCTATCGAC TTAGGGGTAA AGGTCGCTCG CGAAGTTCTG	1952
ATGCGTGCGT CGCTTGAACC ACAAATGGTC GATAGCGTAC TCGCAGGCTC TATGGCTCAA	2012
GCAAGCTTTG ATGCTTACCT GCTCCCGCGG CACATTGGCT TGTACAGCGG TGTTCCCAAG	2072
TCGTTCCGG CCTTGGGGGT GCAGCGCATT TGCGGCACAG GCTTCGAACT GCTTCGGCAG	2132
GCCGGCGAGC AGATTTCCTCA AGGCGCTGAT CACGTGCTGT GTGTCGCGGG CTGCAG	2188

FIG. 2g:

10240-450850

CTGCAGCCGA GCATCGATTG AGCACTTTAC CCAGCTGCGC TGGCTGACCA TTCAGAATGG	60
CCCGCGGCAC TATCCAATCT AAATCGATCT TCGGGCGCCG CGGGCATCAT GCCCAGCGGC	120
CTCGCCTCAT TTCAATCTCT AACTTGATAA AAACAGAGCT GTTCTCCGGT CTTGGTGGAT	180
CAAGGCCAGT CGCGGAGAGT CTCGAAGAGG AGAGTACAGT GAACGCCGAG TCCACATTGC	240
AACCGCAGGC ATCATCATGC TCTGCTCAGC CACGCTACCG CAGTGTGTCG ATTGGTCATC	300
CTCCGGTTGA GGTTACGCAA GACGCTGGAG GTATTGTCCG G ATG CGT TCT CTC GAG	356
Met Arg Ser Leu Glu	
1 5	
GCG CTT CTT CCC TTC CCG GGT CGA ATT CTT GAG CGT CTC GAG CAT TGG	404
Ala Leu Leu Pro Phe Pro Gly Arg Ile Leu Glu Arg Leu Glu His Trp	
10 15 20	
GCT AAG ACC CGT CCA GAA CAA ACC TGC GTT GCT GCC AGG GCG GCA AAT	452
Ala Lys Thr Arg Pro Glu Gln Thr Cys Val Ala Ala Arg Ala Ala Asn	
25 30 35	
GGG GAA TGG CGT CGT ATC AGC TAC GCG GAA ATG TTC CAC AAC GTC CGC	500
Gly Glu Trp Arg Arg Ile Ser Tyr Ala Glu Met Phe His Asn Val Arg	
40 45 50	
GCC ATC GCA CAG AGC TTG CTT CCT TAC GGA CTA TCG GCA GAG CGT CCG	548
Ala Ile Ala Gln Ser Leu Leu Pro Tyr Gly Leu Ser Ala Glu Arg Pro	
55 60 65	
CTG CTT ATC GTC TCT GGA AAT GAC CTG GAA CAT CTT CAG CTG GCA TTT	596
Leu Leu Ile Val Ser Gly Asn Asp Leu Glu His Leu Gln Leu Ala Phe	
70 75 80 85	
GGG GCT ATG TAT GCG GGC ATT CCC TAT TGC CCG GTG TCT CCT GCT TAT	644
Gly Ala Met Tyr Ala Gly Ile Pro Tyr Cys Pro Val Ser Pro Ala Tyr	
90 95 100	
TCA CTG CTG TCG CAA GAT TTG GCG AAG CTG CGT CAC ATC GTA GGT CTT	692
Ser Leu Leu Ser Gln Asp Leu Ala Lys Leu Arg His Ile Val Gly Leu	
105 110 115	
CTG CAA CCG GGA CTG GTC TTT GCT GCC GAT GCA GCA CCT TTC CAG GGG	740
Leu Gln Pro Gly Leu Val Phe Ala Ala Asp Ala Ala Pro Phe Gln	
120 125 130 132	
GAGAGGCGGT TTGCGTATTG GCGCATGCA TAAAACTGT TGTAATTCAT TAAGCATTCT	800
GCCGACATGG AAGCCATCAC AAACGGCATG ATGAACCTGA ATCGCCAGCG GCATCAGCAC	860
CTTGTCGCCT TGCGTATAAT ATTTGCCCAT GGACGCACAC CGTGGAACG GATGAAGGCA	920
CGAACCCAGT TGACATAAGC CTGTTCCGGT CGTAACTGT AATGCAAGTA GCGTATGCGC	980
TCACGCAACT GGTCCAGAAC CTTGACCGAA CGCAGCGGTG GTAACGGCGC AGTGGCGGTT	1040
TTCATGGCTT GTTATGACTG TTTTTTTGTA CAGTCTATGC CTCGGGCATC CAAGCAGCAA	1100

090514-042704

GCGCGTTACG CCGTGGGTCG ATGTTTGATG TTATGGAGCA GCAACG ATG TTA CGC	1155
Met Leu Arg	
1	
AGC AGC AAC GAT GTT ACG CAG CAG GGC AGT CGC CCT AAA ACA AAG TTA	1203
Ser Ser Asn Asp Val Thr Gln Gln Gly Ser Arg Pro Lys Thr Lys Leu	
5 10 15	
GGT GGC TCA AGT ATG GGC ATC ATT CGC ACA TGT AGG CTC GGC CCT GAC	1251
Gly Gly Ser Ser Met Gly Ile Ile Arg Thr Cys Arg Leu Gly Pro Asp	
20 25 30 35	
CAA GTC AAA TCC ATG CGG GCT GCT CTT GAT CTT TTC GGT CGT GAG TTC	1299
Gln Val Lys Ser Met Arg Ala Ala Leu Asp Leu Phe Gly Arg Glu Phe	
40 45 50	
GGA GAC GTA GCC ACC TAC TCC CAA CAT CAG CCG GAC TCC GAT TAC CTC	1347
Gly Asp Val Ala Thr Tyr Ser Gln His Gln Pro Asp Ser Asp Tyr Leu	
55 60 65	
GGG AAC TTG CTC CGT AGT AAG ACA TTC ATC GCG CTT GCT GCC TTC GAC	1395
Gly Asn Leu Leu Arg Ser Lys Thr Phe Ile Ala Leu Ala Ala Phe Asp	
70 75 80	
CAA GAA GCG GTT GTT GGC GCT CTC GCG GCT TAC GTT CTG CCC AGG TTT	1443
Gln Glu Ala Val Val Gly Ala Leu Ala Ala Tyr Val Leu Pro Arg Phe	
85 90 95	
GAG CAG CCG CGT AGT GAG ATC TAT ATC TAT GAT CTC GCA GTC TCC GGC	1491
Glu Gln Pro Arg Ser Glu Ile Tyr Ile Tyr Asp Leu Ala Val Ser Gly	
100 105 110 115	
GAG CAC CGG AGG CAG GGC ATT GCC ACC GCG CTC ATC AAT CTC CTC AAG	1539
Glu His Arg Arg Gln Gly Ile Ala Thr Ala Leu Ile Asn Leu Leu Lys	
120 125 130	
CAT GAG GCC AAC GCG CTT GGT GCT TAT GTG ATC TAC GTG CAA GCA GAT	1587
His Glu Ala Asn Ala Leu Gly Ala Tyr Val Ile Tyr Val Gln Ala Asp	
135 140 145	
TAC GGT GAC GAT CCC GCA GTG GCT CTC TAT ACA AAG TTG GGC ATA CGG	1635
Tyr Gly Asp Asp Pro Ala Val Ala Leu Tyr Thr Lys Leu Gly Ile Arg	
150 155 160	
GAA GAA GTG ATG CAC TTT GAT ATC GAC CCA AGT ACC GCC ACC TAA CAA	1683
Glu Glu Val Met His Phe Asp Ile Asp Pro Ser Thr Ala Thr	
165 170 175 177	
TTCGTTCAAG CCGAGATCGG CTTCCCTT GTT TTG CAA TGG CGG TCG GCG AAA	1735
Val Leu Gln Trp Arg Ser Ala Lys	
563 565 570	
GTT GAT GCG CTG TAT CGT GGT GAA GAT CAA TCC ATG CTG CGT GAC GAG	1783
Val Asp Ala Leu Tyr Arg Gly Glu Asp Gln Ser Met Leu Arg Asp Glu	
575 580 585	

09830514.01201

CTGCAGCCGA GCATCGATTG AGCACTTTAC CCAGCTGCGC TGGCTGACCA TTCAGAATGG	60
CCCGCGGCAC TATCCAATCT AAATCGATCT TCGGGCGCCG CGGGCATCAT GCCCAGCGGC	120
CTCGCCTCAT TTCAATCTCT AACTTGATAA AAACAGAGCT GTTCTCCGGT CTTGGTGGAT	180
CAAGGCCAGT CGCGGAGAGT CTCGAAGAGG AGAGTACAGT GAACGCCGAG TCCACATTGC	240
AACCGCAGGC ATCATCATGC TCTGCTCAGC CACGCTACCG CAGTGTGTCG ATTGGTCATC	300
CTCCGGTTGA GGTTACGCAA GACGCTGGAG GTATTGTCCG G ATG CGT TCT CTC GAG	356
Met Arg Ser Leu Glu	5
1	
GCG CTT CTT CCC TTC CCG GGT CGA ATT CTT GAG CGT CTC GAG CAT TGG	404
Ala Leu Leu Pro Phe Pro Gly Arg Ile Leu Glu Arg Leu Glu His Trp	
10 15 20	
GCT AAG ACC CGT CCA GAA CAA ACC TGC GTT GCT GCC AGG GCG GCA AAT	452
Ala Lys Thr Arg Pro Glu Gln Thr Cys Val Ala Ala Arg Ala Ala Asn	
25 30 35	
GGG GAA TGG CGT CGT ATC AGC TAC GCG GAA ATG TTC CAC AAC GTC CGC	500
Gly Glu Trp Arg Arg Ile Ser Tyr Ala Glu Met Phe His Asn Val Arg	
40 45 50	
GCC ATC GCA CAG AGC TTG CTT CCT TAC GGA CTA TCG GCA GAG CGT CCG	548
Ala Ile Ala Gln Ser Leu Leu Pro Tyr Gly Leu Ser Ala Glu Arg Pro	
55 60 65	
CTG CTT ATC GTC TCT GGA AAT GAC CTG GAA CAT CTT CAG CTG GCA TTT	596
Leu Leu Ile Val Ser Gly Asn Asp Leu Glu His Leu Gln Leu Ala Phe	
70 75 80 85	
GGG GCT ATG TAT GCG GGC ATT CCC TAT TGC CCG GTG TCT CCT GCT TAT	644
Gly Ala Met Tyr Ala Gly Ile Pro Tyr Cys Pro Val Ser Pro Ala Tyr	
90 95 100	
TCA CTG CTG TCG CAA GAT TTG GCG AAG CTG CGT CAC ATC GTA GGT CTT	692
Ser Leu Leu Ser Gln Asp Leu Ala Lys Leu Arg His Ile Val Gly Leu	
105 110 115	
CTG CAA CCG GGA CTG GTC TTT GCT GCC GAT GCA GCA CCT TTC CAG CGC	740
Leu Gln Pro Gly Leu Val Phe Ala Ala Asp Ala Ala Pro Phe Gln Arg	
120 125 130 133	
GCT GTT TTG CAA TGG CGG TCG GCG AAA GTT GAT GCG CTG TAT CGT GGT	788
Ala Val Leu Gln Trp Arg Ser Ala Lys Val Asp Ala Leu Tyr Arg Gly	
562 565 570 575	
GAA GAT CAA TCC ATG CTG CGT GAC GAG GCC ACA CTG TGA GTTGGTCAGG	837
Glu Asp Gln Ser Met Leu Arg Asp Glu Ala Thr Leu	
580 585 589	
GGGGGCTTAC TCGGCGTTTT CCGACACTGC GTTGGTTGCG GCAGTGCGCA CCCCCTGGAT	897
TGATTGCGGG GGTGCCCTGT CGCTGGTGTC GCCTATCGAC TTAGGGGTAA AGGTCGCTCG	957

0240-1150E860

CGAAGTTCTG ATGCGTGCGT CGCTTGAACC ACAAATGGTC GATAGCGTAC TCGCAGGCTC	1017
TATGGCTCAA GCAAGCTTTG ATGCTTACCT GCTCCCGCGG CACATTGGCT TGTACAGCGG	1077
TGTTCCCAAG TCGGTTCCGG CCTTGGGGGT GCAGCGCATT TGCGGCACAG GCTTCGAACT	1137
GCTTCGGCAG GCCGGCGAGC AGATTTCCCA AGGCGCTGAT CACGTGCTGT GTGTCGCGGG	1197
CTGCAG	1203

FIG. 2i:

09044-0424

GAATTCCTCCCT GCGACGAAA GGGCGGCAGG CCGCATGGCC ACGGCTGGGC GGTAAGTATGAT	60
GCTTGCGTTA ATCGTTAACC GTTTGAAATT CCTTGCCAAA TTTCGGCGAG AGAATCATGC	120
GGGTACGCCT TTCCGTGCGC TTTGATCTGC GCTTCCGTGC CTTGAATCAG AAAAATAGTT	180
AATTGACAGA ACTATAGGTT CGCAGTAGCT TTTGCTCACC CACCAAATCC ACAGCACTGG	240
GGTGCACG ATG AAT AGC TAC GAT GGC CGT TGG TCT ACC GTT GAT GTG AAG	290
Met Asn Ser Tyr Asp Gly Arg Trp Ser Thr Val Asp Val Lys	
1 5 10	
GTT GAA GAA GGT ATC GCT TGG GTC ACG CTG AAC CGC CCG GAG AAG CGC	338
Val Glu Glu Gly Ile Ala Trp Val Thr Leu Asn Arg Pro Glu Lys Arg	
15 20 25 30	
AAC GCA ATG AGC CCA ACT CTC AAT CGA GAG ATG GTC GAG GTT CTG GAG	386
Asn Ala Met Ser Pro Thr Leu Asn Arg Glu Met Val Glu Val Leu Glu	
35 40 45	
GTG CTG GAG CAG GAC GCA GAT GCT CGC GTG CTT GTT CTG ACT GGT GCA	434
Val Leu Glu Gln Asp Ala Asp Ala Arg Val Leu Val Leu Thr Gly Ala	
50 55 60	
GGC GAA TCC TGG ACC GCG GGC ATG GAC CTG AAG GAG TAT TTC CGC GAG	482
Gly Glu Ser Trp Thr Ala Gly Met Asp Leu Lys Glu Tyr Phe Arg Glu	
65 70 75	
ACC GAT GCT GGC CCC GAA ATT CTG CAA GAG AAG ATT CGT CGGGGACAGC	531
Thr Asp Ala Gly Pro Glu Ile Leu Gln Glu Lys Ile Arg	
80 85 90 91	
AAGCGAACCG GAATTGCCAG CTGGGGCGCC CTCTGGTAAG GTTGGGAAGC CCTGCAAAGT	591
AAACTGGATG GCTTTCTTGC CGCCAAGGAT CTGATGGCGC AGGGGATCAA GATCTGATCA	651
AGAGACAGGA TGAGGATCGT TTCGC ATG ATT GAA CAA GAT GGA TTG CAC GCA	703
Met Ile Glu Gln Asp Gly Leu His Ala	
1 5	
GGT TCT CCG GCC GCT TGG GTG GAG AGG CTA TTC GGC TAT GAC TGG GCA	751
Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala	
10 15 20 25	
CAA CAG ACA ATC GGC TGC TCT GAT GCC GCC GTG TTC CGG CTG TCA GCG	799
Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala	
30 35 40	
CAG GGG CGC CCG GTT CTT TTT GTC AAG ACC GAC CTG TCC GGT GCC CTG	847
Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu	
45 50 55	
AAT GAA CTG CAG GAC GAG GCA GCG CGG CTA TCG TGG CTG GCC ACG ACG	895
Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr	
60 65 70	

G TTCACCGCC GCAGCGAGTG AACTGGCGC AGCGGGAAAC TGGTATGGGT TTAACGTTA	1935
CCTGGCGGCG GGCATGTTGC GGGGAATTC	1964

FIG. 2k:

10/24/43

GAATTCCCCT GCGACGAAA GGGCGGCAGG CCGCATGGCC ACGGCTGGGC GGTAAGTATG 60
GCTTGCGTTA ATCGTTAACC GTTTGAAATT CCTTGCCAAA TTTCGGCGAG AGAATCATGC 120
GGGTACGCCT TTCCGTGCGC TTTGATCTGC GCTTCCGTGC CTTGAATCAG AAAAATAGTT 180
AATTGACAGA ACTATAGGTT CGCAGTAGCT TTTGCTCACC CACCAAATCC ACAGCACTGG 240
GGTGCACG ATG AAT AGC TAC GAT GGC CGT TGG TCT ACC GTT GAT GTG AAG 290
Met Asn Ser Tyr Asp Gly Arg Trp Ser Thr Val Asp Val Lys
1 5 10
GTT GAA GAA GGT ATC GCT TGG GTC ACG CTG AAC CGC CCG GAG AAG CGC 338
Val Glu Glu Gly Ile Ala Trp Val Thr Leu Asn Arg Pro Glu Lys Arg
15 20 25 30
AAC GCA ATG AGC CCA ACT CTC AAT CGA GAG ATG GTC GAG GTT CTG GAG 386
Asn Ala Met Ser Pro Thr Leu Asn Arg Glu Met Val Glu Val Leu Glu
35 40 45
GTG CTG GAG CAG GAC GCA GAT GCT CGC GTG CTT GTT CTG ACT GGT GCA 434
Val Leu Glu Gln Asp Ala Asp Ala Arg Val Leu Val Leu Thr Gly Ala
50 55 60
GGC GAA TCC TGG ACC GCG GGC ATG GAC CTG AAG GAG TAT TTC CGC GAG 482
Gly Glu Ser Trp Thr Ala Gly Met Asp Leu Lys Glu Tyr Phe Arg Glu
65 70 75
ACC GAT GCT GGC CCC GAA ATT CTG CAA GAG AAG ATT CGT CGC GAG CAG 530
Thr Asp Ala Gly Pro Glu Ile Leu Gln Glu Lys Ile Arg Arg Glu Gln
80 85 90 92 255
GGC ATG AAG CAG TTC CTT GAC GAG AAA AGC ATC AAG CCG GGC TTG CAG 578
Gly Met Lys Gln Phe Leu Asp Glu Lys Ser Ile Lys Pro Gly Leu Gln
260 265 270
ACC TAC AAG CGC TGA TAAATGCGCC GGGGCCCTCG CTGCGCCCCC GGCCTTCCAA 633
Thr Tyr Lys Arg
275 276
TAATGACAAT AATGAGGAGT GCCCAATGTT TCACGTGCCC CTGCTTATTG GTGGTAAGCC 693
TTGTTTCAGCA TCTGATGAGC GCACCTTCGA GCGTCGTAGC CCGCTGACCG GAGAAGTGGT 753
ATCGCGCGTC GCTGCTGCCA GTTTGGAAGA TGCGGACGCC GCAGTGGCCG CTGCACAGGC 813
TGCGTTTCCT GAATGGGCGG CGCTTGCTCC GAGCGAACGC CGTGCCCGAC TGCTGCGAGC 873
GGCGGATCTT CTAGAGGACC GTTCTTCCGA GTTCACCGCC GCAGCGAGTG AACTGGCGC 933
AGCGGGAAAC TGGTATGGGT TTAACGTTTA CCTGGCGGCG GGCATGTTGC GGGGAATTC 992

FIG. 21:

ACG Thr	ACG Thr	GGC Gly	GTT Val	CCT Pro	TGC Cys	GCA Ala	GCT Ala	GTG Val	CTC Leu	GAC Asp	GTT Val	GTC Val	ACT Thr	GAA Glu	GCG Ala	1475	
758085																	
GGA Gly	AGG Arg	GAC Asp	TGG Trp	CTG Leu	CTA Leu	TTG Leu	GGC Gly	GAA Glu	GTG Val	CCG Pro	GGG Gly	CAG Gln	GAT Asp	CTC Leu	CTG Leu	1523	
9095100																	
TCA Ser	TCT Ser	CAC His	CTT Leu	GCT Ala	CCT Pro	GCC Ala	GAG Glu	AAA Lys	GTA Val	TCC Ser	ATC Ile	ATG Met	GCT Ala	GAT Asp	GCA Ala	1571	
105110115																	
ATG Met	CGG Arg	CGG Arg	CTG Leu	CAT His	ACG Thr	CTT Leu	GAT Asp	CCG Pro	GCT Ala	ACC Thr	TGC Cys	CCA Pro	TTC Phe	GAC Asp	CAC His	1619	
120125130135																	
CAA Gln	GCG Ala	AAA Lys	CAT His	CGC Arg	ATC Ile	GAG Glu	CGA Arg	GCA Ala	CGT Arg	ACT Thr	CGG Arg	ATG Met	GAA Glu	GCC Ala	GGT Gly	1667	
140145150																	
CTT Leu	GTC Val	GAT Asp	CAG Gln	GAT Asp	GAT Asp	CTG Leu	GAC Asp	GAA Glu	GAG Glu	CAT His	CAG Gln	GGG Gly	CTC Leu	GCG Ala	CCA Pro	1715	
155160165																	
GCC Ala	GAA Glu	CTG Leu	TTC Phe	GCC Ala	AGG Arg	CTC Leu	AAG Lys	GCG Ala	CGC Arg	ATG Met	CCC Pro	GAC Asp	GGC Gly	GAG Glu	GAT Asp	1763	
170175180																	
CTC Leu	GTC Val	GTG Val	ACC Thr	CAT His	GGC Gly	GAT Asp	GCC Ala	TGC Cys	TTG Leu	CCG Pro	AAT Asn	ATC Ile	ATG Met	GTG Val	GAA Glu	1811	
185190195																	
AAT Asn	GGC Gly	CGC Arg	TTT Phe	TCT Ser	GGA Gly	TTC Phe	ATC Ile	GAC Asp	TGT Cys	GGC Gly	CGG Arg	CTG Leu	GGT Gly	GTG Val	GCG Ala	1859	
200205210215																	
GAC Asp	CGC Arg	TAT Tyr	CAG Gln	GAC Asp	ATA Ile	GCG Ala	TTG Leu	GCT Ala	ACC Thr	CGT Arg	GAT Asp	ATT Ile	GCT Ala	GAA Glu	GAG Glu	1907	
220225230																	
CTT Leu	GGC Gly	GGC Gly	GAA Glu	TGG Trp	GCT Ala	GAC Asp	CGC Arg	TTC Phe	CTC Leu	GTG Val	CTT Leu	TAC Tyr	GGT Gly	ATC Ile	GCC Ala	1955	
235240245																	
GCT Ala	CCC Pro	GAT Asp	TCG Ser	CAG Gln	CGC Arg	ATC Ile	GCC Ala	TTC Phe	TAT Tyr	CGC Arg	CTT Leu	CTT Leu	GAC Asp	GAG Glu	TTC Phe	2003	
250255260																	
TTC Phe	TGA	GCGGGACTCT			GGGGTTTCGAA			ATGACCGACC			AAGCGACGCC			CG	GCC Ala	CAG Gln	2057
264421																	
CGC Arg	GTC Val	GAT Asp	TCG Ser	GGC Gly	ATT Ile	TGC Cys	CAT His	ATC Ile	AAT Asn	GGA Gly	CCG Pro	ACT Thr	GTG Val	CAT His	GAC Asp	2105	
425430435																	

GAG GCT CAG ATG CCA TTC GGT GGG GTG AAG TCC AGC GGC TAC GGC AGC	2153
Glu Ala Gln Met Pro Phe Gly Gly Val Lys Ser Ser Gly Tyr Gly Ser	
440 445 450	
TTC GGC AGT CGA GCA TCG ATT GAG CAC TTT ACC CAG CTG CGC TGG CTG	2201
Phe Gly Ser Arg Ala Ser Ile Glu His Phe Thr Gln Leu Arg Trp Leu	
455 460 465 470	
ACC ATT CAG AAT GGC CCG CGG CAC TAT CCA ATC TAA ATCGATCTTC	2247
Thr Ile Gln Asn Gly Pro Arg His Tyr Pro Ile	
475 480 481	
GGGCGCCGCG GGCATCATGC CCGCGGCGCT CGCCTCATTT CAATCTCTAA CTTGATAAAA	2307
ACAGAGCTGT TCTCCGGTCT TGGTGGATCA AGGCCAGTCG CGGAGAGTCT CGAAGAGGAG	2367
AGTACAGTGA ACGCCGAGTC CACATTGCAA CCGCAGGCAT CATCATGCTC TGCTCAGCCA	2427
CGCTACCGCA GTGTGTCGAT TGGTCATCCT CCGGTTGAGG TTACGCAAGA CGCTGGAGGT	2487
ATTGTCCGGA TGC GTTCTCT CGAGGCGCTT CTTCCCTTCC CGGGTGAAT TC	2539

FIG. 2m:

440-450-460-470-480-490-500-510-520-530-540-550-560-570-580-590-600

GCT CTT GAT CTT TTC GGT CGT GAG TTC GGA GAC GTA GCC ACC TAC TCC	1624
Ala Leu Asp Leu Phe Gly Arg Glu Phe Gly Asp Val Ala Thr Tyr Ser	
45 50 55	
CAA CAT CAG CCG GAC TCC GAT TAC CTC GGG AAC TTG CTC CGT AGT AAG	1672
Gln His Gln Pro Asp Ser Asp Tyr Leu Gly Asn Leu Leu Arg Ser Lys	
60 65 70	
ACA TTC ATC GCG CTT GCT GCC TTC GAC CAA GAA GCG GTT GTT GGC GCT	1720
Thr Phe Ile Ala Leu Ala Ala Phe Asp Gln Glu Ala Val Val Gly Ala	
75 80 85 90	
CTC GCG GCT TAC GTT CTG CCC AGG TTT GAG CAG CCG CGT AGT GAG ATC	1768
Leu Ala Ala Tyr Val Leu Pro Arg Phe Glu Gln Pro Arg Ser Glu Ile	
95 100 105	
TAT ATC TAT GAT CTC GCA GTC TCC GGC GAG CAC CGG AGG CAG GGC ATT	1816
Tyr Ile Tyr Asp Leu Ala Val Ser Gly Glu His Arg Arg Gln Gly Ile	
110 115 120	
GCC ACC GCG CTC ATC AAT CTC CTC AAG CAT GAG GCC AAC GCG CTT GGT	1864
Ala Thr Ala Leu Ile Asn Leu Leu Lys His Glu Ala Asn Ala Leu Gly	
125 130 135	
GCT TAT GTG ATC TAC GTG CAA GCA GAT TAC GGT GAC GAT CCC GCA GTG	1912
Ala Tyr Val Ile Tyr Val Gln Ala Asp Tyr Gly Asp Asp Pro Ala Val	
140 145 150	
GCT CTC TAT ACA AAG TTG GGC ATA CGG GAA GAA GTG ATG CAC TTT GAT	1960
Ala Leu Tyr Thr Lys Leu Gly Ile Arg Glu Glu Val Met His Phe Asp	
155 160 165 170	
ATC GAC CCA AGT ACC GCC ACC TAA CAATTCGTTT AAGCCGAGAT CGGCTTCCCA	2014
Ile Asp Pro Ser Thr Ala Thr	
175 177	
A TTG GCC CAG CGC GTC GAT TCG GGC ATT TGC CAT ATC AAT GGA CCG ACT	2063
Leu Ala Gln Arg Val Asp Ser Gly Ile Cys His Ile Asn Gly Pro Thr	
420 425 430 435	
GTG CAT GAC GAG GCT CAG ATG CCA TTC GGT GGG GTG AAG TCC AGC GGC	2111
Val His Asp Glu Ala Gln Met Pro Phe Gly Gly Val Lys Ser Ser Gly	
440 445 450	
TAC GGC AGC TTC GGC AGT CGA GCA TCG ATT GAG CAC TTT ACC CAG CTG	2159
Tyr Gly Ser Phe Gly Ser Arg Ala Ser Ile Glu His Phe Thr Gln Leu	
455 460 465	
CGC TGG CTG ACC ATT CAG AAT GGC CCG CGG CAC TAT CCA ATC TAA	2204
Arg Trp Leu Thr Ile Gln Asn Gly Pro Arg His Tyr Pro Ile	
470 475 480 481	
ATCGATCTTC GGGCGCCGCG GGCATCATGC CCGCGGCGCT CGCCTCATTT CAATCTCTAA	2264
CTTGATAAAA ACAGAGCTGT TCTCCGGTCT TGGTGGATCA AGGCCAGTCG CGGAGAGTCT	2324

09830544-04204

CGAAGAGGAG AGTACAGTGA ACGCCGAGTC CACATTGCAA CCGCAGGCAT CATCATGCTC	2384
TGCTCAGCCA CGCTACCGCA GTGTGTCGAT TGGTCATCCT CCGGTTGAGG TTACGCAAGA	2444
CGCTGGAGGT ATTGTCCGGA TGCCTTCTCT CGAGGCGCTT CTTCCCTTCC CGGGTGGAAT	2504
TC	2506

FIG. 2n:

49240-4450860

GAATTCCAAT AATGACAATA ATGAGGAGTG CCCA ATG TTT CAC GTG CCC CTG CTT	55
Met Phe His Val Pro Leu Leu	
1 5	
ATT GGT GGT AAG CCT TGT TCA GCA TCT GAT GAG CGC ACC TTC GAG CGT	103
Ile Gly Gly Lys Pro Cys Ser Ala Ser Asp Glu Arg Thr Phe Glu Arg	
10 15 20	
CGT AGC CCG CTG ACC GGA GAA GTG GTA TCG CGC GTC GCT GCT GCC AGT	151
Arg Ser Pro Leu Thr Gly Glu Val Val Ser Arg Val Ala Ala Ala Ser	
25 30 35	
TTG GAA GAT GCG GAC GCC GCA GTG GCC GCT GCA CAG GCT GCG TTT CCT	199
Leu Glu Asp Ala Asp Ala Ala Val Ala Ala Gln Ala Ala Phe Pro	
40 45 50 55	
GAA TGG GCG GCG CTT GCT CCG AGC GAA CGC CGT GCC CGA CTG CTG CGA	247
Glu Trp Ala Ala Leu Ala Pro Ser Glu Arg Arg Ala Arg Leu Leu Arg	
60 65 70	
GCG GCG GAT CTT CTA GAG GAC CGT TCT TCC GAG TTC ACC GCC GCA GCG	295
Ala Ala Asp Leu Leu Glu Asp Arg Ser Ser Glu Phe Thr Ala Ala Ala	
75 80 85	
AGT GAA ACT GGC GCA GCG GGA AAC TGG TAT GGG TTT AAC GTT TAC CTG	343
Ser Glu Thr Gly Ala Ala Gly Asn Trp Tyr Gly Phe Asn Val Tyr Leu	
90 95 100	
GCG GCG GGC ATG TTG CGG GAA GCC GCG GCC ATG ACC ACA CAG ATT CAG	391
Ala Ala Gly Met Leu Arg Glu Ala Ala Ala Met Thr Thr Gln Ile Gln	
105 110 115	
GGC GAT GTC ATT CCG TCC AAT GTG CCC GGT AGC TTT GCC ATG GCG GTT	439
Gly Asp Val Ile Pro Ser Asn Val Pro Gly Ser Phe Ala Met Ala Val	
120 125 130 135	
CGA CAG CCA TGT GGC GTG GTG CTC GGT ATT GCG CCT TGG AAT GCT CCG	487
Arg Gln Pro Cys Gly Val Val Leu Gly Ile Ala Pro Trp Asn Ala Pro	
140 145 150	
GTA ATC CTT GGC GTA CGG GCT GTT GCG ATG CCG TTG GCA TGC GGC AAT	535
Val Ile Leu Gly Val Arg Ala Val Ala Met Pro Leu Ala Cys Gly Asn	
155 160 165	
ACC GTG GTG TTG AAA AGC TCT GAG CTG AGT CCC TTT ACC CAT CGC CTG	583
Thr Val Val Leu Lys Ser Ser Glu Leu Ser Pro Phe Thr His Arg Leu	
170 175 180	
ATT GGT CAG GTG TTG CAT GAT GCT GGT CTG GGG GAT GGC GTG GTG AAT	631
Ile Gly Gln Val Leu His Asp Ala Gly Leu Gly Asp Gly Val Val Asn	
185 190 195	
GTC ATC AGC AAT GCC CCG CAA GAC GCT CCT GCG GTG GTG GAG CGA CTG	679
Val Ile Ser Asn Ala Pro Gln Asp Ala Pro Ala Val Val Glu Arg Leu	
200 205 210 215	

102240-41505860

CCGCAGGCAT CATCATGCTC TGCTCAGCCA CGCTACCGCA GTGTGTCGAT TGGTCATCCT	1489
CCGGTTGAGG TTACGCAAGA CGCTGGAGGT ATTGTCCGGA TGC GTTCTCT CGAGGCGCTT	1549
CTTCCCTTCC CGGGTGGAAT TC	1571

FIG. 20:

0980511-0427
10/24/04 15:06:50

GAATTCCGCG GTCGGCGAAA GTTGATGCGC TGTATCGTGG TGAAGATCAA TCCATGCTGC	60
GTGACGAGGC CACACT GTG AGT TGG TCA GGG GGG GCT TAC TCG GCG TTT TCC	112
Met Ser Trp Ser Gly Gly Ala Tyr Ser Ala Phe Ser	
1 5 10	
GAC ACT GCG TTG GTT GCG GCA GTG CGC ACC CCC TGG ATT GAT TGC GGG	160
Asp Thr Ala Leu Val Ala Ala Val Arg Thr Pro Trp Ile Asp Cys Gly	
15 20 25	
GGT GCC CTG TCG CTG GTG TCG CCT ATC GAC TTA GGG GTA AAG GTC GCT	208
Gly Ala Leu Ser Leu Val Ser Pro Ile Asp Leu Gly Val Lys Val Ala	
30 35 40	
CGC GAA GTT CTG ATG CGT GCG TCG CTT GAA CCA CAA ATG GTC GAT AGC	256
Arg Glu Val Leu Met Arg Ala Ser Leu Glu Pro Gln Met Val Asp Ser	
45 50 55 60	
GTA CTC GCA GGC TCT ATG GCT CAA GCA AGC TTT GAT GCT TAC CTG CTC	304
Val Leu Ala Gly Ser Met Ala Gln Ala Ser Phe Asp Ala Tyr Leu Leu	
65 70 75	
CCG CGG CAC ATT GGC TTG TAC AGC GGT GTT CCC AAG TCG GTT CCG GCC	352
Pro Arg His Ile Gly Leu Tyr Ser Gly Val Pro Lys Ser Val Pro Ala	
80 85 90	
TTG GGG GTG CAG CGC ATT TGC GGC ACA GGC TTC GAA CTG CTT CGG CAG	400
Leu Gly Val Gln Arg Ile Cys Gly Thr Gly Phe Glu Leu Leu Arg Gln	
95 100 105	
GCC GGC GAG CAG ATT TCC CAA GGC GCT GAT CAC GTG CTG TGT GTC GCG	448
Ala Gly Glu Gln Ile Ser Gln Gly Ala Asp His Val Leu Cys Val Ala	
110 115 120	
GCA GAG TCC ATG TCG CGT AAC CCC ATC GCG TCG TAT ACA CAC CGG GGC	496
Ala Glu Ser Met Ser Arg Asn Pro Ile Ala Ser Tyr Thr His Arg Gly	
125 130 135 140	
GGG TTC CGC CTC GGT GCG CCC GTT GAG TTC AAG GAT TTT TTG TGG GAG	544
Gly Phe Arg Leu Gly Ala Pro Val Glu Phe Lys Asp Phe Leu Trp Glu	
145 150 155	
GCA TTG TTT GAT CCT GCT CCA GGA CTC GAC ATG ATC GCT ACC GCA GAA	592
Ala Leu Phe Asp Pro Ala Pro Gly Leu Asp Met Ile Ala Thr Ala Glu	
160 165 170	
AAC CTG GGGACAGCAA GCGAACCGGA ATTGCCAGCT GGGGCGCCCT CTGGTAAGGT	648
Asn Leu	
174	
TGGGAAGCCC TGCAAAGTAA ACTGGATGGC TTTCTTGCCG CCAAGGATCT GATGGCGCAG	708
GGGATCAAGA TCTGATCAAG AGACAGGATG AGGATCGTTT CGC ATG ATT GAA CAA	763
Met Ile Glu Gln	
1	

09830514 042701

GAT Asp 5	GGA Gly	TTG Leu	CAC His	GCA Ala	GGT Gly 10	TCT Ser	CCG Pro	GCC Ala	GCT Ala	TGG Trp 15	GTG Val	GAG Glu	AGG Arg	CTA Leu	TTC Phe 20	811
GGC Gly	TAT Tyr	GAC Asp	TGG Trp	GCA Ala 25	CAA Gln	CAG Gln	ACA Thr	ATC Ile	GGC Gly 30	TGC Cys	TCT Ser	GAT Asp	GCC Ala	GCC Ala 35	GTG Val	859
TTC Phe	CGG Arg	CTG Leu	TCA Ser 40	GCG Ala	CAG Gln	GGG Gly	CGC Arg	CCG Pro 45	GTT Val	CTT Leu	TTT Phe	GTC Val	AAG Lys 50	ACC Thr	GAC Asp	907
CTG Leu	TCC Ser	GGT Gly 55	GCC Ala	CTG Leu	AAT Asn	GAA Glu	CTG Leu 60	CAG Gln	GAC Asp	GAG Glu	GCA Ala	GCG Ala 65	CGG Arg	CTA Leu	TCG Ser	955
TGG Trp 70	CTG Leu	GCC Ala	ACG Thr	ACG Thr	GGC Gly	GTT Val 75	CCT Pro	TGC Cys	GCA Ala	GCT Ala	GTG Val 80	CTC Leu	GAC Asp	GTT Val	GTC Val	1003
ACT Thr 85	GAA Glu	GCG Ala	GGA Gly	AGG Arg	GAC Asp 90	TGG Trp	CTG Leu	CTA Leu	TTG Leu	GGC Gly 95	GAA Glu	GTG Val	CCG Pro	GGG Gly	CAG Gln 100	1051
GAT Asp	CTC Leu	CTG Leu	TCA Ser	TCT Ser 105	CAC His	CTT Leu	GCT Ala	CCT Pro	GCC Ala 110	GAG Glu	AAA Lys	GTA Val	TCC Ser	ATC Ile 115	ATG Met	1099
GCT Ala	GAT Asp	GCA Ala	ATG Met 120	CGG Arg	CGG Arg	CTG Leu	CAT His	ACG Thr 125	CTT Leu	GAT Asp	CCG Pro	GCT Ala	ACC Thr 130	TGC Cys	CCA Pro	1147
TTC Phe	GAC Asp	CAC His 135	CAA Gln	GCG Ala	AAA Lys	CAT His	CGC Arg 140	ATC Ile	GAG Glu	CGA Arg	GCA Ala	CGT Arg 145	ACT Thr	CGG Arg	ATG Met	1195
GAA Glu 150	GCC Ala	GGT Gly	CTT Leu	GTC Val	GAT Asp	CAG Gln 155	GAT Asp	GAT Asp	CTG Leu	GAC Asp	GAA Glu 160	GAG Glu	CAT His	CAG Gln	GGG Gly	1243
CTC Leu 165	GCG Ala	CCA Pro	GCC Ala	GAA Glu	CTG Leu 170	TTC Phe	GCC Ala	AGG Arg	CTC Leu	AAG Lys 175	GCG Ala	CGC Arg	ATG Met	CCC Pro	GAC Asp 180	1291
GGC Gly	GAG Glu	GAT Asp	CTC Leu	GTC Val 185	GTG Val	ACC Thr	CAT His	GGC Gly	GAT Asp 190	GCC Ala	TGC Cys	TTG Leu	CCG Pro	AAT Asn 195	ATC Ile	1339
ATG Met	GTG Val	GAA Glu	AAT Asn 200	GGC Gly	CGC Arg	TTT Phe	TCT Ser	GGA Gly 205	TTC Phe	ATC Ile	GAC Asp	TGT Cys	GGC Gly 210	CGG Arg	CTG Leu	1387
GGT Gly	GTG Val	GCG Ala 215	GAC Asp	CGC Arg	TAT Tyr	CAG Gln	GAC Asp 220	ATA Ile	GCG Ala	TTG Leu	GCT Ala	ACC Thr 225	CGT Arg	GAT Asp	ATT Ile	1435

0930514-012701

GCT GAA GAG CTT GGC GGC GAA TGG GCT GAC CGC TTC CTC GTG CTT TAC	1483
Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr	
230 235 240	
GGT ATC GCC GCT CCC GAT TCG CAG CGC ATC GCC TTC TAT CGC CTT CTT	1531
Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu	
245 250 255 260	
GAC GAG TTC TTC TGA GCGGGACTCT GGGGTTCGAA ATGACCGACC AAGCGACGCC	1586
Asp Glu Phe Phe	
264	
CA TTG AGG GCG CAA GAG GAG AAA TGG ATT GAC CAA GAG ATC GTG GCT	1633
Leu Arg Ala Gln Glu Glu Lys Trp Ile Asp Gln Glu Ile Val Ala	
197 200 205 210	
GTT ACG GAT GAA CAG TTC GAT TTA GAG GGC TAC AAC AGT CGA GCA ATT	1681
Val Thr Asp Glu Gln Phe Asp Leu Glu Gly Tyr Asn Ser Arg Ala Ile	
215 220 225	
GAA CTG CCT CGG AAG GCA AAA TTG TTG ATC GTG ACA GTC ATC CGC GGC	1729
Glu Leu Pro Arg Lys Ala Lys Leu Leu Ile Val Thr Val Ile Arg Gly	
230 235 240	
CTA GCA GTC TTT GAA GCC CTT TCC CGA TTG AAG CCT GTT CAT TCT GGC	1777
Leu Ala Val Phe Glu Ala Leu Ser Arg Leu Lys Pro Val His Ser Gly	
245 250 255	
GGG GTG CAG ACT GCG GGC AAC AGC TGT GCC GTA GTG GAC GGC GCC GCG	1825
Gly Val Gln Thr Ala Gly Asn Ser Cys Ala Val Val Asp Gly Ala Ala	
260 265 270 275	
GCG GCT TTG GTG GCT CGA GAG TCG TCT GCG ACA CAG CCG GTC TTG GCT	1873
Ala Ala Leu Val Ala Arg Glu Ser Ser Ala Thr Gln Pro Val Leu Ala	
280 285 290	
AGG ATA CTG GCT ACC TCC GTA GTC GGG ATC GAG CCC GAG CAT ATG GGG	1921
Arg Ile Leu Ala Thr Ser Val Val Gly Ile Glu Pro Glu His Met Gly	
295 300 305	
CTC GGC CCT GCG CCC GCG ATT CGC CTG CTG CTT GCG CGT AGT GAT CTT	1969
Leu Gly Pro Ala Pro Ala Ile Arg Leu Leu Leu Ala Arg Ser Asp Leu	
310 315 320	
AGT TTG AGG GAT ATC GAC CTC TTT GAG ATA AAC GAG GCG CAG GCC GCC	2017
Ser Leu Arg Asp Ile Asp Leu Phe Glu Ile Asn Glu Ala Gln Ala Ala	
325 330 335	
CAA GTT CTA GCG GTA CAG CAT GAA TTG GGT ATT GAG CAC TCA AAA CTT	2065
Gln Val Leu Ala Val Gln His Glu Leu Gly Ile Glu His Ser Lys Leu	
340 345 350 355	
AAT ATT TGG GGC GGG GCC ATT GCA CTT GGA CAC CCG CTT GCC GCG ACC	2113
Asn Ile Trp Gly Gly Ala Ile Ala Leu Gly His Pro Leu Ala Ala Thr	
360 365 370	

102240"4450E860

AAC CTG GGGGAGAGGC GGTTTGCCTA TTGGGCGCAT GCATAAAAAC TGTTGTAATT 648
Asn Leu
174

CGCAGTGGCG	GTTTT	CATGG	CTTGTT	TATGA	CTGTTTTTTTT	GTACAGTCTA	TGCCTCGGGC	948
ATCCAAGC	AGCAAG	CGCG	TTACGCC	GTG	GGTCGATGTTTG	ATGTTATGGA	GCAGCAACG	1007
ATG TTA CGC AGC AGC AAC GAT GTT ACG CAG CAG GGC AGT CGC CCT AAA	1055							
Met Leu Arg Ser Ser Asn Asp Val Thr Gln Gln Gly Ser Arg Pro Lys								
1 5 10 15								
ACA AAG TTA GGT GGC TCA AGT ATG GGC ATC ATT CGC ACA TGT AGG CTC	1103							
Thr Lys Leu Gly Gly Ser Ser Met Gly Ile Ile Arg Thr Cys Arg Leu								
20 25 30								
GGC CCT GAC CAA GTC AAA TCC ATG CGG GCT GCT CTT GAT CTT TTC GGT	1151							
Gly Pro Asp Gln Val Lys Ser Met Arg Ala Ala Leu Asp Leu Phe Gly								
35 40 45								
CGT GAG TTC GGA GAC GTA GCC ACC TAC TCC CAA CAT CAG CCG GAC TCC	1199							
Arg Glu Phe Gly Asp Val Ala Thr Tyr Ser Gln His Gln Pro Asp Ser								
50 55 60								
GAT TAC CTC GGG AAC TTG CTC CGT AGT AAG ACA TTC ATC GCG CTT GCT	1247							
Asp Tyr Leu Gly Asn Leu Leu Arg Ser Lys Thr Phe Ile Ala Leu Ala								
65 70 75 80								
GCC TTC GAC CAA GAA GCG GTT GTT GGC GCT CTC GCG GCT TAC GTT CTG	1295							
Ala Phe Asp Gln Glu Ala Val Val Gly Ala Leu Ala Ala Tyr Val Leu								
85 90 95								
CCC AGG TTT GAG CAG CCG CGT AGT GAG ATC TAT ATC TAT GAT CTC GCA	1343							
Pro Arg Phe Glu Gln Pro Arg Ser Glu Ile Tyr Ile Tyr Asp Leu Ala								
100 105 110								
GTC TCC GGC GAG CAC CGG AGG CAG GGC ATT GCC ACC GCG CTC ATC AAT	1391							
Val Ser Gly Glu His Arg Arg Gln Gly Ile Ala Thr Ala Leu Ile Asn								
115 120 125								
CTC CTC AAG CAT GAG GCC AAC GCG CTT GGT GCT TAT GTG ATC TAC GTG	1439							
Leu Leu Lys His Glu Ala Asn Ala Leu Gly Ala Tyr Val Ile Tyr Val								
130 135 140								
CAA GCA GAT TAC GGT GAC GAT CCC GCA GTG GCT CTC TAT ACA AAG TTG	1487							
Gln Ala Asp Tyr Gly Asp Asp Pro Ala Val Ala Leu Tyr Thr Lys Leu								
145 150 155 160								
GGC ATA CGG GAA GAA GTG ATG CAC TTT GAT ATC GAC CCA AGT ACC GCC	1535							
Gly Ile Arg Glu Glu Val Met His Phe Asp Ile Asp Pro Ser Thr Ala								
165 170 175								
ACC TAA CAATTCGTTT AAGCCGAGAT CGGCTTCCCA TTG AGG GCG CAA GAG GAG	1589							
Thr Leu Arg Ala Gln Glu Glu								
177 197 200								
AAA TGG ATT GAC CAA GAG ATC GTG GCT GTT ACG GAT GAA CAG TTC GAT	1637							
Lys Trp Ile Asp Gln Glu Ile Val Ala Val Thr Asp Glu Gln Phe Asp								
205 210 215								

0930514-04240-47506860

TTA GAG GGC TAC AAC AGT CGA GCA ATT GAA CTG CCT CGG AAG GCA AAA	1685
Leu Glu Gly Tyr Asn Ser Arg Ala Ile Glu Leu Pro Arg Lys Ala Lys	
220 225 230	
TTG TTG ATC GTG ACA GTC ATC CGC GGC CTA GCA GTC TTT GAA GCC CTT	1733
Leu Leu Ile Val Thr Val Ile Arg Gly Leu Ala Val Phe Glu Ala Leu	
235 240 245 250	
TCC CGA TTG AAG CCT GTT CAT TCT GGC GGG GTG CAG ACT GCG GGC AAC	1781
Ser Arg Leu Lys Pro Val His Ser Gly Gly Val Gln Thr Ala Gly Asn	
255 260 265	
AGC TGT GCC GTA GTG GAC GGC GCC GCG GCG GCT TTG GTG GCT CGA GAG	1829
Ser Cys Ala Val Val Asp Gly Ala Ala Ala Leu Val Ala Arg Glu	
270 275 280	
TCG TCT GCG ACA CAG CCG GTC TTG GCT AGG ATA CTG GCT ACC TCC GTA	1877
Ser Ser Ala Thr Gln Pro Val Leu Ala Arg Ile Leu Ala Thr Ser Val	
285 290 295	
GTC GGG ATC GAG CCC GAG CAT ATG GGG CTC GGC CCT GCG CCC GCG ATT	1925
Val Gly Ile Glu Pro Glu His Met Gly Leu Gly Pro Ala Pro Ala Ile	
300 305 310	
CGC CTG CTG CTT GCG CGT AGT GAT CTT AGT TTG AGG GAT ATC GAC CTC	1973
Arg Leu Leu Leu Ala Arg Ser Asp Leu Ser Leu Arg Asp Ile Asp Leu	
315 320 325 330	
TTT GAG ATA AAC GAG GCG CAG GCC GCC CAA GTT CTA GCG GTA CAG CAT	2021
Phe Glu Ile Asn Glu Ala Gln Ala Ala Gln Val Leu Ala Val Gln His	
335 340 345	
GAA TTG GGT ATT GAG CAC TCA AAA CTT AAT ATT TGG GGC GGG GCC ATT	2069
Glu Leu Gly Ile Glu His Ser Lys Leu Asn Ile Trp Gly Gly Ala Ile	
350 355 360	
GCA CTT GGA CAC CCG CTT GCC GCG ACC GGA TTG CGT CTC TGC ATG ACC	2117
Ala Leu Gly His Pro Leu Ala Ala Thr Gly Leu Arg Leu Cys Met Thr	
365 370 375	
CTC GCT CAC CAA TTG CAA GCT AAT AAC TTT CGA TAT GGA ATT GCC TCG	2165
Leu Ala His Gln Leu Gln Ala Asn Asn Phe Arg Tyr Gly Ile Ala Ser	
380 385 390	
GCA TGC ATT GGT GGG GGA CAG GGG ATG GCG GTT CTT TTA GAG AAT CCC	2213
Ala Cys Ile Gly Gly Gly Gln Gly Met Ala Val Leu Leu Glu Asn Pro	
395 400 405 410	
CAC TTC GGT TCG TCC TCT GCA CGA AGT TCG ATG ATT AAC AGA GTT GAC	2261
His Phe Gly Ser Ser Ser Ala Arg Ser Ser Met Ile Asn Arg Val Asp	
415 420 425	
CAC TAT CCA CTG AGC TAA CGGGCATCTC CTTTGTGCT TTGAGGTGGC	2309
His Tyr Pro Leu Ser	
430 431	

0050504020

GCACGAAGGA	GGGCTCGAAA	ATCTCTGCTA	AAAACAAGAA	GAAGGAACAG	GGAACATGAT	2369
TAGTTTCGCT	CGTATGGCAG	AAAGTTTAGG	AGTCCAGGCT	AAACTTGCCC	TTGCCTTCGC	2429
ACTCGTATTA	TGTGTCGGGC	TGATTGTTAC	CGGCACGGGT	TTCTACAGTG	TACATACCTT	2489
GTCAGGGTTG	GTGGGAATTC					2509

FIG. 2q:

19/2/40 1450660

GAATTCGCG	GTCGGCGAAA	GTGATGCGC	TGTATCGTG	TGAAGATCAA	TCCATGCTGC		60
GTGACGAGGC	CACACT	GTG AGT TGG TCA GGG GGG GCT TAC TCG GCG TTT TCC					112
		Met Ser Trp Ser Gly Gly Ala Tyr Ser Ala Phe Ser					
		1		5		10	
GAC ACT GCG TTG GTT GCG GCA GTG CGC ACC CCC TGG ATT GAT TGC GGG							160
Asp Thr Ala Leu Val Ala Ala Val Arg Thr Pro Trp Ile Asp Cys Gly							
	15			20		25	
GGT GCC CTG TCG CTG GTG TCG CCT ATC GAC TTA GGG GTA AAG GTC GCT							208
Gly Ala Leu Ser Leu Val Ser Pro Ile Asp Leu Gly Val Lys Val Ala							
	30			35		40	
CGC GAA GTT CTG ATG CGT GCG TCG CTT GAA CCA CAA ATG GTC GAT AGC							256
Arg Glu Val Leu Met Arg Ala Ser Leu Glu Pro Gln Met Val Asp Ser							
	45			50		55	60
GTA CTC GCA GGC TCT ATG GCT CAA GCA AGC TTT GAT GCT TAC CTG CTC							304
Val Leu Ala Gly Ser Met Ala Gln Ala Ser Phe Asp Ala Tyr Leu Leu							
			65			70	75
CCG CGG CAC ATT GGC TTG TAC AGC GGT GTT CCC AAG TCG GTT CCG GCC							352
Pro Arg His Ile Gly Leu Tyr Ser Gly Val Pro Lys Ser Val Pro Ala							
			80			85	90
TTG GGG GTG CAG CGC ATT TGC GGC ACA GGC TTC GAA CTG CTT CGG CAG							400
Leu Gly Val Gln Arg Ile Cys Gly Thr Gly Phe Glu Leu Leu Arg Gln							
		95				100	105
GCC GGC GAG CAG ATT TCC CAA GGC GCT GAT CAC GTG CTG TGT GTC GCG							448
Ala Gly Glu Gln Ile Ser Gln Gly Ala Asp His Val Leu Cys Val Ala							
		110				115	120
GCA GAG TCC ATG TCG CGT AAC CCC ATC GCG TCG TAT ACA CAC CGG GGC							496
Ala Glu Ser Met Ser Arg Asn Pro Ile Ala Ser Tyr Thr His Arg Gly							
		125				130	140
GGG TTC CGC CTC GGT GCG CCC GTT GAG TTC AAG GAT TTT TTG TGG GAG							544
Gly Phe Arg Leu Gly Ala Pro Val Glu Phe Lys Asp Phe Leu Trp Glu							
			145			150	155
GCA TTG TTT GAT CCT GCT CCA GGA CTC GAC ATG ATC GCT ACC GCA GAA							592
Ala Leu Phe Asp Pro Ala Pro Gly Leu Asp Met Ile Ala Thr Ala Glu							
			160			165	170
AAC CTG GCG CGC A TTG AGG GCG CAA GAG GAG AAA TGG ATT GAC CAA GAG							641
Asn Leu Ala Arg Leu Arg Ala Gln Glu Glu Lys Trp Ile Asp Gln Glu							
		175	176	197		200	205
ATC GTG GCT GTT ACG GAT GAA CAG TTC GAT TTA GAG GGC TAC AAC AGT							689
Ile Val Ala Val Thr Asp Glu Gln Phe Asp Leu Glu Gly Tyr Asn Ser							
		210				215	220
CGA GCA ATT GAA CTG CCT CGG AAG GCA AAA TTG TTG ATC GTG ACA GTC							737
Arg Ala Ile Glu Leu Pro Arg Lys Ala Lys Leu Leu Ile Val Thr Val							
		225				230	235
							240

ATC CGC GGC CTA GCA GTC TTT GAA GCC CTT TCC CGA TTG AAG CCT GTT	785
Ile Arg Gly Leu Ala Val Phe Glu Ala Leu Ser Arg Leu Lys Pro Val	
245 250 255	
CAT TCT GGC GGG GTG CAG ACT GCG GGC AAC AGC TGT GCC GTA GTG GAC	833
His Ser Gly Gly Val Gln Thr Ala Gly Asn Ser Cys Ala Val Val Asp	
260 265 270	
GGC GCC GCG GCG GCT TTG GTG GCT CGA GAG TCG TCT GCG ACA CAG CCG	881
Gly Ala Ala Ala Leu Val Ala Arg Glu Ser Ser Ala Thr Gln Pro	
275 280 285	
GTC TTG GCT AGG ATA CTG GCT ACC TCC GTA GTC GGG ATC GAG CCC GAG	929
Val Leu Ala Arg Ile Leu Ala Thr Ser Val Val Gly Ile Glu Pro Glu	
290 295 300	
CAT ATG GGG CTC GGC CCT GCG CCC GCG ATT CGC CTG CTG CTT GCG CGT	977
His Met Gly Leu Gly Pro Ala Pro Ala Ile Arg Leu Leu Leu Ala Arg	
305 310 315 320	
AGT GAT CTT AGT TTG AGG GAT ATC GAC CTC TTT GAG ATA AAC GAG GCG	1025
Ser Asp Leu Ser Leu Arg Asp Ile Asp Leu Phe Glu Ile Asn Glu Ala	
325 330 335	
CAG GCC GCC CAA GTT CTA GCG GTA CAG CAT GAA TTG GGT ATT GAG CAC	1073
Gln Ala Ala Gln Val Leu Ala Val Gln His Glu Leu Gly Ile Glu His	
340 345 350	
TCA AAA CTT AAT ATT TGG GGC GGG GCC ATT GCA CTT GGA CAC CCG CTT	1121
Ser Lys Leu Asn Ile Trp Gly Gly Ala Ile Ala Leu Gly His Pro Leu	
355 360 365	
GCC GCG ACC GGA TTG CGT CTC TGC ATG ACC CTC GCT CAC CAA TTG CAA	1169
Ala Ala Thr Gly Leu Arg Leu Cys Met Thr Leu Ala His Gln Leu Gln	
370 375 380	
GCT AAT AAC TTT CGA TAT GGA ATT GCC TCG GCA TGC ATT GGT GGG GGA	1217
Ala Asn Asn Phe Arg Tyr Gly Ile Ala Ser Ala Cys Ile Gly Gly Gly	
385 390 395 400	
CAG GGG ATG GCG GTT CTT TTA GAG AAT CCC CAC TTC GGT TCG TCC TCT	1265
Gln Gly Met Ala Val Leu Leu Glu Asn Pro His Phe Gly Ser Ser Ser	
405 410 415	
GCA CGA AGT TCG ATG ATT AAC AGA GTT GAC CAC TAT CCA CTG AGC TAA	1313
Ala Arg Ser Ser Met Ile Asn Arg Val Asp His Tyr Pro Leu Ser	
420 425 430 431	
CGGGCATCTC CTTTGTGCT TTGAGGTGGC GCACGAAGGA GGGCTCGAAA ATCTCTGCTA	1373
AAAACAAGAA GAAGGAACAG GGAACATGAT TAGTTTCGCT CGTATGGCAG AAAGTTTAGG	1433
AGTCCAGGCT AAACCTGCCC TTGCCTTCGC ACTCGTATTA TGTGTCGGGC TGATTGTTAC	1493
CGGCACGGGT TTCTACAGTG TACATACCTT GTCAGGGTTG GTGGGAATTC	1543

FIG. 2r:

09830544-042704

Sequence 1

CTGCAGCCAG	GGCTGAAAAG	GAGGGATTCA	GTGAGGTCAT	GAAGGGAGGG	GACGGCGCCT	60
GGCTCCAATT	GCTCGATGGC	GCCGCGATTG	AGTGTCTTGG	GCGCGGTCTT	GGAGAGTTCG	120
GCTAGGGAGA	TAAATTTGCT	GGCCATGGTG	GCGGCCCCTG	ATGGGTGGGA	TGATTTTCTG	180
CATTCTGCAT	CATGAAATTC	ATGAAATCAT	CACTTTTTCG	GGGGTGGGTG	CACGGGATTG	240
AAGGTTGCTA	GGAGAGTGCA	TTGCTCGTAA	GCCCAGGAAG	CACGCGGGTT	TCAGGATGGT	300
GCATGGAAAT	GGCATGAGCT	TTGCTGGATA	TGATTAGAGA	CATTAACTAT	TTTGGCGGAA	360
TGGAAGCACG	ATTCCTCGCC	CGGTAGAGCG	GTAACCGCGA	CATTCAGGAC	CGTAAAAAGG	420
AAAGAGCATG	CAACTGACCA	ACAAGAAAAT	CGTCGTCACC	GGAGTGTCTT	CCGGTATCGG	480
TGCCGAAACT	GCCGCGTTC	TGCGCTCTCA	CGGCGCCACA	GTGATTGGCG	TAGATCGCAA	540
CATGCCGAGC	CTGACTCTGG	ATGCTTTCTG	TCAGGCTGAC	CTGAGCCATC	CTGAAGGCAT	600
CGATAAGGCC	ATCGGGACAG	CAAGCGAACC	GGAATTGCCA	GCTGGGGCGC	CCTCTGGTAA	660
GGTTGGGAAG	CCTTGCAAAG	TAAACTGGAT	GGCTTTCTTG	CCGCCAAGGA	TCTGATGGCG	720
CAGGGGATCA	AGATCTGATC	AAGAGACAGG	ATGAGGATCG	TTTCGCATGA	TTGAACAAGA	780
TGGATTGCAC	GCAGGTTCTC	CGGCCGCTTG	GGTGGAGAGG	CTATTCGGCT	ATGACTGGGC	840
ACAACAGACA	ATCGGCTGCT	CTGATGCCGC	CGTGTTCCGG	CTGTCAGCGC	AGGGGCGCCC	900
GGTTC'TTTT	GTCAAGACCG	ACCTGTCCGG	TGCCCTGAAT	GAAGTGCAGG	ACGAGGCAGC	960
GCGGCTATCG	TGGCTGGCCA	CGACGGGCGT	TCCTTGCGCA	GCTGTGCTCG	ACGTTGTCAC	1020
TGAAGCGGGA	AGGGACTGGC	TGCTATTGGG	CGAAGTGCCG	GGGCAGGATC	TCCTGTCATC	1080
TCACCTTGCT	CCTGCCGAGA	AAGTATCCAT	CATGGCTGAT	GCAATGCGGC	GGCTGCATAC	1140
GCTTGATCCG	GCTACCTGCC	CATTGACCA	CCAAGCGAAA	CATCGCATCG	AGCGAGCACG	1200
TACTCGGATG	GAAGCCGGTC	TTGTGATCA	GGATGATCTG	GACGAAGAGC	ATCAGGGGCT	1260
CGCGCCAGCC	GAAGTGTTCG	CCAGGCTCAA	GGCGCGCATG	CCCACGGCG	AGGATCTCGT	1320
CGTGACCCAT	GGCGATGCCT	GCTTGCCGAA	TATCATGGTG	GAAAATGGCC	GCTTTTCTGG	1380
ATTCATCGAC	TGTGGCCGCG	TGGGTGTGGC	GGACCGCTAT	CAGGACATAG	CGTTGGCTAC	1440
CCGTGATATT	GCTGAAGAGC	TTGGCGGCGA	ATGGGCTGAC	CGCTTCCTCG	TGCTTTACGG	1500
TATCGCCGCT	CCCGATTGCG	AGCGCATCGC	CTTCTATCGC	CTTCTTGACG	AGTTCTTCTG	1560
AGCGGGACTC	TGGGGTTCGA	AATGACCGAC	CAAGCGACGC	CCTGGCCGCG	GTGATTGCAT	1620
TCATGTGTGC	TGAGGAGTCA	CGTTGGATCA	ACGGCATAAA	TATTCCAGTG	GACGGAGGTT	1680
TGGCATCGAC	CTACGTGTAA	GTTCTGTGGC	GCCCTTTGCA	CGCGCACTAT	ATCTCTATGC	1740
AGCAGCTGAA	AGCAGCTTTG	GTTTTGATCG	GAGGTAGCGG	GCGGAAAGGT	GCAGAATGTC	1800
TAAATAATAA	AGGATTCTTG	TGAAGCTTTA	GTTGTCCGTA	AACGAAAATA	AAAATAAAGA	1860
GGAATGATAT	GAAAGCAAGT	AGATCAGTCT	GCACTTTCAA	AATAGCTACC	CTGGCAGGCG	1920
CCATTTATGC	AGCGCTGCCA	ATGTCAGCTG	CAAACCTCGAT	GCAGCTGGAT	GTAGGTAGCT	1980
CGGATTGGAC	GGTGCCTTGG	GGACAACACC	CTCAAGTATA	GCCTTGCCCTC	TCGCCTGAAT	2040
GAGCAAGACT	CAAGTCTGAC	AAATGCGCCG	ACTGTCAATG	GTTATATCCG	GATATTCAAA	2100
GTCAGGGTGA	TCGTAAC'TTT	GACCGGGGGC	TTGGTATCCA	ATCGTCTCGA	TATTCTGGCT	2160
GCAG						2164

0930514 042704

Sequence 2

CTGCAGCCAG	GGCTGAAAAG	GAGGGATTCA	GTGAGGTCAT	GAAGGGAGGG	GACGGCGCCT	60
GGCTCCAATT	GCTCGATGGC	GCCGCGATTG	AGTGTCTTGG	GCGCGGTCTT	GGAGAGTTCTG	120
GCTAGGGAGA	TAAATTTGCT	GGCCATGGTG	GCGGCCCTTG	ATGGGTGGA	TGATTTTCTG	180
CATTCTGCAT	CATGAAATTC	ATGAAATCAT	CAC'TTTTCGG	GGGGTGGGTG	CACGGGATTG	240
AAGGTTGCTA	GGAGAGTGCA	TTGCTCGTAA	GCCCAGGAAG	CACGCGGGTT	TCAGGATGGT	300
GCATGGAAAT	GGCATGAGCT	TTGCTGGATA	TGATTAGAGA	CATTAACAT	TTTGGCGGAA	360
TGGAAGCACG	ATTCTCGCC	CGGTAGAGCG	GTAACCGCGA	CATTTCAGGAC	CGTAAAAAGG	420
AAAGAGCATG	CAACTGACCA	ACAAGAAAAT	CGTCGTCACC	GGAGTGTCTT	CCGGTATCGG	480
TGCCGAAACT	GCCCGCGTTC	TGCGCTCTCA	CGGCGCCACA	GTGATTGGCG	TAGATCGCAA	540
CATGCCGAGC	CTGACTCTGG	ATGCTTTCTG	TCAGGCTGAC	CTGAGCCATC	CTGAGGGGAG	600
AGGCGGTTTG	CGTATTGGGC	GCATGCATAA	AAACTGTTGT	AATTCATTAA	GCATTCTGCC	660
GACATGGAAG	CCATCACAAA	CGGCATGATG	AACCTGAATC	GCCAGCGGCA	TCAGCACCTT	720
GTCGCCTTGC	GTATAATATT	TGCCCATGGA	CGCACACCGT	GGAAACGGAT	GAAGGCACGA	780
ACCCAGTTGA	CATAAGCCTG	TTTCGGTTCGT	AAACTGTAAT	GCAAGTAGCG	TATGCGCTCA	840
CGCAACTGGT	CCAGAACCTT	GACCGAACGC	AGCGGTGGTA	ACGGCGCAGT	GGCGGTTTTC	900
ATGGCTTGTT	ATGACTGTTT	TTTTGTACAG	TCTATGCCTC	GGGCATCCAA	GCAGCAAGCG	960
CGTTACGCCG	TGGGTCGATG	TTTGATGTTA	TGGAGCAGCA	ACGATGTTAC	GCAGCAGCAA	1020
CGATGTTACG	CAGCAGGGCA	GTCGCCCTAA	AACAAAGTTA	GGTGGCTCAA	GTATGGGCAT	1080
CATTTCGCACA	TGTAGGCTCG	GCCCTGACCA	AGTCAAATCC	ATGCGGGCTG	CTCTTGATCT	1140
TTTCGGTTCGT	GAGTTCGGAG	ACGTAGCCAC	CTACTCCCAA	CATCAGCCCG	ACTCCGATTA	1200
CCTCGGGAAC	TTGCTCCGTA	GTAAGACATT	CATCGCGCTT	GCTGCCTTCG	ACCAAGAAGC	1260
GGTTGTTGGC	GCTCTCGCGG	CTTACGTTCT	GCCCAGGTTT	GAGCAGCCGC	GTAGTGAGAT	1320
CTATATCTAT	GATCTCGCAG	TCTCCGGCGA	GCACCGGAGG	CAGGGCATTG	CCACCGCGCT	1380
CATCAATCTC	CTCAAGCATG	AGGCCAACGC	GCTTGGTGCT	TATGTGATCT	ACGTGCAAGC	1440
AGATTACGGT	GACGATCCCG	CAGTGGCTCT	CTATACAAAG	TTGGGCATAC	GGGAAGAAGT	1500
GATGCAC'TTT	GATATCGACC	CAAGTACCGC	CACCTAACAA	TTCGTTCAAG	CCGAGATCGG	1560
C'TTCCCTGAT	TGCATTTCATG	TGTGCTGAGG	AGTCACGTTG	GATCAACGGC	ATAAATATTC	1620
CAGTGGACGG	AGGTTTGGCA	TCGACCTACG	TGTAAGTTTCG	TGGACGCCCT	TTGCACGCGC	1680
ACTATATCTC	TATGCAGCAG	CTGAAAGCAG	CTTTGGTTTT	GATCGGAGGT	AGCGGGCGGA	1740
AAGGTGCAGA	ATGTCTAAAT	AATAAAGGAT	TCTTGTGAAG	CTTTAGTTGT	CCGTAAACGA	1800
AAATAAAAAT	AAAGAGGAAT	GATATGAAAG	CAAGTAGATC	AGTCTGCACT	TTCAAAATAG	1860
CTACCCTGGC	AGGCGCCATT	TATGCAGCGC	TGCCAATGTC	AGCTGCAAAC	TCGATGCAGC	1920
TGGATGTAGG	TAGCTCGGAT	TGGACGGTGC	GTTGGGGACA	ACACCTCAA	GTATAGCCTT	1980
GCCTCTCGCC	TGAATGAGCA	AGACTCAAGT	CTGACAAATG	CGCCGACTGT	CAATGGTTAT	2040
ATCCGGATAT	TCAAAGTCAG	GGTGATCGTA	ACTTTGACCG	GGGGCTTGGT	ATCCAATCGT	2100
CTCGATATTC	TGGCTGCAG					2119

Sequence 3

CTGCAGCCAG	GGCTGAAAAG	GAGGGATTCA	GTGAGGTCAT	GAAGGGAGGG	GACGGCGCCT	60
GGCTCCAATT	GCTCGATGGC	CCCGCGATTG	AGTGTCTTGG	GCGCGGTCTT	GGAGAGTTCG	120
GCTAGGGAGA	TAAATTTGCT	GGCCATGGTG	GCGGCCCCTG	ATGGGTGGGA	TGATTTTCTG	180
CATTCTGCAT	CATGAAATTC	ATGAAATCAT	CACTTTTTCG	GGGGTGGGTG	CACGGGATTG	240
AAGGTTGCTA	GGAGAGTGCA	TTGCTCGTAA	GCCCAGGAAG	CACGCGGGTT	TCAGGATGGT	300
GCATGGAAAT	GGCATGAGCT	TTGCTGGATA	TGATTAGAGA	CATTAACAT	TTTGGCGGAA	360
TGGAAGCACG	ATTCTTCGCC	CGGTAGAGCG	GTAACCGCGA	CATTTCAGGAC	CGTAAAAAGG	420
AAAGAGCATG	CAACTGACCA	ACAAGAAAAT	CGTCGTCACC	GGAGTGTCC	CCGGTATCGG	480
TGCCGAAACT	GCCCGCGTTC	TGCGCTCTCA	CGGCGCCACA	GTGATTGGCG	TAGATCGCAA	540
CATGCCGAGC	CTGACTCTGG	ATGCTTTCGT	TCAGGCTGAC	CTGAGCCATC	CTGAAGGCAT	600
CGATCAACGG	CATAAATATT	CCAGTGGACG	GAGGTTTGGC	ATCGACCTAC	GTGTAAGTTC	660
GTGGACGCCC	TTTGCACGCG	CACTATATCT	CTATGCAGCA	GCTGAAAGCA	GCTTTGGTTT	720
TGATCGGAGG	TAGCGGGCGG	AAAGGTGCAG	AATGTCTAAA	TAATAAAGGA	TTCTTGTGAA	780
GCTTTAGTTG	TCCGTAAACG	AAAATAAAAA	TAAAGAGGAA	TGATATGAAA	GCAAGTAGAT	840
CAGTCTGCAC	TTTCAAAATA	GCTACCCTGG	CAGGCGCCAT	TTATGCAGCG	CTGCCAATGT	900
CAGCTGCAAA	CTCGATGCAG	CTGGATGTAG	GTAGCTCGGA	TTGGACGGTG	CGTTGGGGAC	960
AACACCCTCA	AGTATAGCCT	TGCCTCTCGC	CTGAATGAGC	AAGACTCAAG	TCTGACAAAT	1020
GCGCCGACTG	TCAATGGTTA	TATCCGGATA	TTCAAAGTCA	GGGTGATCGT	AACTTTGACC	1080
GGGGGCTTGG	TATCCAATCG	TCTCGATATT	CTGGCTGCAG			1120

090054-04201

Sequence 4

GAATTCCGCG	TATCGCCCCG	TTCTATCAGC	GGGCCGCTTT	CGAAAGTCAT	GGTGTTAGCC	60
GGTAGGGTCT	TTTTCTTGCC	CATGCTTGTT	GCCTGAACCT	TCGTTGACAT	AGGGCAGAGG	120
TGCGTTTGCC	GCTTCGCTTC	GCGATGAACC	GCATCGAGAT	GCTGAGGTCA	GGATTTTCC	180
TTAACTCGCG	TAAGCATTCT	GTCATTTTTT	TGGTGGCTTT	GAACAGCCTG	ATGAAAGGTG	240
GTCTCGCCCT	TTGAGGCCGA	TTCTTGGGCG	CTTGGCGGCG	TCGAAGCGAT	GCTCCACTAC	300
CGATTAAGAT	AATTAAAATA	AGGAAACCGC	ATGGTTTCTT	ATGTGAATTT	GTCTGGCATA	360
CTCCAGCTCA	AGGGCAATTT	TTGGGCTATT	GGCTGAGCAG	TTGCCCTCTAT	ATGGTTATTTC	420
AGAATAACAA	TTGACTCCTC	AGGAGGTCAG	CGATGAGCAT	TCTTGTTTTC	AATGGTGCCC	480
CGTCCGAGC	TGAGCAGCTG	GGCTCGGCTC	TTGATCGCAT	GAAGAAGGCG	CACCTGGAGC	540
AGGGGCCTGC	AAACTTGGAG	CTGCGTCTGA	GTAGGCTGGA	TCGTGCGATT	GCAATGCTTC	600
TGGAATAATCG	TGAAGCAATT	GCCGACGCGG	TTTCTGCTGA	CTTTGGCAAT	CGCAGCCGTG	660
AGCAAACACT	GCTTTGCGAC	ATTGCTGGCT	CGGTGGCAAG	CCTGAAGGAT	AGCCGCGAGC	720
ACGTGGCCAA	ATGGATGGAG	CCCGAACATC	ACAAGGCGAT	GTTTCCAGGG	GCGGAGGCAC	780
GCGTTGAGTT	TCAGCCGCTG	GGTGTCGTTG	GGGTCATTAG	TCCCTGGAAC	TTCCCTATCG	840
TACTGGCCTT	TGGGCCGCTG	GCCGGCATAT	TCGCAGCAGG	TAATCGCGCC	ATGCTCAAGC	900
CGTCCGAGCT	TACCCCGCGG	ACTTCTGCCC	TGCTTGCGGA	GCTAATTGCT	CGTTACTTCC	960
ATGAAACTGA	GCTGACTACA	GTGCTGGGCG	ACGCTGAAGT	CGGTGCGCTG	TTCACTGCTC	1020
AGCCTTTCGA	TCATCTGATC	TTCACCGGCG	GCACTGCCGT	GGCCAAGCAC	ATCATGCGTG	1080
CCGCGGCGGA	TAACCTAGTG	CCCGTTACCC	TGGAATTGGG	TGGCAAATCG	CCGGTGATCG	1140
TTTCCCGCAG	TGCAGATATG	GCGGACGTTG	CACAACGGGT	GTTGACGGTG	AAAACCTTCA	1200
ATGCCGGGCA	AATCTGTCTG	GCACCGGACT	ATGTGCTGCT	GCCGGAAGGG	ACAGCAAGCG	1260
AACCGGAATT	GCCAGCTGGG	GCGCCCTCTG	GTAAGGTTGG	GAAGCCCTGC	AAAGTAAACT	1320
GGATGGCTTT	CTTGCCGCCA	AGGATCTGAT	GGCGCAGGGG	ATCAAGATCT	GATCAAGAGA	1380
CAGGATGAGG	ATCGTTTCGC	ATGATTGAAC	AAGATGGATT	GCACGCAGGT	TCTCCGGCCG	1440
CTTGGGTGGA	GAGGCTATTG	GGCTATGACT	GGGCACAACA	GACAATCGGC	TGCTCTGATG	1500
CCGCCGTGTT	CCGGCTGTCA	GCGCAGGGGC	GCCCCGTTCT	TTTTGTCAAG	ACCGACCTGT	1560
CCGGTGCCCT	GAATGAACTG	CAGGACGAGG	CAGCGCGGCT	ATCGTGGCTG	GCCACGACGG	1620
GCGTTCCTTG	GCGAGCTGTG	CTCGACGTTG	TACTGAAGC	GGGAAGGGAC	TGGCTGCTAT	1680
TGGGCGAAGT	GCCGGGGCAG	GATCTCCTGT	CATCTCACCT	TGCTCCTGCC	GAGAAAAGTAT	1740
CCATCATGGC	TGATGCAATG	CGGCGGCTGC	ATACGCTTGA	TCCGGCTACC	TGCCCATTCTG	1800
ACCACCAAGC	GAAACATCGC	ATCGAGCGAG	CACGTACTCG	GATGGAAGCC	GGTCTTGTCG	1860
ATCAGGATGA	TCTGGACGAA	GAGCATCAGG	GGCTCGCGCC	AGCCGAACTG	TTCGCCAGGC	1920
TCAAGGCGCG	CATGCCCCGAC	GGCGAGGATC	TCGTCGTGAC	CCATGGCGAT	GCCTGCTTGC	1980
CGAATATCAT	GGTGAAAAAT	GGCCGCTTTT	CTGGATTTCAT	CGACTGTGGC	CGGCTGGGTG	2040
TGGCGGACCG	CTATCAGGAC	ATAGCGTTGG	CTACCCGTGA	TATTGCTGAA	GAGCTTGGCG	2100
GCGAATGGGC	TGACCGCTTC	CTCGTGCTTT	ACGGTATCGC	CGCTCCCGAT	TCGCAGCGCA	2160

00000514-04201

TCGCCTTCTA	TCGCCTTCTT	GACGAGTTCT	TCTGAGCGGG	ACTCTGGGGT	TCGAAATGAC	2220
CGACCAAGCG	ACGCCCGCCA	TGCCAAGCCT	GTTCTCGTGC	AAAGTCCTGT	GGGTGAGTCG	2280
AACTTGCGCA	TGCGCGCACC	CTACGGAGAA	GCGATCCACG	GACTGCTCTC	TGTCCTCCTT	2340
TCAACGGAGT	GTTAGAACCG	TTGGTAGTGG	TTTTGGACGG	GCCCAGGAGC	ATGCGCTTCT	2400
GGGCCCCGTTT	CTTGAGTATT	CATTGGATAG	TCACGCGTGG	TAGCTTCGAG	CCTGCACAGC	2460
TGATGAGCAC	CCTGGAAGGC	GCGCTGTACG	CGGACGACTG	GGTTCATCTT	CGCCATTTCAT	2520
GACGGAATC	CGTTCCCCAG	TACCGCGATG	ACTATTTTGC	CTCTTCCGAT	GTCCGATTCC	2580
ACGCCGCCTG	ACGCTAAGCG	GGGGCGGGGG	CGCCCGCATC	CCAGCCCAGA	CAGCAACAAA	2640
TGAGTAGGCT	CTTGATGCC	GCGGCGGCTG	AGATTGGTAA	CGGCAATTTC	GTCAATGTGA	2700
CGATGGATTG	GATTGCCCCG	GCTGCCGGCG	TCTCAAAAAA	AACGCTGTAC	GTCTTGGTGG	2760
CGAGCAAGGA	AGAACTCATT	TCCCGGTTAG	TGGCTCGAGA	CATGTCCAAC	CTTGAGGAAT	2820
TC						2822

0930514-042704

Sequence 5

GAATTCGCG	TATCGCCCG	TTCTATCAGC	GGGCCGCTTT	CGAAAGTCAT	GGTGTAGCC	60
GGTAGGGTCT	TTTTCTTGGC	CATGCTTGTT	GCCTGAACCT	TCGTTGACAT	AGGGCAGAGG	120
TGCGTTTGCC	GCTTCGCTTC	GCGATGAACC	GCATCGAGAT	GCTGAGGTCA	GGATTTTTCC	180
TTAACTCGCG	TAAGCATTCT	GTCATTTTTT	TGGTGGCTTT	GAACAGCCTG	ATGAAAGGTG	240
GTCTCGCCCT	TTGAGGCCGA	TTCTTGGGCG	CTTGGCGGCG	TCGAAGCGAT	GCTCCACTAC	300
CGATTAAGAT	AATTAAAATA	AGGAAACCGC	ATGGTTTCTT	ATGTGAATTT	GTCTGGCATA	360
CTCCAGCTCA	AGGGCAATTT	TTGGGCTATT	GGCTGAGCAG	TTGCCTCTAT	ATGGTTATTC	420
AGAATAACAA	TTGACTCCTC	AGGAGGTCAG	CGATGAGCAT	TCTTGGTTTG	AATGGTGCCC	480
CGGTCGGAGC	TGAGCAGCTG	GGCTCGGCTC	TTGATCGCAT	GAAGAAGGCG	CACCTGGAGC	540
AGGGGCCTGC	AAACTTGGAG	CTGCGTCTGA	GTAGGCTGGA	TCGTGCGATT	GCAATGCTTC	600
TGGAAAATCG	TGAAGCAATT	GCCGACGCGG	TTTCTGCTGA	CTTTGGCAAT	CGCAGCCGTG	660
AGCAAACACT	GCTTTGCGAC	ATTGCTGGCT	CGGTGGCAAG	CCTGAAGGAT	AGCCGCGAGC	720
ACGTGGCCAA	ATGGATGGAG	CCCGAACATC	ACAAGGCGAT	GTTTCCAGGG	GCGGAGGCAC	780
GCGTTGAGTT	TCAGCCGCTG	GGTGTCTGTT	GGGTCATTAG	TCCCTGGAAC	TTCCCTATCG	840
TACTGGCCTT	TGGGCCGCTG	GCCGGCATAT	TCGCAGCAGG	TAATCGCGCC	ATGCTCAAGC	900
CGTCCGAGCT	TACCCCGCGG	ACTTCTGCCC	TGCTTGCGGA	GCTAATTGCT	CGTTACTTCG	960
ATGAAACTGA	GCTGACTACA	GTGCTGGGCG	ACGCTGAAGT	CGGTGCGCTG	TTCAGTGCTC	1020
AGCCTTTTGA	TCATCTGATC	TTCACCGGCG	GCACTGCCGT	GGCCAAGCAC	ATCATGCGTG	1080
CCGCGGCGGA	TAACCTAGTG	CCCGTTACCC	TGGAATTGGG	TGGCAAATCG	CCGGTGATCG	1140
TTTCCCGCAG	TGCAGATATG	GCGGACGTTG	CACAACGGGT	GTTGACGGTG	AAAACCTTCA	1200
ATGCCGGGCA	AATCTGTCTG	GCACCGGACT	ATGTGCTGGG	GGAGAGGCGG	TTTGCGTATT	1260
GGGCGCATGC	ATAAAACTG	TTGTAATTCA	TTAAGCATTC	TGCCGACATG	GAAGCCATCA	1320
CAAACGGCAT	GATGAACCTG	AATCGCCAGC	GGCATCAGCA	CCTTGTCGCC	TTGCGTATAA	1380
TATTTGCCCA	TGGACGCACA	CCGTGGAAAC	GGATGAAGGC	ACGAACCCAG	TTGACATAAG	1440
CCTGTTCGGT	TCGTAAACTG	TAATGCAAGT	AGCGTATGCG	CTCACGCAAC	TGGTCCAGAA	1500
CCTTGACCGA	ACGCAGCGGT	GGTAACGGCG	CAGTGGCGGT	TTTCATGGCT	TGTTATGACT	1560
GTTTTTTTTGT	ACAGTCTATG	CCTCGGGCAT	CCAAGCAGCA	AGCGCGTTAC	GCCGTGGGTC	1620
GATGTTTGAT	GTTATGGAGC	AGCAACGATG	TTACGCAGCA	GCAACGATGT	TACGCAGCAG	1680
GGCAGTCGCC	CTAAAACAAA	GTTAGTGCG	TCAAGTATGG	GCATCATTCG	CACATGTAGG	1740
CTCGGCCCTG	ACCAAGTCAA	ATCCATGCGG	GCTGCTCTTG	ATCTTTTCGG	TCGTGAGTTC	1800
GGAGACGTAG	CCACCTACTC	CCAACATCAG	CCGGACTCCG	ATTACCTCGG	GAACCTTGCTC	1860
CGTAGTAAGA	CATTTCATCGC	GCTTGCTGCC	TTCGACCAAG	AAGCGGTTGT	TGGCGCTCTC	1920
GCGGCTTACG	TTCTGCCCAG	GTTTGAGCAG	CCGCGTAGTG	AGATCTATAT	CTATGATCTC	1980
GCAGTCTCCG	GCGAGCACCG	GAGGCAGGGC	ATTGCCACCG	CGCTCATCAA	TCTCCTCAAG	2040
CATGAGGCCA	ACGCGCTTGG	TGCTTATGTG	ATCTACGTGC	AAGCAGATTA	CGGTGACGAT	2100
CCCGCAGTGG	CTCTCTATAC	AAAGTTGGGC	ATACGGGAAG	AAGTGATGCA	CTTTGATATC	2160

09030514 042701

GACCCAAGTA	CCGCCACCTA	ACAATTTCGT	CAAGCCGAGA	TCGGCTTCCC	TGCAAAGTCC	2220
TGTGGGTGAG	TCGAACTTGG	CGATGCGCGC	ACCCTACGGA	GAAGCGATCC	ACGACTGCT	2280
CTCTGTCTCT	CTTTCAACGG	AGTGTTAGAA	CCGTTGGTAG	TGGTTTGTGA	CGGGCCCAAG	2340
AGCATGCGCT	TCTGGGCGG	TTTCTTAGT	ATTCAATGGA	TAGTACGCG	TGGTAGCTTC	2400
GAGCTGTGAC	AGCTGATGAG	CACCCGTGAA	GGCGCGCTGT	ACGCGGACGA	CTGGGTTTCA	2460
CTTCGCCATT	CATGACGGAA	CTCCGTTCCC	CAGTACGCG	ATGACTATTT	TGCTCTTCC	2520
GATGTCCGAT	TCCACGCCGC	CTGACGCTAA	GCGGGGGCGG	GGGCGCCCGC	ATCCAGCCC	2580
AGACAGCAAC	AAATGAGTAG	GCTCTTGGAT	GCCGCGGCGG	CTGAGATTGG	TAACGGCAAT	2640
TTCGTCAATG	TGACGATGGA	TTCGATTGCC	CGTGCTGCCG	GCGTCTCAAA	AAAAACGCTG	2700
TACGTTCTGG	TGGCGAGCAA	GGAAGAACTC	ATTTCCCGGT	TAGTGGCTCG	AGACATGTCC	2760
AACCTTGAGG	AATTC					2775

Sequence 6

GAATTCCGCG	TATCGCCCGG	TTCTATCAGC	GGGCCGCTTT	CGAAAGTCAT	GGTGTTAGCC	60
GGTAGGGTCT	TTTTCTTGGC	CATGCTTGTT	GCCTGAACCT	TCGTTGACAT	AGGGCAGAGG	120
TGCGTTTGCC	GCTTCGCTTC	GCGATGAACC	GCATCGAGAT	GCTGAGGTCA	GGATTTTTTC	180
TTAACTCGCG	TAAGCATTCT	GTCATTTTTT	TGGTGGCTTT	GAACAGCCTG	ATGAAAAGGTG	240
GTCTCGCCCT	TTGAGGCCGA	TTCTTGGGCG	CTTGGCGGCG	TCGAAGCGAT	GCTCCACTAC	300
CGATTAAGAT	AATTAAAATA	AGGAAACCGC	ATGGTTTCTT	ATGTGAATTT	GTCTGGCATA	360
CTCCAGCTCA	AGGGCAATTT	TTGGGCTATT	GGCTGAGCAG	TTGCCTCTAT	ATGGTTATTC	420
AGAATAACAA	TTGACTCCTC	AGGAGGTCAG	CGATGAGCAT	TCTTGGTTTG	AATGGTGCCC	480
CGGTCGGAGC	TGAGCAGCTG	GGCTCGGCTC	TTGATCGCAT	GAAGAAGGCG	CACCTGGAGC	540
AGGGGCCCTG	AAACTTGGAG	CTGCGTCTGA	GTAGGCTGGA	TCGTGCGATT	GCAATGCCTC	600
TGGAAAATCG	TGAAGCAATT	GCCGACGCGG	TTTCTGCTGA	CTTTGGCAAT	CGCAGCCGTG	660
AGCAAACACT	GCTTTGCGAC	ATTGCTGGCT	CGGTGGCAAG	CCTGAAGGAT	AGCCGCGAGC	720
ACGTGGCCAA	ATGGATGGAG	CCCGAACATC	ACAAGGCGAT	GTTTCCAGGG	GCGGAGGCAC	780
GCGTTGAGTT	TCAGCCGCTG	GGTGTCGTTG	GGGTCATTAG	TCCCTGGAAC	TTCCCTATCG	840
TACTGGCCTT	TGGGCCGCTG	GCCGGCATAT	TCGCAGCAGG	TAATCGCGCC	ATGCTCAAGC	900
CGTCCGAGCT	TACCCCGCGG	ACTTCTGCCC	TGCTTGCGGA	GCTAATTGCT	CGTTACTTCG	960
ATGAAACTGA	GCTGACTACA	GTGCTGGGCG	ACGCTGAAGT	CGGTGCGCTG	TTCAGTGCTC	1020
AGCCTTTCGA	TCATCTGATC	TTCAACGGCG	GCACTGCCGT	GGCCAAGCAC	ATCATGCGTG	1080
CCGCGGCGGA	TAACCTAGTG	CCCGTTACCC	TGGAATTGGG	TGGCAAATCG	CCGGTGATCG	1140
TTTCCCGCAG	TGCAGATATG	GCGGACGTTG	CACAACGGGT	GTTGACGGTG	AAAACCTTCA	1200
ATGCCGGGCA	AATCTGTCTG	GCACCGTGGA	TGAGTCGAAC	TTGGCGATGC	GCGCACCCTA	1260
CGGAGAAGCG	ATCCACGGAC	TGCTCTCTGT	CCTCCTTTCA	ACGGAGTGTT	AGAACCGTTG	1320
GTAGTGGTTT	TGGACGGGCC	CAGGAGCATG	CGCTTCTGGG	CCCGTTTCTT	GAGTATTTCAT	1380
TGGATAGTCA	CGCGTGGTAG	CTTCGAGCCT	GCACAGCTGA	TGAGCACCCCT	GGAAGGCGCG	1440
CTGTACGCGG	ACGACTGGGT	TCATCTTCGC	CATTTCATGAC	GGAACTCCGT	TCCCCAGTAC	1500
CGCGATGACT	ATTTTGCCCTC	TTCCGATGTC	CGATTCCACG	CCGCCCTGACG	CTAAGCGGGG	1560
GCGGGGGCGC	CCGCATCCCA	GCCCAGACAG	CAACAAATGA	GTAGGCTCTT	GGATGCCGCG	1620
GCGGCTGAGA	TTGGTAACGG	CAATTTTCGTC	AATGTGACGA	TGGATTTCGAT	TGCCCCGTGCT	1680
GCCGGCCTCT	CAAAAAAAC	GCTGTACGTC	TTGGTGGCGA	GCAAGGAAGA	ACTCATTTC	1740
CGGTTAGTGG	CTCGAGACAT	GTCCAACCTT	GAGGAATTC			1779

Sequence 7

CTGCAGCCGA	GCATCGATTG	AGCACTTTAC	CCAGCTGCGC	TGGCTGACCA	TTCAGAATGG	60
CCCGCGGCAC	TATCCAATCT	AAATCGATCT	TCGGGCGCCG	CGGGCATCAT	GCCCCGCGCG	120
CTCGCCTCAT	TTCAATCTCT	AACTTGATAA	AAACAGAGCT	GTTCTCCGGT	CTTGGTGGAT	180
CAAGGCCAGT	CGCGGAGAGT	CTCGAAGAGG	AGAGTACAGT	GAACGCCGAG	TCCACATTGC	240
AACCGCAGGC	ATCATCATGC	TCTGCTCAGC	CACGCTACCG	CAGTGTGTCG	ATTGGTCATC	300
CTCCGGTTGA	GGTTACGCAA	GACGCTGGAG	GTATTGTCCG	GATGCGTTCT	CTCGAGGCGC	360
TTCTTCCCCT	CCCGGGTCGA	ATTCTTGAGC	GTCTCGAGCA	TTGGGCTAAG	ACCCGTCCAG	420
AACAAACCTG	CGTTGCTGCC	AGGGCGGCAA	ATGGGGAATG	GCGTCGTATC	AGCTACGCGG	480
AAATGTTCCA	CAACGTCCGC	GCCATCGCAC	AGAGCTTGCT	TCCTTACGGA	CTATCGGCAG	540
AGCGTCCGCT	GCTTATCGTC	TCTGGAATG	ACCTGGAACA	TCTTCAGCTG	GCATTTGGGG	600
CTATGTATGC	GGGCATTCCC	TATTGCCCCG	TGTCTCCTGC	TTATTCACTG	CTGTCGCAAG	660
ATTTGGCGAA	GCTGCGTCAC	ATCGTAGGTC	TTCTGCAACC	GGGACTGGTC	TTTGCTGCCC	720
ATGCAGCACC	TTTCCAGGGG	ACAGCAAGCG	AACCGBAATT	GCCAGCTGGG	GCGCCCTCTG	780
GTAAGGTTGG	GAAGCCCTGC	AAAGTAAACT	GGATGGCTTT	CTTGCCGCCA	AGGATCTGAT	840
GGCGCAGGGG	ATCAAGATCT	GATCAAGAGA	CAGGATGAGG	ATCGTTTCGC	ATGATTGAAC	900
AAGATGGATT	GCACGCAGGT	TCTCCGGCCG	CTTGGGTGGA	GAGGCTATTG	GGCTATGACT	960
GGGCACAACA	GACAATCGGC	TGCTCTGATG	CCGCCGTGTT	CCGGCTGTCA	GCGCAGGGGC	1020
GCCCGGTTCT	TTTTGTCAAG	ACCGACCTGT	CCGGTGCCCT	GAATGAACTG	CAGGACGAGG	1080
CAGCGCGGCT	ATCGTGGCTG	GCCACGACGG	GCGTTTCCTT	GCGAGCTGTG	CTCGACGTTG	1140
TCACTGAAGC	GGGAAGGGAC	TGGCTGCTAT	TGGGCGAAGT	GCCGGGGCAG	GATCTCCTGT	1200
CATCTCACCT	TGCTCCTGCC	GAGAAAGTAT	CCATCATGGC	TGATGCAATG	CGGCGGCTGC	1260
ATACGCTTGA	TCCGGCTACC	TGCCCATTCT	ACCACCAAGC	GAAACATCGC	ATCGAGCGAG	1320
CACGTACTCG	GATGGAAGCC	GGTCTTGTCG	ATCAGGATGA	TCTGGACGAA	GAGCATCAGG	1380
GGCTCGCGCC	AGCCGAACTG	TTCCGCCAGG	TCAAGGCGCG	CATGCCCGAC	GGCGAGGATC	1440
TCGTCTGTAC	CCATGGCGAT	GCCTGCTTGC	CGAATATCAT	GGTGGAAAAT	GGCCGCTTTT	1500
CTGGATTTCAT	CGACTGTGGC	CGGCTGGGTG	TGGCGGACCG	CTATCAGGAC	ATAGCGTTGG	1560
CTACCCGTGA	TATTGCTGAA	GAGCTTGGCG	GCGAATGGGC	TGACCGCTTC	CTCGTGCTTT	1620
ACGGTATCGC	CGCTCCCGAT	TCGACGCGCA	TCGCCTTCTA	TCGCCTTCTT	GACGAGTTCT	1680
TCTGAGCGGG	ACTCTGGGGT	TCGAAATGAC	CGACCAAGCG	ACGCCCCCTG	TTTGCAATGG	1740
CGGTCGGCGA	AAGTTGATGC	GCTGTATCGT	GGTGAAGATC	AATCCATGCT	GCGTGACGAG	1800
GCCACACTGT	GAGTTGGTCA	GGGGGGGCTT	ACTCGGCGTT	TTCCGACACT	GCGTTGGTTG	1860
CGGCAGTGCG	CACCCCTTGG	ATTGATTGCG	GGGGTGCCCT	GTCGCTGGTG	TCGCCTATCG	1920
ACTTAGGGGT	AAAGGTCGCT	CGCGAAGTTC	TGATGCGTGC	GTCGCTTGAA	CCACAAATGG	1980
TCGATAGCGT	ACTCGCAGGC	TCTATGGCTC	AAGCAAGCTT	TGATGCTTAC	CTGCTCCCCG	2040
GGCACATTGG	CTTGACAGC	GGTGTTCCCA	AGTCGGTTCC	GGCCTTGGGG	GTGCAGCGCA	2100
TTTGCGGCAC	AGGCTTCGAA	CTGCTTCGGC	AGGCCGGCGA	GCAGATTTC	CAAGGCGCTG	2160
ATCACGTGCT	GTGTGTCGCG	GGCTGCAG				2188

Sequence 8

CTGCAGCCGA	GCATCGATTG	AGCACTTTAC	CCAGCTGCGC	TGGCTGACCA	TTCAGAATGG	60
CCCGCGGCAC	TATCCAATCT	AAATCGATCT	TCGGGCGCCG	CGGGCATCAT	GCCCGCGGCG	120
CTCGCCTCAT	TTCAATCTCT	AAC TTGATAA	AAACAGAGCT	GTTCTCCGGT	CTTGGTGGAT	180
CAAGGCCAGT	CGCGGAGAGT	CTCGAAGAGG	AGAGTACAGT	GAACGCCGAG	TCCACATTGC	240
AACCGCAGGC	ATCATCATGC	TCTGCTCAGC	CACGCTACCG	CAGTGTGTCG	ATTGGTCATC	300
CTCCGGTTGA	GGTTACGCAA	GACGCTGGAG	GTATTGTCCG	GATGCGTTCT	CTCGAGGCGC	360
TTCTTCCCTT	CCCGGGTCGA	ATTCTTGAGC	GTCTCGAGCA	TTGGGCTAAG	ACCCGTCCAG	420
AACAAACCTG	CGTTGCTGCC	AGGGCGGCAA	ATGGGGGAATG	GCGTCGTATC	AGCTACGCGG	480
AAATGTTCCA	CAACGTCCGC	GCCATCGCAC	AGAGCTTGCT	TCCTTACGGA	CTATCGGCAG	540
AGCGTCCGCT	GCTTATCGTC	TCTGGAATG	ACCTGGAACA	TCTTCAGCTG	GCATTTGGGG	600
CTATGTATGC	GGGCATTCCC	TATTGCCCGG	TGTCTCCTGC	TTATTCACTG	CTGTCGCAAG	660
ATTTGGCGAA	GCTGCGTCAC	ATCGTAGGTC	TTCTGCAACC	GGGACTGGTC	TTTGCTGCCG	720
ATGCAGCACC	TTTCCAGGGG	GAGAGGCGGT	TTGCGTATTG	GGCGCATGCA	TAAAAACTGT	780
TGTAATTCAT	TAAGCATTCT	GCCGACATGG	AAGCCATCAC	AAACGGCATG	ATGAACCTGA	840
ATCGCCAGCG	GCATCAGCAC	CTTGTCGCCT	TGCGTATAAT	ATTTGCCCAT	GGACGCACAC	900
CGTGGAACG	GATGAAGGCA	CGAACCCAGT	TGACATAAGC	CTGTTCGGTT	CGTAAACTGT	960
AATGCAAGTA	GCGTATGCGC	TCACGCAACT	GGTCCAGAAC	CTTGACCGAA	CGCAGCGGTG	1020
GTAACGGCGC	AGTGGCGGTT	TTCATGGCTT	GTTATGACTG	TTTTTTTGTA	CAGTCTATGC	1080
CTCGGGCATC	CAAGCAGCAA	GCGCGTTACG	CCGTGGGTGCG	ATGTTTGATG	TTATGGAGCA	1140
GCAACGATGT	TACGCAGCAG	CAACGATGTT	ACGCAGCAGG	GCAGTCGCCC	TAAAACAAAG	1200
TTAGGTGGCT	CAAGTATGGG	CATCATTCGC	ACATGTAGGC	TCGGCCCTGA	CCAAGTCAAA	1260
TCCATGCGGG	CTGCTCTTGA	TCTTTTCGGT	CGTGAGTTCG	GAGACGTAGC	CACCTACTCC	1320
CAACATCAGC	CGGACTCCGA	TTACCTCGGG	AACTTGCTCC	GTAAGTAAAG	ATTTCATCGCG	1380
CTTGCTGCCT	TCGACCAAGA	AGCGGTGTTT	GGCGCTCTCG	CGGCTTACGT	TCTGCCCAGG	1440
TTTGAGCAGC	CGCGTAGTGA	GATCTATATC	TATGATCTCG	CAGTCTCCGG	CGAGCACCGG	1500
AGGCAGGGCA	TTGCCACCGC	GCTCATCAAT	CTCCTCAAGC	ATGAGGCCAA	CGCGCTTGGT	1560
GCTTATGTGA	TCTACGTGCA	AGCAGATTAC	GGTGACGATC	CCGCAGTGGC	TCTCTATACA	1620
AAGTTGGGCA	TACGGGAAGA	AGTGATGCAC	TTTGATATCG	ACCCAAGTAC	CGCCACCTAA	1680
CAATTTCGTT	AAGCCGAGAT	CGGCTTCCCC	TGTTTTGCAA	TGGCGGTGCG	CGAAAGTTGA	1740
TGCGCTGTAT	CGTGGTGAAG	ATCAATCCAT	GCTGCGTGAC	GAGGCCACAC	TGTGAGTTGG	1800
TCAGGGGGGG	CTTACTCGGC	GTTTTCCGAC	ACTGCGTTGG	TTGCGGCAGT	GCGCACCCCC	1860
TGGATTGATT	GCGGGGGTGC	CCTGTCGCTG	GTGTCGCCTA	TCGACTTAGG	GGTAAAGGTC	1920
GCTCGCGAAG	TTCTGATGCG	TGCGTCGCTT	GAACCACAAA	TGGTCGATAG	CGTACTCGCA	1980
GGCTCTATGG	CTCAAGCAAG	CTTTGATGCT	TACCTGCTCC	CGCGGCACAT	TGGCTTGTAC	2040
AGCGGTGTTT	CCAAGTCGGT	TCCGGCCTTG	GGGGTGACGC	GCATTTGCGG	CACAGGCTTC	2100
GAAC TGCTTC	GGCAGGCCGG	CGAGCAGATT	TCCCAAGGCG	CTGATCACGT	GCTGTGTGTC	2160
GCGGGCTGCA	G					2171

1024045000

Sequence 9

CTGCAGCCGA	GCATCGATTG	AGCACTTTAC	CCAGCTGCGC	TGGCTGACCA	TTCAGAAATGG	60
CCCGCGGCAC	TATCCAATCT	AAATCGATCT	TCGGGCGCCG	CGGGCATCAT	GCCCCGCGCG	120
CTCGCCTCAT	TTCAATCTCT	AACTTGATAA	AAACAGAGCT	GTTCTCCGGT	CTTGGTGGAT	180
CAAGGCCAGT	CGCGGAGAGT	CTCGAAGAGG	AGAGTACAGT	GAACGCCGAG	TCCACATTGC	240
AACCGCAGGC	ATCATCATGC	TCTGCTCAGC	CACGCTACCG	CAGTGTGTCG	ATTGGTCATC	300
CTCCGGTTGA	GGTTACGCAA	GACGCTGGAG	GTATTGTCCG	GATGCGTTCT	CTCGAGGCGC	360
TTCTTCCCTT	CCCGGGTCGA	ATTCTTGAGC	GTCTCGAGCA	TTGGGCTAAG	ACCCGTCCAG	420
AACAAACCTG	CGTTGCTGCC	AGGGCGGCAA	ATGGGGAATG	GCGTCGTATC	AGCTACGCGG	480
AAATGTTCCA	CAACGTCCGC	GCCATCGCAC	AGAGCTTGCT	TCCTTACGGA	CTATCGGCAG	540
AGCGTCCGCT	GCTTATCGTC	TCTGGAAATG	ACCTGGAACA	TCTTCAGCTG	GCATTTGGGG	600
CTATGTATGC	GGGCATTCCC	TATTGCCCCG	TGTCTCCTGC	TTATTCACTG	CTGTCGCAAG	660
ATTTGGCGAA	GCTGCGTCAC	ATCGTAGGTC	TTCTGCAACC	GGGACTGGTC	TTTGCTGCCG	720
ATGCAGCACC	TTTCCAGCGC	GCTGTTTTGC	AATGGCGGTC	GGCGAAAGTT	GATGCGCTGT	780
ATCGTGGTGA	AGATCAATCC	ATGCTGCGTG	ACGAGGCCAC	ACTGTGAGTT	GGTCAGGGGG	840
GGCTTACTCG	GCGTTTTCCG	ACACTGCGTT	GGTTGCGGCA	GTGCGCACCC	CCTGGATTGA	900
TTGCGGGGGT	GCCCTGTCGC	TGGTGTCGCC	TATCGACTTA	GGGGTAAAGG	TCGCTCGCGA	960
AGTTCTGATG	CGTGCGTCGC	TTGAACCACA	AATGGTCGAT	AGCGTACTCG	CAGGCTCTAT	1020
GGCTCAAGCA	AGCTTTGATG	CTTACCTGCT	CCCGCGGCAC	ATTGGCTTGT	ACAGCGGTGT	1080
TCCCAAGTCG	GTTCCGGCCT	TGGGGGTGCA	GCGCATTGTC	GGCACAGGCT	TCGAACTGCT	1140
TCGGCAGGCC	GGCGAGCAGA	TTTCCCAAGG	CGCTGATCAC	GTGCTGTGTG	TCGCGGGCTG	1200
CAG						1203

0950514-04341

Sequence 10

GAATTCCCCT	GGCGACGAAA	GGGCGGCAGG	CCGCATGGCC	ACGGCTGGGC	GGTAACTGAT	60
GCTTGCGTTA	ATCGTTAACC	GTTTGAAATT	CCTTGCCAAA	TTTCGGCGAG	AGAATCATGC	120
GGGTACGCCT	TTCCGTGCGC	TTTGATCTGC	GCTTCCGTGC	CTTGAATCAG	AAAAATAGTT	180
AATTGACAGA	ACTATAGGTT	CGCAGTAGCT	TTTGCTCACC	CACCAAATCC	ACAGCACTGG	240
GGTGCACGAT	GAATAGCTAC	GATGGCCGTT	GGTCTACCGT	TGATGTGAAG	GTTGAAGAAG	300
GTATCGCTTG	GGTCACGCTG	AACCGCCCGG	AGAAGCGCAA	CGCAATGAGC	CCAACCTCTCA	360
ATCGAGAGAT	GGTCGAGGTT	CTGGAGGTGC	TGGAGCAGGA	CGCAGATGCT	CGCGTGCTTG	420
TTCTGACTGG	TGCAGGCGAA	TCCTGGACCG	CGGGCATGGA	CCTGAAGGAG	TATTTCCGCG	480
AGACCGATGC	TGGCCCCGAA	ATTCTGCAAG	AGAAGATTCTG	TCGGGGACAG	CAAGCGAACC	540
GGAATTGCCA	GCTGGGGCGC	CCTCTGGTAA	GGTTGGGAAG	CCCTGCAAAG	TAAACTGGAT	600
GGCTTTCTTG	CCGCCAAGGA	TCTGATGGCG	CAGGGGATCA	AGATCTGATC	AAGAGACAGG	660
ATGAGGATCG	TTTCGCAATGA	TTGAACAAGA	TGGATTGCAC	GCAGGTTCTC	CGGCCGCTTG	720
GGTGGAGAGG	CTATTCGGCT	ATGACTGGGC	ACAACAGACA	ATCGGCTGCT	CTGATGCCGC	780
CGTGTTCCGG	CTGTCAGCGC	AGGGGCGCCC	GGTTCTTTTT	GTCAAGACCG	ACCTGTCCGG	840
TGCCCTGAAT	GAAGTGCAGG	ACGAGGCAGC	GCGGCTATCG	TGGCTGGCCA	CGACGGGCGT	900
TCCTTGCGCA	GCTGTGCTCG	ACGTTGTCAC	TGAAGCGGGA	AGGGACTGGC	TGCTATTGGG	960
CGAAGTGCCG	GGGCAGGATC	TCCTGTCATC	TCACCTTGCT	CCTGCCGAGA	AAGTATCCAT	1020
CATGGCTGAT	GCAATGCGGC	GGCTGCATAC	GCTTGATCCG	GCTACCTGCC	CATTCGACCA	1080
CCAAGCGAAA	CATCGCATCG	AGCGAGCACG	TACTCGGATG	GAAGCCGGTC	TTGTTCGATCA	1140
GGATGATCTG	GACGAAGAGC	ATCAGGGGCT	CGCGCCAGCC	GAAGTGTTCG	CCAGGCTCAA	1200
GGCGCGCATG	CCCAGCGGCG	AGGATCTCGT	CGTGACCCAT	GGCGATGCCT	GCTTGCCGAA	1260
TATCATGGTG	GAAAATGGCC	GCTTTTCTGG	ATTTCATCGAC	TGTGGCCGGC	TGGGTGTGGC	1320
GGACCGCTAT	CAGGACATAG	CGTTGGCTAC	CCGTGATATT	GCTGAAGAGC	TTGGCGGCGA	1380
ATGGGCTGAC	CGCTTCCTCG	TGCTTTACGG	TATCGCCGCT	CCCGATTTCG	AGCGCATCGC	1440
CTTCTATCGC	CTTCTTGACG	AGTTCTTCTG	AGCGGGACTC	TGGGGTTTCA	AATGACCGAC	1500
CAAGCGACGC	CCCAGCAGG	GCATGAAGCA	GTTCCCTTGAC	GAGAAAAGCA	TCAAGCCGGG	1560
CTTGACAGAC	TACAAGCGCT	GATAAATGCG	CCGGGGCCCT	CGCTGCGCCC	CCGGCCCTTC	1620
AATAATGACA	ATAATGAGGA	GTGCCCAATG	TTTCACGTGC	CCCTGCTTAT	TGGTGGTAAG	1680
CCTTGTTTCA	CATCTGATGA	GCGCACCTTC	GAGCGTCGTA	GCCCGCTGAC	CGGAGAAGTG	1740
GTATCGCGCG	TCGCTGCTGC	CAGTTTGGAA	GATGCGGACG	CCGCAGTGGC	CGCTGCACAG	1800
GCTGCGTTTC	CTGAATGGGC	GGCGCTTGCT	CCGAGCGAAC	GCCGTGCCCC	ACTGCTGCGA	1860
GCGGCGGATC	TTCTAGAGGA	CCGTTCTTCC	GAGTTCACCG	CCGCAGCGAG	TGAAACTGGC	1920
GCAGCGGGAA	ACTGGTATGG	GTTTAAACGTT	TACCTGGCGG	CGGGCATGTT	GCGGGGAATT	1980
C						1981

Sequence 11

GAATTCCCCT	GGCGACGAAA	GGGCGGCAGG	CCGCATGGCC	ACGGCTGGGC	GGTAACTGAT	60
GCTTGCGTTA	ATCGTTAACC	GTTTGAAATT	CCTTGCCAAA	TTCGCGCAG	AGAATCATGC	120
GGGTACGCCT	TTCCGTGCGC	TTTGATCTGC	GCTTCCGTGC	CTTGAATCAG	AAAAATAGTT	180
AATTGACAGA	ACTATAGGTT	CGCAGTAGCT	TTTGCTCACC	CACCAAATCC	ACAGCACTGG	240
GGTGACGAT	GAATAGCTAC	GATGGCCGTT	GGTCTACCGT	TGATGTGAAG	GTTGAAGAAG	300
GTATCGCTTG	GGTCACGCTG	AACCGCCCGG	AGAAGCGCAA	CGCAATGAGC	CCAACTCTCA	360
ATCGAGAGAT	GGTCGAGGTT	CTGGAGGTGC	TGGAGCAGGA	CGCAGATGCT	CGCGTGCTTG	420
TTCTGACTGG	TGCAGGCGAA	TCCTGGACCG	CGGGCATGGA	CCTGAAGGAG	TATTTCCGCG	480
AGACCGATGC	TGGCCCCGAA	ATTCTGCAAG	AGAAGATTCT	TCGGGGGAGA	GGCGGTTTGC	540
GTATTGGGCG	CATGCATAAA	AACTGTTGTA	ATTCAATTAAG	CATTCTGCCG	ACATGGAAGC	600
CATCACAAAC	GGCATGATGA	ACCTGAATCG	CCAGCGGCAT	CAGCACCTTG	TCGCCCTTGCG	660
TATAATATTT	GCCCATGGAC	GCACACCGTG	GAAACGGATG	AAGGCACGAA	CCCAGTTGAC	720
ATAAGCCGTG	TCGGTTCGTA	AACTGTAATG	CAAGTAGCGT	ATGCGCTCAC	GCAACTGGTC	780
CAGAACCTTG	ACCGAACGCA	GCGGTGGTAA	CGGCGCAGTG	GCGGTTTTCA	TGGCTTGTTA	840
TGACTGTTTT	TTTGTAAGT	CTATGCCTCG	GGCATCCAAG	CAGCAAGCGC	GTTACGCCGT	900
GGGTCGATGT	TTGATGTTAT	GGAGCAGCAA	CGATGTTACG	CAGCAGCAAC	GATGTTACGC	960
AGCAGGGCAG	TCGCCCTAAA	ACAAAGTTAG	GTGGCTCAAG	TATGGGCATC	ATTCGCACAT	1020
GTAGGCTCGG	CCCTGACCAA	GTCAAATCCA	TGCGGGCTGC	TCTTGATCTT	TTCGGTCGTG	1080
AGTTCGGAGA	CGTAGCCACC	TACTCCCAAC	ATCAGCCGGA	CTCCGATTAC	CTCGGGAAC	1140
TGCTCCGTAG	TAAGACATTC	ATCGCGCTTG	CTGCCTTCGA	CCAAGAAGCG	GTTGTTGGCG	1200
CTCTCGCGGC	TTACGTCTTG	CCCAGGTTTG	AGCAGCCGCG	TAGTGAGATC	TATATCTATG	1260
ATCTCGCAGT	CTCCGGCGAG	CACCGGAGGC	AGGGCATTGC	CACCGCGCTC	ATCAATCTCC	1320
TCAAGCATGA	GGCCAACGCG	CTTGGTGCTT	ATGTGATCTA	CGTGCAAGCA	GATTACGGTG	1380
ACGATCCCGC	AGTGGCTCTC	TATACAAAGT	TGGGCATACG	GGAAGAAGTG	ATGCACTTTG	1440
ATATCGACCC	AAGTACCGCC	ACCTAACAAAT	TCGTTCAAGC	CGAGATCGGC	TTCCCCGAGC	1500
AGGGCATGAA	GCAGTTCCTT	GACGAGAAAA	GCATCAAGCC	GGGCTTGCG	ACCTACAAGC	1560
GCTGATAAAT	GCGCCGGGGC	CCTCGCTGCG	CCCCCGGCCT	TCCAATAATG	ACAATAATGA	1620
GGAGTGCCCA	ATGTTTCACG	TGCCCCTGCT	TATTGGTGGT	AAGCCTTGTT	CAGCATCTGA	1680
TGAGCGCAC	TTGAGCGTC	GTAGCCCGCT	GACCGGAGAA	GTGGTATCGC	GCGTCGCTGC	1740
TGCCAGTTTG	GAAGATGCGG	ACGCCGCAGT	GGCCGCTGCA	CAGGCTGCGT	TTCTTGAATG	1800
GGCGGCGCTT	GCTCCGAGCG	AACGCCGTGC	CCGACTGCTG	CGAGCGGCGG	ATCTTCTAGA	1860
GGACCGTTCT	TCCGAGTTCA	CCGCCGCAGC	GAGTGAAACT	GGCGCAGCGG	GAAACTGGTA	1920
TGGGTTTAAC	GTTTACCTGG	CGGCGGGCAT	GTTGCGGGGA	ATTC		1964

090514 042704

Sequence 12

GAATTCCCCT	GGCGACGAAA	GGGCGGCAGG	CCGCATGGCC	ACGGCTGGGC	GGTAAC TGAT	60
GCTTGCGTTA	ATCGTTAACC	GTTTGAAATT	CCTTGCCAAA	TTTCGGCGAG	AGAATCATGC	120
GGGTACGCCT	TTCCGTGCGC	TTTGATCTGC	GCTTCCGTGC	CTTGAATCAG	AAAAATAGTT	180
AATTGACAGA	ACTATAGGTT	CGCAGTAGCT	TTTGCTCACC	CACCAAATCC	ACAGCAC'TGG	240
GGTGACGAT	GAATAGCTAC	GATGGCCGTT	GGTCTACCGT	TGATGTGAAG	GT'TGAAGAAG	300
GTATCGCTTG	GGTCACGCTG	AACCGCCCGG	AGAAGCGCAA	CGCAATGAGC	CCAAC'TCTCA	360
ATCGAGAGAT	GGTCGAGGTT	CTGGAGGTGC	TGGAGCAGGA	CGCAGATGCT	CGCGTGCTTG	420
TTCTGACTGG	TGCAGGCGAA	TCCTGGACCG	CGGGCATGGA	CCTGAAGGAG	TATTTCCGCG	480
AGACCGATGC	TGGCCCCGAA	ATTCTGCAAG	AGAAGATTCTG	TCGCGAGCAG	GGCATGAAGC	540
AGTTCCTTGA	CGAGAAAAAGC	ATCAAGCCGG	GCTTGCAGAC	CTACAAGCGC	TGATAAATGC	600
GCCGGGGCCC	TCGCTGCGCC	CCCGGCCTTC	CAATAATGAC	AATAATGAGG	AGTGCCCAAT	660
GTTTCACGTG	CCCCTGCTTA	TTGGTGGTAA	GCCTTGTTCA	GCATCTGATG	AGCGCACCTT	720
CGAGCGTCGT	AGCCCGCTGA	CCGAGAAAGT	GGTATCGCGC	GTCGCTGCTG	CCAGTTTGGA	780
AGATGCGGAC	GCCGCACTGG	CCGCTGCACA	GGCTGCGTTT	CCTGAATGGG	CGGCGCTTGC	840
TCCGAGCGAA	CGCCGTGCCC	GACTGCTGCG	AGCGGCGGAT	CTTCTAGAGG	ACCGTTCTTC	900
CGAGTTCACC	GCCGCAAGCA	GTGAAACTGG	CGCAGCGGGA	AACTGGTATG	GGTTTAACGT	960
TTACCTGGCG	GCGGGCATGT	TGCGGGGAAT	TC			992

09830514.042701

Sequence 13

GAATTTCAAT	AATGACAATA	ATGAGGAGTG	CCCAATGTTT	CACGTGCCCC	TGCTTATTGG	60
TGGTAAGCCT	TGTTTCAGCAT	CTGATGAGCG	CACCTTCGAG	CGTCGTAGCC	CGCTGACCGG	120
AGAAGTGGTA	TCGCGCGTCG	CTGCTGCCAG	TTTGGAAGAT	GCGGACGCCG	CAGTGGCCGC	180
TGCACAGGCT	GCGTTTCCTG	AATGGGCGGC	GCTTGCTCCG	AGCGAACGCC	GTGCCCCACT	240
GCTGCGAGCG	GCGGATCTTC	TAGAGGACCG	TTCTTCCGAG	TTCACCGCCG	CAGCGAGTGA	300
AACTGGCGCA	GCGGGAAACT	GGTATGGGT	TAACGTTTAC	CTGGCGGCGG	GCATGTTGCG	360
GGAAGCCGCG	GCCATGACCA	CACAGATTCA	GGGCGATGTC	ATTCCGTCCA	ATGTGCCCCG	420
TAGCTTTGCC	ATGGCGGTTC	GACAGCCATG	TGGCGTGTTG	CTCGGTATTG	CGCCTTGGA	480
TGCTCCGGTA	ATCCTTGGCG	TACGGGCTGT	TGCGATGCCG	TTGGCATGCG	GCAATACCGT	540
GGTGTGAAA	AGCTCTGAGC	TGAGTCCCTT	TACCCATCGC	CTGATTGGTC	AGGTGTTGCA	600
TGATGCTGGT	CTGGGGGATG	GCGTGGTGAA	TGTCATCAGC	AATGCCCCGC	AAGACGCTCC	660
TGCGGTGGTG	GAGCGACTGA	TTGCAAATCG	TGCGGTACGT	CGAGTGAAGT	TCACCGGTTC	720
GACCCACGTT	GGACGGATCA	TTGGTGAGCT	GTCTGCGCGT	CATCTGAAGC	CTGCTGTGCT	780
GGAATTAGGT	GGTAAGGCTC	CGTTCTTGGT	CTTGACGAT	GCCGACCTCG	ATGCGGCGGT	840
CGAAGCGGCG	GCCTTTGGTG	CCTACTTCAA	TCAGGGTCAA	ATCTGCATGT	CCACTGAGCG	900
TCTGATTGTG	ACAGCAGTCG	CAGACGCCTT	TGTTGAAAAG	CTGGCGAGGA	AGGTCGCCAC	960
ACTGCGTGCT	GGCGATCCTA	ATGATCCGCA	ATCGGTCTTG	GGTTCGTTGA	TTGATGCCAA	1020
TGCAGGTCAA	CGCATCCAGG	TTCTGGTCGA	TGATGCGCTC	GGGGACAGCA	AGCGAACCGG	1080
AATTGCCAGC	TGGGGCGCCC	TCTGGTAAGG	TTGGGAAGCC	CTGCAAAGTA	AACTGGATGG	1140
CTTTCTTGCC	GCCAAGGATC	TGATGGCGCA	GGGGATCAAG	ATCTGATCAA	GAGACAGGAT	1200
GAGGATCGTT	TCGCATGATT	GAACAAGATG	GATTGCACGC	AGGTTCTCCG	GCCGCTTGGG	1260
TGGAGAGGCT	ATTCGGCTAT	GAATGGGCAC	AACAGACAAT	CGGCTGCTCT	GATGCCGCCG	1320
TGTTCCGGCT	GTCAGCGCAG	GGGCGCCCCG	TTCTTTTTGT	CAAGACCGAC	CTGTCCGGTG	1380
CCCTGAATGA	ACTGCAGGAC	GAGGCAGCGC	GGCTATCGTG	GCTGGCCACG	ACGGGCGTTC	1440
CTTGCGCAGC	TGTGCTCGAC	GTTGTCACTG	AAGCGGGAAG	GGACTGGCTG	CTATTGGGCG	1500
AAGTGCCGGG	GCAGGATCTC	CTGTCATCTC	ACCTTGCTCC	TGCCGAGAAA	GTATCCATCA	1560
TGGCTGATGC	AATGCGGCGG	CTGCATACGC	TTGATCCGGC	TACCTGCCCA	TTCGACCACC	1620
AAGCGAAACA	TCGCATCGAG	CGAGCACGTA	CTCGGATGGA	AGCCGGTCTT	GTCGATCAGG	1680
ATGATCTGGA	CGAAGAGCAT	CAGGGGCTCG	CGCCAGCCGA	ACTGTTTCGCC	AGGCTCAAGG	1740
CGCGCATGCC	CGACGGCGAG	GATCTCGTCG	TGACCCATGG	CGATGCCTGC	TTGCCGAATA	1800
TCATGGTGGA	AAATGGCCGC	TTTTCTGGAT	TCATCGACTG	TGGCCGGCTG	GGTGTGGCGG	1860
ACCGCTATCA	GGACATAGCG	TTGGCTACCC	GTGATATTGC	TGAAGAGCTT	GGCGGCCAAT	1920
GGGCTGACCG	CTTCCTCGTG	CTTTACGGTA	TCGCCGCTCC	CGATTTCGAG	CGCATCGCCT	1980
TCTATCGCCT	TCTTGACGAG	TTCTTCTGAG	CGGGACTCTG	GGGTTGAAA	TGACCGACCA	2040
AGCGACGCCC	GGCCCAGCGC	GTCGATTCCG	GCATTTGCCA	TATCAATGGA	CCGACTGTGC	2100
ATGACGAGGC	TCAGATGCCA	TTCCGTGGGG	TGAAGTCCAG	CGGCTACGGC	AGCTTCGGCA	2160

0930514.042701

Sequence 14

GAATTCCAAT	AATGACAATA	ATGAGGAGTG	CCCAATGTTT	CACGTGCCCC	TGCTTATTGG	60
TGGTAAGCCT	TGTTTCAGCAT	CTGATGAGCG	CACCTTCGAG	CGTCGTAGCC	CGCTGACCGG	120
AGAAGTGGTA	TCGCGCGTCG	CTGCTGCCAG	TTTGGAAGAT	GCGGACGCCG	CAGTGGCCGC	180
TGCACAGGCT	GCGTTTCCTG	AATGGGCGGC	GCTTGCTCCG	AGCGAACGCC	GTGCCCCACT	240
GCTGCGAGCG	GCGGATCTTC	TAGAGGACCG	TTCTTCCGAG	TTACCCGCCG	CAGCGAGTGA	300
AACTGGCGCA	GCGGGAACCT	GGTATGGGTT	TAACGTTTAC	CTGGCGGCCG	GCATGTTGCG	360
GGAAGCCGCG	GCCATGACCA	CACAGATTCA	GGGCGATGTC	ATTCCGTCCA	ATGTGCCCGG	420
TAGCTTTGCC	ATGGCGGTTT	GACAGCCATG	TGGCGTGGTG	CTCGGTATTG	CGCCTTGGAA	480
TGCTCCGGTA	ATCCTTGCGG	TACGGGCTGT	TGCGATGCCG	TTGGCATGCG	GCAATACCGT	540
GGTGTTGAAA	AGCTCTGAGC	TGAGTCCCTT	TACCCATCGC	CTGATTGGTC	AGGTGTTGCA	600
TGATGCTGGT	CTGGGGGATG	GCGTGGTGAA	TGTCATCAGC	AATGCCCCCG	AAGACGCTCC	660
TGCGGTGGTG	GAGCGACTGA	TTGCAAATCC	TGCGGTACGT	CGAGTGAAC	TCACCGGTTT	720
GACCCACGTT	GGACGGATCA	TTGGTGAGCT	GTCTGCGCGT	CATCTGAAGC	CTGCTGTGCT	780
GGAATTAGGT	GGTAAGGCTC	CGTTCTTGGT	CTTGACGAT	GCCGACCTCG	ATGCGGCGGT	840
CGAAGCGGCG	GCCTTTGGTG	CCTACTTCAA	TCAGGGTCAA	ATCTGCATGT	CCACTGAGCG	900
TCTGATTGTG	ACAGCAGTCG	CAGACGCCTT	TGTTGAAAAG	CTGGCGAGGA	AGGTCGCCAC	960
ACTGCGTGCT	GGCGATCCTA	ATGATCCGCA	ATCGGTCTTG	GGTTCGTTGA	TTGATGCCAA	1020
TGCAGGTCAA	CGCATCCAGG	TGGGGAGAGG	CGGTTTGCGT	ATTGGGCGCA	TGCATAAAAA	1080
CTGTTGTAAT	TCATTAAGCA	TTCTGCCGAC	ATGGAAGCCA	TCACAAACGG	CATGATGAAC	1140
CTGAATCGCC	AGCGGCATCA	GCACCTTGTC	GCCTTGCGTA	TAATATTTGC	CCATGGACGC	1200
ACACCGTGGA	AACGGATGAA	GGCACGAACC	CAGTTGACAT	AAGCCTGTTC	GGTTCGTAAA	1260
CTGTAATGCA	AGTAGCGTAT	GCGCTCACGC	AACTGGTCCA	GAACCTTGAC	CGAACGCAGC	1320
GGTGGTAACG	GCGCAGTGGC	GGTTTTTCATG	GCTTGTTATG	ACTGTTTTTT	TGTACAGTCT	1380
ATGCCTCGGG	CATCCAAGCA	GCAAGCGCGT	TACGCCGTGG	GTGATGTTT	GATGTTATGG	1440
AGCAGCAACG	ATGTTACGCA	GCAGCAACGA	TGTTACGCAG	CAGGGCAGTC	GCCCTAAAAC	1500
AAAGTTAGGT	GGCTCAAGTA	TGGGCATCAT	TCGCACATGT	AGGCTCGGCC	CTGACCAAGT	1560
CAAATCCATG	CGGGCTGCTC	TTGATCTTTT	CGGTCGTGAG	TTCCGGAGACG	TAGCCACCTA	1620
CTCCCAACAT	CAGCCGGACT	CCGATTACCT	CGGGAACCTG	CTCCGTAGTA	AGACATTCTA	1680
CGCGCTTGCT	GCCTTCGACC	AAGAAGCGGT	TGTTGGCGCT	CTCGCGGCTT	ACGTTCTGCC	1740
CAGGTTTGAG	CAGCCGCGTA	GTGAGATCTA	TATCTATGAT	CTCGCAGTCT	CCGGCGAGCA	1800
CCGGAGGCAG	GGCATTGCCA	CCGCGCTCAT	CAATCTCCTC	AAGCATGAGG	CCAACGCGCT	1860
TGGTGCTTAT	GTGATCTACG	TGCAAGCAGA	TTACGGTGAC	GATCCCGCAG	TGGCTCTCTA	1920
TACAAAGTTG	GGCATACGGG	AAGAAGTGAT	GCACTTTGAT	ATCGACCCAA	GTACCGCCAC	1980
CTAACAATTC	GTTCAAGCCG	AGATCGGCTT	CCCAATTGGC	CCAGCGCGTC	GATTCGGGCA	2040
TTTGCCATAT	CAATGGACCG	ACTGTGCATG	ACGAGGCTCA	GATGCCATTG	GGTGGGTTGA	2100
AGTCCAGCGG	CTACGGCAGC	TTGCGCAGTC	GAGCATCGAT	TGAGCACTTT	ACCCAGCTGC	2160

09830514-042701

GCTGGCTGAC	CATTCAGAAAT	GGCCCGCGGC	ACTATCCAAT	CTAAATCGAT	CTTCGGGCGC	2220
CGCGGGCATC	ATGCCCGCGG	CGCTCGCCTC	ATTTCAATCT	CTAACTTGAT	AAAAACAGAG	2280
CTGTTCTCCG	GTCTTGGTGG	ATCAAGGCCA	GTCGCGGAGA	GTCTCGAAGA	GGAGAGTACA	2340
GTGAACGCCG	AGTCCACATT	GCAACCGCAG	GCATCATCAT	GCTCTGCTCA	GCCACGCTAC	2400
CGCAGTGTCT	CGATTGGTCA	TCTCTCGGTT	GAGGTTACGC	AAGACGCTGG	AGGTATTGTC	2460
CGGATGCGTT	CTCTCGAGGC	GCTTCTTCCC	TTCCCGGGTG	GAATTC		2506

Sequence 15

GAATTCCAAT	AATGACAATA	ATGAGGAGTG	CCCAATGTTT	CACGTGCCCC	TGCTTATTGG	60
TGGTAAGCCT	TGTTCAGCAT	CTGATGAGCG	CACCTTCGAG	CGTCGTAGCC	CGCTGACCGG	120
AGAAGTGGTA	TCGCGCGTCG	CTGCTGCCAG	TTTGGAAGAT	GCGGACGCCG	CAGTGGCCGC	180
TGCACAGGCT	GCGTTTCCTG	AATGGGCGGC	GCTTGCTCCG	AGCGAACGCC	GTGCCCCGACT	240
GCTGCGAGCG	GCGGATCTTC	TAGAGGACCG	TTCTTCCGAG	TTCACCGCCG	CAGCGAGTGA	300
AAC TGCGCA	GCGGGAAACT	GGTATGGGTT	TAACGTTTAC	CTGGCGGCCG	GCATGTTGCG	360
GGAAGCCGCG	GCCATGACCA	CACAGATTCA	GGGCGATGTC	ATTCCGTCCA	ATGTGCCCGG	420
TAGCTTTGCC	ATGGCGGTTT	GACAGCCATG	TGGCGTGGTG	CTCGGTATTG	CGCCTTGGA	480
TGCTCCGGTA	ATCCTTGCGG	TACGGGCTGT	TGCGATGCCG	TTGGCATGCG	GCAATACCGT	540
GGTGTTGAAA	AGCTCTGAGC	TGAGTCCCTT	TACCCATCGC	CTGATTGGTC	AGGTGTTGCA	600
TGATGCTGGT	CTGGGGGATG	GCGTGGTGAA	TGTCATCAGC	AATGCCCCGC	AAGACGCTCC	660
TGCGGTGGTG	GAGCGACTGA	TTGCAAATCC	TGCGGTACGT	CGAGTGAAC	TCACCGGTTT	720
GACCCACGTT	GGACGGATCA	TTGGTGAGCT	GTCTGCGCGT	CATCTGAAGC	CTGCTGTGCT	780
GGAATTAGGT	GGTAAGGCTC	CGTTCTTGGT	CTTGACGAT	GCCGACCTCG	ATGCGGCGGT	840
CGAAGCGGCG	GCCTTTGGTG	CCTACTTCAA	TCAGGGTCAA	ATCTGCATGT	CCACTGAGCG	900
TCTGATTGTG	ACAGCAGTCG	CAGACGCCTT	TGTTGAAAAG	CTGGCGAGGA	AGGTCGCCAC	960
ACTGCGTGCT	GGCGATCCTA	ATGATCCGCA	ATCGGTCTTG	GGTTCGTTGA	TTGATGCCAA	1020
TGCAGGTCAA	CGCATCCAGG	TTCTGGTCGA	TGATGCGCTC	GCAAAAGGCG	CGCAATGGAA	1080
TTGGCCCAGC	GCGTCGATTC	GGGCATTTGC	CATATCAATG	GACCGACTGT	GCATGACGAG	1140
GCTCAGATGC	CATTGCGGTG	GGTGAAGTCC	AGCGGCTACG	GCAGCTTCGG	CAGTCGAGCA	1200
TCGATTGAGC	ACTTTACCCA	GCTGCGCTGG	CTGACCATTG	AGAATGGCCC	GCGGCACTAT	1260
CCAATCTAAA	TCGATCTTCG	GGCGCCGCGG	GCATCATGCC	CGCGGCGCTC	GCCTCATTTC	1320
AATCTCTAAC	TTGATAAAAA	CAGAGCTGTT	CTCCGGTCTT	GGTGGATCAA	GGCCAGTCGC	1380
GGAGAGTCTC	GAAGAGGAGA	GTACAGTGAA	CGCCGAGTCC	ACATTGCAAC	CGCAGGCATC	1440
ATCATGCTCT	GCTCAGCCAC	GCTACCGCAG	TGTGTCGATT	GGTCATCCTC	CGGTTGAGGT	1500
TACGCAAGAC	GCTGGAGGTA	TTGTCCGGAT	GCGTTCTCTC	GAGGCGCTTC	TTCCCTTCCC	1560
GGGTGGAATT	C					1571

Sequence 16

GAATTCCGCG	GTCGGCGAAA	GTTGATGCGC	TGTATCGTGG	TGAAGATCAA	TCCATGCTGC	60
GTGACGAGGC	CACACTGTGA	GTTGGTCAGG	GGGGGCTTAC	TCGGCGTTTT	CCGACACTGC	120
GTTGGTTGCG	GCAGTGCGCA	CCCCCTGGAT	TGATTGCGGG	GGTGCCCTGT	CGCTGGTGTC	180
GCCTATCGAC	TTAGGGGTAA	AGGTCGCTCG	CGAAGTTCTG	ATGCGTGCGT	CGCTTGAACC	240
ACAAATGGTC	GATAGCGTAC	TCGCAGGCTC	TATGGCTCAA	GCAAGCTTTG	ATGCTTACCT	300
GCTCCCGCGG	CACATTGGCT	TGTACAGCGG	TGTTCCCAAG	TCGGTTCCGG	CCTTGGGGGT	360
GCAGCGCATT	TGCGGCACAG	GCTTCGAACT	GCTTCGGCAG	GCCGGCGAGC	AGATTTCCCA	420
AGGCGCTGAT	CACGTGCTGT	GTGTGCGCGC	AGAGTCCATG	TCGCGTAACC	CCATCGCGTC	480
GTATACACAC	CGGGGCGGGT	TCCGCCTCGG	TGCGCCCGTT	GAGTTCAAGG	ATTTTTTGTC	540
GGAGGCATTG	TTTGATCCTG	CTCCAGGACT	CGACATGATC	GCTACCGCAG	AAAACCTGGG	600
GACAGCAAGC	GAACCGGAAT	TGCCAGCTGG	GGCGCCCTCT	GGTAAGGTTG	GGAAGCCCTG	660
CAAAGTAAAC	TGGATGGCTT	TCTTGCCGCC	AAGGATCTGA	TGGCGCAGGG	GATCAAGATC	720
TGATCAAGAG	ACAGGATGAG	GATCGTTTCG	CATGATTGAA	CAAGATGGAT	TGCACGCAGG	780
TTCTCCGGCC	GCTTGGGTGG	AGAGGCTATT	CGGCTATGAC	TGGGCACAAC	AGACAATCGG	840
CTGCTCTGAT	GCCGCCGTGT	TCCGGCTGTC	AGCGCAGGGG	CGCCCGGTTC	TTTTTGTCAA	900
GACCGACCTG	TCCGGTGCCC	TGAATGAACT	GCAGGACGAG	GCAGCGCGGC	TATCGTGGCT	960
GGCCACGACG	GGCGTTCCTT	GCGCAGCTGT	GCTCGACGTT	GTCACTGAAG	CGGGAAGGGA	1020
CTGGCTGCTA	TTGGGCGAAG	TGCCGGGGCA	GGATCTCCTG	TCATCTCACC	TTGCTCCTGC	1080
CGAGAAAGTA	TCCATCATGG	CTGATGCAAT	GCGGCGGCTG	CATACGCTTG	ATCCGGCTAC	1140
CTGCCCATTC	GACCACCAAG	CGAAACATCG	CATCGAGCGA	GCACGTACTC	GGATGGAAGC	1200
CGGTCTTGTC	GATCAGGATG	ATCTGGACGA	AGAGCATCAG	GGGCTCGCGC	CAGCCGAACT	1260
GTTCGCCAGG	CTCAAGGCGC	GCATGCCCCG	CGGCGAGGAT	CTCGTCGTGA	CCCATGGCGA	1320
TGCCTGCTTG	CCGAATATCA	TGGTGGAAAA	TGGCCGCTTT	TCTGGATTCA	TCGACTGTGG	1380
CCGGCTGGGT	GTGGCGGACC	GCTATCAGGA	CATAGCGTTG	GCTACCCGTG	ATATTGCTGA	1440
AGAGCTTGGC	GGCGAATGGG	CTGACCGCTT	CCTCGTGCTT	TACGGTATCG	CCGCTCCCCG	1500
TTCGCAGCGC	ATCGCCTTCT	ATCGCCTTCT	TGACGAGTTC	TTCTGAGCGG	GACTCTGGGG	1560
TTCGAAATGA	CCGACCAAGC	GACGCCCATT	GAGGGCGCAA	GAGGAGAAAT	GGATTGACCA	1620
AGAGATCGTG	GCTGTTACGG	ATGAACAGTT	CGATTTAGAG	GGCTACAACA	GTCGAGCAAT	1680
TGAACTGCCT	CGGAAGGCAA	AATTGTTGAT	CGTGACAGTC	ATCCGCGGCC	TAGCAGTCTT	1740
TGAAGCCCTT	TCCCATTGA	AGCCTGTTCA	TTCTGGCGGG	GTGCAGACTG	CGGGCAACAG	1800
CTGTGCCGTA	GTGGACGGCG	CCGCGGCGGC	TTTGGTGGCT	CGAGAGTCGT	CTGCGACACA	1860
GCCGGTCTTG	GCTAGGATAC	TGGCTACCTC	CGTAGTCGGG	ATCGAGCCCG	AGCATATGGG	1920
GCTCGGCCCT	GCGCCCGCGA	TTCGCCTGCT	GCTTGCGCGT	AGTGATCTTA	GTTTGAGGGA	1980
TATCGACCTC	TTTGAGATAA	ACGAGGCGCA	GGCCGCCCAA	GTTCTAGCGG	TACAGCATGA	2040
ATTGGGTATT	GAGCACTCAA	AACTTAATAT	TTGGGGCGGG	GCCATTGCAC	TTGGACACCC	2100
GCTTGCCGCG	ACCGGATTGC	GTCTCTGCAT	GACCCTCGCT	CACCAATTGC	AAGCTAATAA	2160

0930514 042701

CTTTCGATAT	GGAATTGCCT	CGGCATGCAT	TGGTGGGGGA	CAGGGGATGG	CGGTTCTTTT	2220
AGAGAATCCC	CAC TTCGGTT	CGTCCTCTGC	ACGAAGTTCG	ATGATTAACA	GAGTTGACCA	2280
CTATCCACTG	AGCTAACGGG	CATCTCCTTT	GTTGCTTTGA	GGTGGCGCAC	GAAGGAGGGC	2340
TCGAAAATCT	CTGCTAAAAA	CAAGAAGAAG	GAACAGGGAA	CATGATTAGT	TTCGCTCGTA	2400
TGGCAGAAAG	TTTAGGAGTC	CAGGCTAAAC	TTGCCCTTGC	CTTCGCACTC	GTATTATGTG	2460
TCGGGCTGAT	TGTTACCGGC	ACGGGTTTCT	ACAGTGTACA	TACCTTGTC	GGGTTGGTGG	2520
GAATTC						2526

090514-01201
102240-11508860

Sequence 17

GAATTCGCG	GTCGGCGAAA	GTTGATGCGC	TGTATCGTGG	TGAAGATCAA	TCCATGCTGC	60
GTGACGAGGC	CACACTGTGA	GTTGGTCAGG	GGGGGCTTAC	TCGGCGTTTT	CCGACACTGC	120
GTTGGTTGCG	GCAGTGC GCA	CCCCCTGGAT	TGATTGCGGG	GGTGCCCTGT	CGCTGGTGTC	180
GCCTATCGAC	TTAGGGGTAA	AGGTCGCTCG	CGAAGTTCTG	ATGCGTGCGT	CGCTTGAACC	240
ACAAATGGTC	GATAGCGTAC	TCGCAGGCTC	TATGGCTCAA	GCAAGCTTTG	ATGCTTACCT	300
GCTCCCGCGG	CACATTGGCT	TGTACAGCGG	TGTTCCCAAG	TCGGTTCCGG	CCTTGGGGGT	360
GCAGCGCATT	TGCGGCACAG	GCTTCGAACT	GCTTCGGCAG	GCCGGCGAGC	AGATTTCCCA	420
AGGCGCTGAT	CACGTGCTGT	GTGTCGCGGC	AGAGTCCATG	TCGCGTAACC	CCATCGCGTC	480
GTATACACAC	CGGGGCGGGT	TCCGCCTCGG	TGCGCCCGTT	GAGTTCAAGG	ATTTTTTGTC	540
GGAGGCATTG	TTTGATCCTG	CTCCAGGACT	CGACATGATC	GCTACCGCAG	AAAACCTGGG	600
GGAGAGGCGG	TTTGCGTATT	GGGCGCATGC	ATAAAAACTG	TTGTAATTCA	TTAAGCATTG	660
TGCCGACATG	GAAGCCATCA	CAAACGGCAT	GATGAACCTG	AATCGCCAGC	GGCATCAGCA	720
CCTTGTCGCC	TTGCGTATAA	TATTTGCCCA	TGGACGCACA	CCGTGGAAAC	GGATGAAGGC	780
ACGAACCCAG	TTGACATAAG	CCTGTTCCGG	TCGTAAACTG	TAATGCAAGT	AGCGTATGCG	840
CTCACGCAAC	TGGTCCAGAA	CCTTGACCGA	ACGCAGCGGT	GGTAACGGCG	CAGTGGCGGT	900
TTTCATGGCT	TGTTATGACT	GTTTTTTTGT	ACAGTCTATG	CCTCGGGCAT	CCAAGCAGCA	960
AGCCGCTTAC	GCCGTGGGTC	GATGTTTGAT	GTTATGGAGC	AGCAACGATG	TTACGCAGCA	1020
GCAACGATGT	TACGCAGCAG	GGCAGTCGCC	CTAAACAAAA	GTTAGGTGGC	TCAAGTATGG	1080
GCATCATTCG	CACATGTAGG	CTCGGCCCTG	ACCAAGTCAA	ATCCATGCGG	GCTGCTCTTG	1140
ATCTTTTCGG	TCGTGAGTTC	GGAGACGTAG	CCACCTACTC	CCAACATCAG	CCGGACTCCG	1200
ATTACCTCGG	GAACCTTGCTC	CGTAGTAAGA	CATTCATCGC	GCTTGCTGCC	TTCGACCAAG	1260
AAGCGGTTGT	TGGCGCTCTC	GCGGCTTACG	TTCTGCCCAG	GTTTGAGCAG	CCGCGTAGTG	1320
AGATCTATAT	CTATGATCTC	GCAGTCTCCG	GCGAGCACCG	GAGGCAGGGC	ATTGCCACCG	1380
CGCTCATCAA	TCTCCTCAAG	CATGAGGCCA	ACGCGCTTGG	TGCTTATGTG	ATCTACGTGC	1440
AAGCAGATTA	CGGTGACGAT	CCCGCAGTGG	CTCTCTATAC	AAAGTTGGGC	ATACGGGAAG	1500
AAGTGATGCA	CTTTGATATC	GACCCAAGTA	CCGCCACCTA	ACAATTTCGTT	CAAGCCGAGA	1560
TCGGCTTCCC	ATTGAGGGCG	CAAGAGGAGA	AATGGATTGA	CCAAGAGATC	GTGGCTGTTA	1620
CGGATGAACA	GTTGATTTTA	GAGGGCTACA	ACAGTCGAGC	AATTGAACTG	CCTCGGAAGG	1680
CAAAATTGTT	GATCGTGACA	GTCATCCGCG	GCCTAGCAGT	CTTTGAAGCC	CTTTCCCGAT	1740
TGAAGCCTGT	TCATTCTGGC	GGGGTGCAGA	CTGCGGGCAA	CAGCTGTGCC	GTAGTGGACG	1800
GCGCCGCGGC	GGCTTTGGTG	GCTCGAGAGT	CGTCTGCGAC	ACAGCCGGTC	TTGGCTAGGA	1860
TACTGGCTAC	CTCCGTAGTC	GGGATCGAGC	CCGAGCATAT	GGGGCTCGGC	CCTGCGCCCC	1920
CGATTGCGCT	GCTGCTTGCG	CGTAGTGATC	TTAGTTTGAG	GGATATCGAC	CTCTTTGAGA	1980
TAAACGAGGC	GCAGGCCGCC	CAAGTTCTAG	CGGTACAGCA	TGAATTGGGT	ATTGAGCACT	2040
CAAAACTTAA	TATTTGGGGC	GGGGCCATTG	CAC'TTGGACA	CCCGCTTGCC	GCGACCGGAT	2100
TGCGTCTCTG	CATGACCCTC	GCTCACCAAT	TGCAAGCTAA	TAAC'TTTCGA	TATGGAATTG	2160

083054.0429

CCTCGGCATG	CATTGGTGGG	GGACAGGGGA	TGGCGGTTCT	TTTAGAGAAAT	CCCCACTTCG	2220
GTTTCGTCTC	TGCAGCAAGT	TCGATGATTA	ACAGAGTTGA	CCACTATCCA	CTGAGCTAAC	2280
GGGCATCTCC	TTTGTGTGCT	TGAGGTGGCG	CACGAAGGAG	GGCTCGAAAA	TCTCTGCTAA	2340
AAACAAGAAG	AAGGAACAGG	AACATGATT	AGTTTCGCCT	GTATGGCAGA	AAGTTTAGGA	2400
GTCCAGGCTA	AACTTGCCCT	TGCC TTCGCA	CTCGTATTAT	GTGTCGGGCT	GATTGTTACC	2460
GGCACGGGTT	TCTACAGTGT	ACATACCTTG	TCAGGGTTGG	TGGGAATTC		2509

Sequence 18

GAATTCCGCG	GTCGGCGAAA	GTTGATGCGC	TGTATCGTGG	TGAAGATCAA	TCCATGCTGC	60
GTGACGAGGC	CACACTGTGA	GTTGGTCAGG	GGGGGCTTAC	TCGGCGTTTT	CCGACACTGC	120
GTTGGTTGCG	GCAGTGCACA	CCCCCTGGAT	TGATTGCGGG	GGTGCCCTGT	CGCTGGTGTC	180
GCCTATCGAC	TTAGGGGTAA	AGGTCGCTCG	CGAAGTTCTG	ATGCGTGCGT	CGCTTGAACC	240
ACAAATGGTC	GATAGCGTAC	TCGCAGGCTC	TATGGCTCAA	GCAAGCTTTG	ATGCTTACCT	300
GCTCCCGCGG	CACATTGGCT	TGTACAGCGG	TGTTCCCAAG	TCGGTTCCGG	CCTTGGGGGT	360
GCAGCGCATT	TGCGGCACAG	GCTTCGAACT	GCTTCGGCAG	GCCGGCGAGC	AGATTTCCCA	420
AGGCGCTGAT	CACGTGCTGT	GTGTCGCGGC	AGAGTCCATG	TCGCGTAACC	CCATCGCGTC	480
GTATACACAC	CGGGGCGGGT	TCCGCCTCGG	TGCGCCCGTT	GAGTTCAAGG	ATTTTTTGTC	540
GGAGGCATTG	TTTGATCCTG	CTCCAGGACT	CGACATGATC	GCTACCGCAG	AAAACCTGGC	600
GCGCATTGAG	GGCGCAAGAG	GAGAAATGGA	TTGACCAAGA	GATCGTGGCT	GTTACGGATG	660
AACAGTTCGA	TTTAGAGGGC	TACAACAGTC	GAGCAATTGA	ACTGCCTCGG	AAGGCAAAAT	720
TGTTGATCGT	GACAGTCATC	CGCGGCCTAG	CAGTCTTTGA	AGCCCTTTCC	CGATTGAAGC	780
CTGTTTCATC	TGGCGGGGTG	CAGACTGCGG	GCAACAGCTG	TGCCGTAGTG	GACGGCGCCG	840
CGGCGGCTTT	GGTGGCTCGA	GAGTCGTCTG	CGACACAGCC	GGTCTTGGCT	AGGATACTGG	900
CTACCTCCGT	AGTCGGGATC	GAGCCCGAGC	ATATGGGGCT	CGGCCCTGCG	CCCGCGATTC	960
GCCTGCTGCT	TGCGCGTAGT	GATCTTAGTT	TGAGGGATAT	CGACCTCTTT	GAGATAAACG	1020
AGGCGCAGGC	CGCCCAAGTT	CTAGCGGTAC	AGCATGAATT	GGGTATTGAG	CACTCAAAAC	1080
TTAATATTTG	GGGCGGGGCC	ATTGCACTTG	GACACCCGCT	TGCCGCGACC	GGATTGCGTC	1140
TCTGCATGAC	CCTCGCTCAC	CAATTGCAAG	CTAATAACTT	TCGATATGGA	ATTGCCTCGG	1200
CATGCATTGG	TGGGGGACAG	GGGATGGCGG	TTCTTTTAGA	GAATCCCCAC	TTCGGTTCGT	1260
CCTCTGCACG	AAGTTCGATG	ATTAACAGAG	TTGACCACTA	TCCACTGAGC	TAACGGGCAT	1320
CTCCTTTGTT	GCTTTGAGGT	GGCGCACGAA	GGAGGGCTCG	AAAATCTCTG	CTAAAAACAA	1380
GAAGAAGGAA	CAGGGAACAT	GATTAGTTTC	GCTCGTATGG	CAGAAAGTTT	AGGAGTCCAG	1440
GCTAAACTTG	CCCTTGCCCT	CGCACTCGTA	TTATGTGTCT	GGCTGATTGT	TACCGGCACG	1500
GGTTTCTACA	GTGTACATAC	CTTGTCAGGG	TTGGTGGAAT	TTC		1543

0930514.04294




Fig. 1a



Fig. 1b




Fig. 1c




Fig. 1d



Fig. 1e




Fig. 1f




Fig. 1g



Fig. 1h




Fig. 1i




Fig. 1j




Fig. 1k




Fig. 1l




Fig. 1m




Fig. 1n




Fig. 1o




Fig. 1p




Fig. 1q




Fig. 1r

COMBINED DECLARATION AND POWER OF ATTORNEY

ATTORNEY DOCKET NO

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought

on the invention entitled

"CONSTRUCTION OF PRODUCTION STRAINS FOR PRODUCING SUBSTITUTED PHENOLS BY SPECIFICALLY INACTIVATING GENES OF THE EUGENOL AND FERULIC ACID CATABOLISM"

the specification of which is attached hereto,

or was filed on **October 20, 1999**

as a PCT Application Serial No. **PCT/EP99/07952**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s), the priority(ies) of which is/are to be claimed:

198 50 242.7
(Number)

Germany
(Country)

October 31, 1998
(Month/Day/Year Filed)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose the material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

JOSEPH C. GIL, Patent Office Registration Number 26,602
ARON PREIS, Patent Office Registration Number 29,426
LYNDANNE M. WHALEN, Patent Office Registration Number 29,457
THOMAS W. ROY, Patent Office Registration Number 29,582
RICHARD E. L. HENDERSON, Patent Office Registration Number 31,619
GODFRIED R. AKORLI, Patent Office Registration Number 28,779
N. DENISE BROWN, Patent Office Registration Number 36,097
NOLAND J. CHEUNG, Patent Office Registration Number 39,138
DIDERICO VAN EYL, Patent Office Registration Number 38,641
CAROLYN M. SLOANE, Patent Office Registration Number 44,339
JAMES R. FRANKS, Patent Office Registration Number 42,552
JACKIE ANN ZURCHER, Patent Office Registration Number 42,251

all of Bayer Corporation, Pittsburgh, Pennsylvania 15205-9741

12

Send Correspondence To:
Patent Department
Bayer Corporation
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741

Direct Telephone Calls To:

(412) 777-2349

FULL NAME OF SOLE OR FIRST INVENTOR <u>Jürgen Rabenhorst</u>		INVENTOR'S SIGNATURE <u>Jürgen Rabenhorst</u>	DATE <u>30.3.2001</u>
RESIDENCE <u>D 37671 Höxter, Germany</u>		CITIZENSHIP <u>German</u>	
POST OFFICE ADDRESS <u>c/o HAARMANN & REIMER GMBH, D 37601 Holzminden, Germany</u>			
FULL NAME OF SECOND INVENTOR <u>Alexander Steinbüchel</u>		INVENTOR'S SIGNATURE <u>Alexander Steinbüchel</u>	DATE <u>17.4.2001</u>
RESIDENCE <u>D 48341 Altenberge, Germany</u>		CITIZENSHIP <u>German</u>	
POST OFFICE ADDRESS <u>Rönnenthal 27, D 48341 Altenberge, Germany</u>			
FULL NAME OF THIRD INVENTOR <u>Horst Priefert</u>		INVENTOR'S SIGNATURE <u>Horst Priefert</u>	DATE <u>19.4.2001</u>
RESIDENCE <u>D 48291 Telgte, Germany</u>		CITIZENSHIP <u>German</u>	
POST OFFICE ADDRESS <u>Potthoffskamp 5, D 48291 Telgte, Germany</u>			
FULL NAME OF FOURTH INVENTOR <u>Jörg Overhage</u>		INVENTOR'S SIGNATURE <u>Jörg Overhage</u>	DATE <u>18.4.2001</u>
RESIDENCE <u>D 59192 Bergkamen, Germany</u>		CITIZENSHIP <u>German</u>	
POST OFFICE ADDRESS <u>Rotherbachstr. 42A, D 59192 Bergkamen, Germany</u>			
FULL NAME OF FIFTH INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			